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Multiple myeloma (MM) is a fatal haematological malignancy characterised by the clonal 
proliferation of malignant plasma cells (PC) within the bone marrow (BM). In most instances, 
MM PCs are reliant on factors made by cells of the BM stroma for their survival and growth. 
To date, the nature and cellular composition of the BM tumour microenvironment and the 
critical factors which drive tumour progression remain imprecisely defined. The studies 
presented here show that Gremlin1 (Grem1), a highly conserved protein, which is abundantly 
secreted by a subset of BM mesenchymal stromal cells, plays a critical role in MM disease 
development. We describe, for the first time, a novel positive feedback loop between MM PCs 
and BM stroma, and that inhibiting this vicious cycle with a neutralising antibody directed 
against Grem1 dramatically reduced tumour burden in a preclinical mouse model of MM. 
Analysis of human BM stromal samples by quantitative PCR showed that GREM1 expression 
was significantly higher in MM patient-derived BM stromal cells compared to stromal cells 
from healthy, age-matched individuals (p<0.01 t-test). Additionally, a positive correlation 
between MM tumour burden and stromal-cell associated Grem1 expression was observed in 
5TGM1 MM PC tumour-bearing mice (p<0.05, R=0.64, Pearson Correlation). Furthermore, 
BM-stromal cells cultured with 5TGM1 MM PCs expressed significantly higher levels of 
Grem1, compared to stromal cells alone (p<0.01, t-test), suggesting that MM PCs promote 
increased Grem1 expression in stromal cells. MM PC induction of stromal-Grem1 serves to 
drive a positive feedback loop, as proliferation of the murine MM cell line, 5TGM1, was found 
to be significantly increased when co-cultured with Grem1-overexpressing stromal cells 
(p<0.01, t-test). 
To further examine the role of Grem1 in MM tumour establishment and growth in vivo, we 
utilised the 5TGM1/KaLwRij mouse model of MM. Following 5TGM1 tumour cell 
inoculation, mice were randomly assigned to either a neutralising Grem1 antibody (anti-Grem1 
antibody, UCB-Pharma) or IgG control treatment arm. Our studies showed that compared to 
Ig control-treated mice, anti-Grem1-treated mice showed a 54% decrease in tumour burden. 
This effect was even more pronounced when mice received treatment with a Grem1 
neutralising antibody prior to 5TGM1 tumour cell inoculation, resulting in an 80% reduction 
in tumour burden. Moreover, MM tumour burden was reduced in a Vk*MYC/Grem1-genetic 




Collectively, the data presented in this thesis suggests that Grem1 is a key stromal-derived PC 
mitogen that promotes MM disease initiation and progression, and that antibody-mediated 
targeting of Grem1 significantly reduces disease burden.  With few effective therapies directed 
against the critical relationship between MM PCs and the BM, the findings presented here, 
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1.1. Multiple Myeloma  
Multiple Myeloma (MM) is a haematological malignancy characterised by the clonal proliferation of 
plasma cells within the bone marrow (BM). MM accounts for approximately 1% of all new cancer 
diagnoses and despite advances in treatment, has a 10-year survival rate of only 18%1. The prognosis 
for those with MM has improved significantly in the past twenty years as knowledge of this disease has 
increased and new therapeutic options have become available. However, the absence of truly curative 
therapies still means that the majority of patients face the inevitability of disease relapse.  
1.1.1. Incidence and Survival  
MM is the second most common haematological malignancy behind non-Hodgkin’s lymphoma2. Over 
the past 30 years there has been a steady increase in the annual number of MM diagnoses, with over 
1800 new diagnoses in Australia in 20181. MM affects slightly more males than females, and there is a 
markedly higher incidence of MM in the African-American population compared with people of 
European descent3. MM accounts for approximately 1000 deaths in Australia annually and over 2.1 
million disability adjusted life-years worldwide4. 10-year survival rates have increased by over 20% in 
the past thirty years owing to advances in treatment options; but the five-year survival rate from 
diagnosis still remains below 50%1. Furthermore, the 5-year survival rate for MM is significantly lower 
than for other more common cancers, including breast, lung and gut1. This can be partially attributed to 
the fact that as a “liquid” cancer, MM PCs are already disseminated throughout the skeleton at the time 
of diagnoses, and therefore surgical excision of tumours or localized radiotherapy are not viable 
therapeutic options.  
1.1.2. Clinical Manifestations 
MM is a malignancy of terminally differentiated B cells, known as plasma cells (PCs), that secrete 
monoclonal antibody (paraprotein)1. The excessive production of paraprotein is a hallmark of MM, as 
the levels of paraprotein and monoclonal antibody free light chains (FLC) (a structural component of 
paraprotein) are direct biomarkers of disease/tumour burden being secreted into the peripheral blood2. 
The major clinical manifestations of MM are due to both the expanded numbers of clonal PCs within 
the BM and their indirect effects on other organs.  
1.1.2.1 Bone Disease in MM 
Bone disease is the primary comorbidity for MM, with approximately 90% of all MM patients 
developing osteolytic lesions, which are commonly associated with skeletal-related events (SRE) such 
as severe bone pain, pathological fractures, spinal cord compression and hypercalcemia3. Bone disease 
significantly impacts the quality of life in MM patients, as well as their morbidity and mortality, with 
an increase number of bone lesions associated with poor prognosis in patients4. MM bone disease is a 




consequence of increased numbers and activity of bone-resorptive osteoclast numbers (Section 1.2.2.) 
and decreased numbers of bone-forming osteoblasts (Section 1.2.3.), resulting in altered bone 
remodeling5.  
1.1.2.2. Other Clinical Manifestations 
Increased levels of calcium in the blood (hypercalcemia) is a related side-effect of osteoclast-mediated 
osteolysis, and can cause a range of symptoms such as confusion, disorientation and muscle weakness6. 
Hypercalcemia, along with the large amounts of FLC in the blood, also contribute to impaired renal 
function, which occurs in 20-40% of MM patients6. Additionally, anemia is found in approximately 
70% of all newly diagnosed MM patients, which often presents with debilitating fatigue6. Furthermore, 
infection is another common comorbidity and cause of mortality in MM, attributable to the disease-
driven and/or treatment-induced immune suppression observed in almost all MM patients7. Anemia and 
reduced leucocyte counts can be attributable to the expansion of malignant PCs compromising normal 
haematopoiesis within the BM6 8. 
1.1.3. Disease Stages 
1.1.3.1. Monoclonal Gammopathy of Undetermined Significance (MGUS) 
MM is a progressive disease that develops from an indolent, asymptomatic precursor stage, known as 
Monoclonal Gammopathy of Undetermined Significance (MGUS). MGUS is defined by the presence 
of less than 3g/dL serum monoclonal protein (paraprotein), clonal BM PC burden of less than 10% and 
the absence of end-organ damage or amyloidosis that can be attributed to the PC proliferative disorder6 
11. Over 3% of individuals over the age of 60 will present with a clonal expansion of plasma cells in the 
form of MGUS. Almost 15% of patients with MGUS will progress to MM, with a progression rate to 
MM of 1% per annum8-11. The time to progression (TTP) of MGUS is highly variable and it is currently 
not possible to predict if, or when, progression will occur. Therefore, the current recommended 
management of MGUS is ongoing monitoring without therapeutic intervention11-13. 
1.1.3.2. Smouldering MM (SMM) 
Smouldering MM (SMM) is an intermediate disease stage between MGUS and MM that is still 
asymptomatic but has a higher tumour burden than MGUS. SMM is defined by the presence of serum 
monoclonal protein (paraprotein) of 3g/dL or greater, and/or 10-60% BM PC burden without evidence 
of end-organ damage11. SMM has a risk to progression to MM of 10% per year within the first 5 years, 
decreasing to 3% per year for the following 5 years, and to 1.5% per year, each year thereafter16. 
However, SMM generally comprises of low and high risk stratified patients, with 50% of newly 
diagnosed SMM patients likely to progress within 5 years, but approximately one-third remaining 
progression-free 10-years post-diagnosis17. To more readily identify those patients at high-risk of 
disease progression the Mayo Clinic developed the “20-2-20” risk stratification system incorporating 




the revised 2014 International Myeloma Working Group criteria for SMM. This model determines 
patients to be at high risk if they meet at least two of three independent risk factors of time to 
progression, including; >20% BM MM PC, >2g/dL paraprotein and a serum FLC ratio of >2017.  
Currently, the recommended management of SMM is ongoing monitoring, however given that those 
classified as high risk have a 50% likelihood of progression within 2 years, there is great debate as to 
whether this subset of patients should receive early treatment17-19. In support of this, recent studies have 
demonstrated that the use of lenalidomide in high-risk SMM patients resulted in a 3-year progression-
free survival (PFS) of 91%, compared to 66% for the observation only cohort20. However, 25% of those 
receiving treatment also experienced adverse events to treatment20, highlighting the need for careful 
consideration of those who do receive treatment to balance the potential of treatment toxicities with the 
more-favourable disease outcomes.  
1.1.3.3. MM 
The definition of MM, as defined by the 2014 International Myeloma Working Group criteria, requires 
a patient to have a clonal BM plasma cell burden of 10% or greater and one or more of the following 
diagnostic criteria; hypercalcemia, renal insufficiency, anaemia, bone lesions, clonal plasma cell 
infiltrate greater than 60%, involved/uninvolved serum FLC ratio greater than 100 or, two or more focal 
lesions based on magnetic resonance imaging (MRI) of the skeleton10 11.  
1.1.3.4. Plasma Cell Leukaemia (PCL) 
In the later stages of MM, the MM PC can lose their reliance on the BM microenvironment and undergo 
a leukemic transformation, with many PCs present in the peripheral circulation; a disease stage is known 
as plasma cell leukemia (PCL). PCL is classified as >20% circulating clonal MM PCs and a PC count 
of more than 2 x 109/L of peripheral blood21-23. The clinical course of PCL is characterised by short 
remissions and an overall poor prognosis, with a survey of 281 PCL patients between 1973 and 2004 
showing a median survival time of just 4 months24 25. The significant improvement in survival rates seen 
for MM patients over the past 20 years has not been observed in PCL, even though treatment 
recommendations between disease states are similar14.  
1.1.4. Treatment Modalities 
Standard treatment of MM differs depending on the risk classification of the patient, in conjunction 
with other factors such as age, disease stage and health status. Most common initial treatment regimens 
will include 4-6 rounds of a combination of current frontline therapies bortezomib, lenalidomide, 
dexamethasone and carfilzomib prior to an autologous stem cell transplant (depending on eligibility of 
the patient) followed by a period of maintenance therapy6 8 (Figure 1.1). However, the dosing regimens 
of these therapies often varies greatly to balance the toxicities of each therapy and treatment 
effectiveness. In addition, MM patients invariably relapse with the subsequent salvage treatment 




strategies employed dependent on treatment-related factors, such as prior response and resistance, 
patient risk stratification and other associated patient comorbidities26 27. Treatment of MM also often 









Figure 1.1: Treatment flow chart for newly diagnosed MM. Adapted from Eslick et al8.  
 
 




1.1.4.1. Proteasome Inhibitors 
Proteasome inhibitors (PIs) are the cornerstone of MM therapy with 3 agents, bortezomib, carfilzomib 
and ixazomib, currently approved for use by the FDA28. This class of drug targets the 26S proteasome, 
a critical complex of the ubiquitin-proteasome system which coordinates the regulation and degradation 
of intracellular proteins. This pathway is dysregulated in the MM PC and is responsible for the 
degradation of key tumour suppressors such as p53 and the NFĸβ inhibitor, IFĸβ, and the upregulation 
of pro-tumorigenic signaling factors such as TNF-α and IL-6, key cell adhesion molecules ICAM-1 and 
VCAM-1, and the proangiogenic signaling VEGF pathway28-30. Furthermore, MM PCs are particularly 
sensitive to 26S proteasome inhibition due to their excessive production of monoclonal 
immunoglobulins (paraprotein), whereby the accumulation of misfolded and unfolded proteins 
following proteasome inhibition induces a terminal unfolded protein response and apoptosis29. The 
primary dose limiting toxicity associated with use of PIs is peripheral neuropathy, however other side 
effects can include thrombocytopenia, neutropenia and gastrointestinal toxicities29.  
1.1.4.2. Immunomodulatory Drugs 
Immunomodulatory imide drugs (IMiDs) are a class of compounds that are analogs of the first 
generation thalidomide, with 3 compounds in this group currently approved for use in MM by the FDA, 
including thalidomide, lenalidomide and pomalidomide31. IMiDs have a wide range of biological 
activities that contribute to their anti-MM effect, including immune modulatory, anti-angiogenic, anti-
inflammatory and anti-proliferative effects32. The mechanism of action of IMiDs relies on binding of 
the drugs to the protein cereblon, a critical component that forms part of the CRL4 complex which has 
ubiquitin ligase activity. IMiDs primarily work by stabilizing cereblon, thereby inhibiting its own 
ubiquitination and promoting the degradation of cereblon target proteins, Ikaros and Aiolos31-33. MM 
patients have an increased risk of venous and thrombotic events and this can be exacerbated with the 
use of IMiDs32. Additionally, an increased rate of secondary primary malignancies has been reported 
following use of IMiDs32.  
1.1.4.3. Corticosteroids 
The addition of the glucocorticosteroids dexamethasone and prednisone to MM chemotherapeutic 
combinations has demonstrated significant increases in the overall survival rates of MM patients, 
especially those with refractory MM34. The primary mechanism of action for this class of drug relies on 
their binding to glucocorticoid receptors that translocate to the nucleus, leading to the transactivation 
and transrepression of target genes, resulting in inhibition of the key pro-MM signaling pathways, 
including NFĸβ and IL-634. There are significant toxicities associated with high-dose dexamethasone 
treatment that has led to their use at low dose. The main adverse events associated with these agents are 
muscular atrophy6.  




1.1.4.4. Alkylating Agents 
Alkylating agents melphalan and cyclophosphamide have been used in the treatment of MM for over 
50 years35 36. These therapeutic agents are non-specific DNA alkylating agents that primarily function 
through crosslinking DNA, whereby DNA synthesis and downstream transcription is inhibited, leading 
to cellular apoptosis15. Use of these therapeutics is particularly effective in the relapsed/refractory MM 
disease setting, as patients that have become refractory to proteasome inhibitors and IMiDs are often 
still sensitive to alkylating agents16. However, there are significant toxicities associated with their use, 
with the most severe adverse events in patients including grade 3/4 fever and neutropenia16.  
1.1.4.5. Monoclonal Antibodies 
In recent years, the emergence of several highly effective monoclonal antibody-based therapies that 
target MM PC cell surface proteins CD38 (Daratumumab and Isatuximab) and SLAMF7 (CS1; 
Elotuzumab) has contributed significantly to the MM treatment landscape. Daratumumab treatment has 
demonstrated significant effectiveness as a single agent37, and in just 8 years has progressed from 
preclinical testing38 39 and use in relapsed/refractory patients40 41 to exhibiting clinical benefit as a 
frontline therapy in improving overall depth of response and progression free survival for MM patients 
as part of the ongoing CASSIOPEIA trial 17. In contrast, Elotuzumab has failed to show clinical activity 
in MM as a single agent, but has demonstrated a significant reduction in risk of progression and death 
when used in combination with lenalidomide/dexamethasone and pomalidomide/dexamethasone as part 
of the ELOQUENT-218 and ELOQUENT-319 trials, respectively20. Overall, the use of monoclonal 
antibody-based therapies in MM has so far demonstrated a good safety profile, with primary adverse 
events, including as infusion-related events during drug administration and hematological toxicities, 
such as thrombocytopenia and neutropenia20.  
1.1.4.6. Emerging Treatments 
Targeting of B-cell maturation antigen (BCMA), a transmembrane glycoprotein expressed at high levels 
by PCs, has shown promise in pre-clinical45 and early clinical studies46 47. Early clinical success has 
been demonstrated for both chimeric antigen receptor (CAR) T-cell and antibody-drug conjugate 
BCMA-targeting strategies in relapsed/refractory MM patients, highlighting BCMA as a promising 
MM target antigen48 49. Furthermore, the B-cell lymphoma 2 (Bcl-2) inhibitor venetoclax has shown 
potential in clinical trials as a new therapeutic option for relapsed/refractory MM 21-23.  
1.1.5. Genetic Aetiology of MM  
1.1.5.1. Primary Genetic Events 
Plasma cells develop from haematopoietic stem cells, which undergo several rounds of differentiation 
in the bone marrow and peripheral lymphoid organs (PLOs) to B cells and eventually to PCs. It is in 
these PLOs where these PC first acquire primary, and potentially, secondary mutations and 




translocations, resulting in the initiation of MM disease53. The initiating events for the MM PC are 
thought to occur in the post-germinal centre B cell as it transitions to an antibody-producing PC. These 
primary disease “initiating” events, that occur within the PC, often involve one of two mutually 
exclusive cytogenetic abnormalities; hyperdiploidy (greater than 48 chromosomes) or translocations 
involving the IgH locus on chromosome 14 (14q32)54 55. These events occur at a similar frequency 
between MGUS and MM patients, indicating that these “initiating” events are necessary, but 
insufficient for disease progression56 57.  
During normal PC development, naïve B cells are exposed to their cognate antigens and subsequently 
undergo affinity maturation to produce highly specific functional antibodies as part of the adaptive 
immune response5. This process requires somatic hypermutation (SHM) of the hypervariable regions 
of the immunoglobulin heavy chain and class switch recombination (CSR)5. Both of these processes 
require the expression of activation induced deaminase (AID) and are mediated by the generation of 
double strand DNA breaks in the Ig loci. Unlike normal PCs, in MM PC this sometimes results in the 
aberrant translocations that lead to the juxtaposition of proto-oncogene(s) to the IgH enhancer on 
chromosome 145 58. The most common of these translocations in MM is t(11;14)(q13;q32)59 60. This 
translocation is responsible for the overexpression of the cyclinD1 (CCND1) gene and progression 
through the G1 phase of the cell cycle24. The second most common translocation observed in MM is 
t(4;14)(p15;q32), which leads to the overexpression of the histone methyltransferase gene nuclear 
receptor binding SET domain protein 2 (NSD2) (in 100% t(4;14) patients) and the  FGFR3 gene (in 
70% of t(4;14) patients) 62 63. The upregulation of a histone methyltransferase results in epigenetic 
reprogramming, and key expression changes in genes responsible for cellular adhesion, proliferation 
and survival63 64. Other common translocations t(14;16)(q32;q23) and t(14;20)(q32;q11) result in 
overexpression of oncogenic MAF transcription factors (MAF or MAFB), and subsequently cyclinD2 
(CCND2) and APOBEC cytidine deaminases that leads to an increased DNA mutation burden within 
the MM PC25. Approximately 40% of MM patients will have a primary translocation involving 
chromosome 14 and one of 5 partner chromosomes (4, 6, 11, 14 or 20)26 27.  
Hyperdiploidy is the primary disease-initiating event in ~55% of MM cases, associated with multiple 
trisomies in odd numbered chromosomes 3, 5, 7, 9, 11, 15, 19 and/or 215 65. The mechanism by which 
these trisomies occur remains unknown, but it has been suggested that they are gained through a single 
catastrophic event involving the missegregation of chromosomes during mitosis28. Similar to recurrent 
IgH translocations, hyperdiploidy also results in the upregulation of group D cyclins, specifically D1 
and D224. Therefore, deregulation of G1-S phase cell cycle transition appears to be an early unifying 
event that drives the development of MGUS, and subsequently MM.  
1.1.5.2. Secondary Genetic Events 




Copy number alterations, which are the gains or losses of genomic regions, are a common secondary 
event in MM. High frequency and recurrent copy number alterations are likely driver events for the 
pathogenesis of MM, and thus one or more of the genes within minimally affected regions may be 
important for MM disease development and progression5 65.  A recent study has demonstrated that loss 
of heterozygosity (LOH) greater than 4.6% across the genome was found to be associated with 
significantly poorer prognosis in MM patients29. This finding suggests that increased copy number 
alterations is associated with the disruption of tumour suppressor genes and hence promotes MM 
disease progression. Important regions of LOH include those associated with checkpoint regulation of 
G1/S phase transition, such as chromosome 1p32 (the site negative cell cycle regulators CDKN2C and 
CDKN2A), and negative regulators of the nuclear factor κ-light-chain-enhancer of activated B cells 
(NF-ĸβ) pathway, including chromosome 11q (the site of BIRC2 and BIRC3 genes), 16q (the site of 
CYCLD) and 14q32 (the site of TRAF)30-33. 
In addition to aneuploidy, translocations and copy number variants, MM PCs harbor a number of single 
nucleotide variants (SNVs) and insertion/deletion (in/del) mutations. Recently, a large-scale whole 
exome sequencing study of 1273 newly diagnosed MM patients by Walker et al., demonstrated a 
median of 5 driver mutations per MM PC sample, and that there was an association between an increase 
in the number of driver mutations and poor patient outcomes72.  Similar to other haematological 
malignancies, such as acute myeloid leukaemia, there are few recurrently mutated genes in MM, with 
a wide degree of inter-patient heterogeneity73 74.  While there are few mutated genes that are affected in 
greater than 10% of MM PC patients, there are a number of genes that have been identified as being 
recurrently mutated at a frequency of 5% or below65 72 74 75. These MM mutated driver genes cluster in 
particular pathways, suggesting that the dysregulation of pathways, rather than specific genes, is 
pathogenically important65 72.  This is demonstrated by the fact that approximately 50% of MM patients 
have an oncogenic mutation in a gene involved in the pro-proliferative MEK/ERK signalling pathway, 
including KRAS (~20% patients), NRAS (~20% patients) and BRAF (~7% patients)65 72 76. 
Furthermore, approximately 11% of MM patients have inactivating mutations in genes involved in the 
NF-ĸβ pro-survival pathway, including TRAF3 (~5%) and CYLD (~3%)5 72 74 76. FAM46C and DIS3 are 
also among the most frequently mutated genes, with 13% and 11% of patients displaying these 
mutations respectively, with the products of both of these genes being involved in RNA processing5 72 
76. 
MYC rearrangements are common secondary translocations present in the PCs of MM patients. 
Approximately 15% of newly diagnosed MM patients are found to have secondary translocations 
involving the MYC oncogene at 8q2477-79. MYC translocations and gains were found to be associated 
with poor prognosis and have been shown to be associated with significantly reduced PFS and OS of 
MM patients78 80 81. Further, the activation of MYC via the misdirection of AID is sufficient to drive 




MM PC development in a MGUS-prone mouse strain, demonstrating a clear role for MYC in MM 
disease development34.  
1.1.5.3. Progression from MGUS to MM 
Patients with MGUS and SMM have a risk of progression to MM of 1% and 10% per annum,  
respectively12 (Figure 1.2). The progression from the benign MGUS to symptomatic MM was 
previously thought to be driven by the acquisition of further genetic mutations, however recent studies 
have highlighted that in many instances, there is little change in the genetic landscape of the PC between 
the pre-malignant and malignant stages of disease83-85. This is evidenced by a whole exome sequencing 
study from our laboratory that analysed serial patient samples from MGUS, SMM and MM disease 
stages. In this study the subclonal malignant MM PC populations were found to be already present at 
the MGUS disease stage, suggesting the possibility that PC extrinsic mechanisms play a major role in 
disease progression83. The is further highlighted by Das et al. who demonstrated that when stable 
patient-derived MGUS cells were transplanted into immunodeficient, humanized mouse models, these 
PC cells were capable of developing progressive symptomatic disease86. This supports the notion that 
the MM PC clone/s is already present at the pre-malignant MGUS disease stage and that outside the 
constraints of the human immune system, is capable of developing disease without acquiring further 
genetic “hits”. Together these studies demonstrate the importance of extrinsic control of tumour growth.  
  
Figure 1.2: MM disease progression. MM disease initiating events are thought to occur in the post-
germinal centre (GC) B cell. The mature, differentiated PCs home to and colonize the bone marrow 
(BM). Within the BM microenvironment, extrinsic factors contribute to the progression of the pre-
malignant MGUS PC and SMM PC to the symptomatic, malignant MM PC and end-stage leukemic PC 
that is no longer reliant on the support of the BM microenvironment. Image modified from Morgan et 
al5. 




1.2. The BM microenvironment in MM 
Similar to their normal counterparts, MM PCs migrate to CXCL12-rich regions within the bone marrow 
where they adhere to extracellular matrix proteins, BM stromal cells and other juxtaposed cells35 36. It 
is well established that MM PCs are reliant on the tumour microenvironment for continued growth and 
survival, and as a consequence are difficult to maintain outside of this environment, suggesting the 
presence of BM microenvironment-derived factors that support MM PC growth37 38. Furthermore, a 
study in our laboratory by Hewett et al. whereby genetically identical mouse MM PC were tagged with 
unique identifying barcodes demonstrated that MM PC clones exhibit vastly different fates depending 
on where they “land” within the BM, highlighting the importance of extrinsic selection pressures on 
MM disease course39. Additionally, Lawson et al. demonstrated that the cellular make-up of the 
endosteal niche within the BM determined the proliferative state of MM PC, with MM PC in contact 
with osteoblast and bone-lining cells exhibiting a dormant, non-proliferative phenotype, while MM PC 
interaction with osteoclasts promotes active proliferation40. This finding further demonstrates that MM 
disease progression relies, at least in part, on extrinsic signals from the tumour microenvironment. The 
importance of the bone marrow tumour microenvironment in driving cancer progression has also been 
highlighted by a study by Kode, et al., that revealed that an activating mutation of β-catenin in mouse 
osteoblasts (a component of the BM microenvironment) was sufficient to alter the differentiation 
potential of haematopoietic stem cells (HSC) and promotes the development of acute myeloid 
leukaemia41.  
The BM provides a unique environment that consists of a compilation of accessory cells, including 
osteoblasts, osteoclasts, mesenchymal stem cells (MSC), endothelial cells, haematopoietic stem cells, 
as well as trophic factors such as chemokines and cytokines42-45. The CXCL12/CXCR4 signaling axis 
works to attract circulating tumour cells where contact with the milieu of cells within the bone marrow 
initiates further signaling pathways35 45 46. However, much remains to be elucidated in order to fully 
understand the fundamental disease biology which underpins these cell-cell signaling mechanisms that 
initiate and sustain MM.  
 







Figure 1.3: Interaction of MM PCs with other cell types in their BM niche. MM PC interacts with 
cellular and non-cellular components of the BM. Solid arrows indicate secretion and/or effect on target 
cell. Key cell types, signaling cascades and transmembrane proteins are represented. CAF, cancer-
associated fibroblast; CD138, cluster of differentiation 138 (Syndecan-1); CXCL12, chemokine (C-X-
C motif) ligand 12; ECM, extracellular matrix; ICAM-1, intercellular adhesion molecule 1; IGF-1, 
insulin like growth factor-1; IL-1β, interleukin 1β; IL-6, interleukin-6; MDSC, myeloid-derived 
suppressor cell; MM PC, myeloma plasma cell; MSC, mesenchymal stem cell; NK cell, natural killer 
cell; OPG, osteoprotegrin; PD-1, programmed cell death 1; PD-L1, programmed ligand death 1; TNFα, 
tumour necrosis factor α; VCAM-1, vascular cell adhesion molecule 1; VEGF-A, vascular endothelial 
growth factor-A. Adapted from Bianchi and Munshi47. 
1.2.1. BM stromal cells 
BM stromal cells (BMSC) are progenitors of skeletal tissue components such as bone, cartilage and 
adipocytes48. Within the MM BM microenvironment there is an increase in the number of STRO-1+ 
mesenchymal stromal cells, and subsequently an increase in BMSC signaling49. The expression of the 
chemoattractant CXCL12 by BMSC plays a critical role in the homing and retention of MM PCs to the 
BM via the CXCR4/CXCL12 signaling axis49. Furthermore, the adherence of MM PC to BMSC triggers 
changes in signaling that optimizes the BM environment for MM growth49. These MM PC-BMSC 
interactions trigger stromal NF-ĸβ and interleukin-6 (IL-6) signaling that in turn promotes the 
expression of VEGF by MM PCs, promoting increased angiogenesis; a hallmark of MM progression49-
51. In addition, the BMSC population expresses receptor activator of NK-ĸβ ligand (RANKL), a factor 
that activates osteoclasts: a cell population that further works to support MM PC growth. The interaction 
of MM PC and BMSC stromal cells is also responsible for the upregulation of Notch signaling, whereby 




the interaction of Notch ligands on both MM PC and the BMSC population activates downstream IL-
6, VEGF and IGF-1 signaling pathways that are associated with MM PC proliferation and survival52 53. 
Moreover, compared to normal BMSCs, MM BMSCs have increased expression of a range of other 
cytokines, including interleukin-1beta (IL-1β), tumour necrosis factor alpha (TNF-α), interleukin-10 
(IL-10), B-cell activating factor of the TNF family (BAFF) and hepatocyte growth factor (HGF), that 
can induce osteoclast stimulation, angiogenesis and MM PC adhesion, proliferation and migration54-56. 
The differences in the cytokine profile of normal BMSCs and MM patient-derived BMSCs highlights 
that the reciprocal interaction between MM PC and BMSC works to optimize the BM for MM PC 
growth and survival54. Importantly, BMSCs also play an important role in protecting MM PCs from 
drug-induced apoptosis via modulation of numerous survival signaling pathways, such as NF-ĸβ, MUC-
1 and microRNA-15a57-60.  
1.2.2. Osteoclasts 
A balance between bone resorption and new formation is usually maintained in normal bone 
homeostasis, balanced by the actions of the bone-resorbing osteoclast cells and the bone forming-
osteoblasts. However, in MM this balance is often lost, resulting in the common diagnostic feature of 
osteolytic bone lesions. The increased osteoclast activity often observed in MM is prompted by the 
increased expression of osteoclast activation factors such as, RANKL, MIP-1a, IL-3 and IL-6, resulting 
from the interactions of MM PC with BMSC49 61. In particular, the RANKL expressed on the surface of 
MSCs and osteoblasts within the BM microenvironment interacts with RANK on the surface of 
osteoclast precursors to stimulate their differentiation to osteoclasts. This is a key contributor to the 
increase in the number of osteoclasts within the MM tumour microenvironment (Figure 1.4)62. 
Osteoclasts produce the MM PC stimulating factors, osteopontin and IL-6, which supports the 
continued growth and survival of the malignant tumour cell population63. Moreover, the bidirectional 
signaling between the MM PC and osteoclasts promotes an immune suppressive microenvironment via 
the inhibition of proliferating CD4+ and CD8+ T cells, mediated in part by the upregulation of a 
proliferation-induced ligand (APRIL) by osteoclasts and programmed cell death ligand-1 (PD-L1) on 
the surface of MM PC, thereby allowing MM PCs to evade immune targeting64 65.  Supporting the pro-
tumorigenic role for osteoclasts in MM is a study by Yaccoby et al. that demonstrated that the inhibition 
of osteoclasts in SCID-hu mice with zoledronate or pamidronate resulted in a significant reduction in 
MM PC growth and MM-induced bone resorption, highlighting the importance of the osteoclasts in 
MM disease progression66. Conversely, an increase in the number and activity of osteoclasts within the 
BM has been shown to reactivate dormant cells within the endosteal niche, allowing them to further 
contribute to disease progression and/or relapse40. Furthermore, primary MM PCs, which are known for 
being highly dependent on the BM microenvironment and difficult to sustain in vitro, were shown to 
have significantly increased proliferation and survival when cultured in the presence of osteoclasts 
when compared to when cultured alone63.  





The number of bone-forming osteoblasts within the MM BM microenvironment is significantly reduced 
compared to healthy BM49. The reduction in osteoblast number can be attributed to a decrease in 
osteogenic differentiation of MSCs within the MM BM microenvironment (Figure 1.4). Studies by 
Oshima et al., and Giuliani et al., have demonstrated that this skew in the differentiation of MSCs is 
driven by the MM PCs themselves, with MSCs cultured with either human myeloma cell lines or  
conditioned media from human myeloma cells showing a decrease in osteogenic differentiation67 68. 
Osteoblasts are suppressed as a result of Dickopf-1 (DKK1), soluble frizzled related protein (sFRP), 
IL-17 and IL-3 expression from MM PCs. The decrease in active osteoblast function contributes to the 
osteolytic bone disease commonly observed in MM patients49 69. Moreover, osteoblasts have been 
demonstrated to suppress proliferation and maintain the dormancy of MM PC, hence a reduction in 
osteoblast number within the BM microenvironment during MM disease would serve to support the 
continued growth of the malignant PC40 70. Conversely, some studies have demonstrated that osteoblasts 
may support MM PC growth, as co-culture of MM PCs with primary human osteoblasts promotes a 
significant increase in osteoblast IL-6 production which in turn supports the growth of MM PC71. 
However, given the number of other cellular sources of IL-6 within the BM, coupled with the decreased 
number of osteoblasts in MM, osteoblasts are unlikely to be a major supportive factor within the MM 
BM niche.  
1.2.4. Macrophages 
Macrophages are a component of the immune system that are derived from the mononuclear phagocytic 
lineage found in most adult tissues. Infiltrating macrophages can be classified based on their 
polarization as M1 or M2 macrophages. M1-type macrophages are classically activated by interferon-
γ and toll-like receptor ligands and play a role in anti-tumour immunity, while M2-type macrophages 
are activated by IL-4 and IL-13 and have been shown to promote tumour growth and progression72. To 
this end, MM PC have been shown to recruit tumour-supportive macrophages through the 
CXCR4/CXCL12 signaling axis and promote their polarization toward a M2 phenotype73. Furthermore, 
a study by Chen et al. demonstrated that a higher proportion of M2 macrophages within the BM of MM 
patients is an independent prognostic factor, with worse progression-free and overall survival 
observed74. Moreover, macrophages have been shown to play an essential role in MM disease 
establishment and progression, with an increase in the number of BM-associated macrophages in MM 
compared to MGUS a marker of poor prognosis75-77. In addition, recent studies by our laboratory have 
demonstrated that depleting macrophages with clodronate liposomes in a mouse model of MM 
significantly reduces MM disease establishment and progression, with a decrease in MM PC BM 
homing and retention also observed75. Like osteoclasts, macrophages are well-documented to protect 
MM PCs from drug-induced apoptosis, conferring drug resistance78-80.  Furthermore, macrophages are 




a rich source of pro-angiogenic cytokines that support MM PC growth, and interestingly81, also 
contribute to the MM blood vessel network via “vasculogenic mimicry”82. 
 
 
Figure 1.4: Osteoblast and osteoclast differentiation in the MM BM niche. MM PC alter the 
differentiation potential of MSC and HSC within the BM microenvironment of MM to favour 

















1.2.5. MM and OCR-SC Gremlin1+ expressing skeletal stem cells 
While the exact composition of the BM microenvironment remains unknown, MM PCs are thought to 
colonize areas that normally support HSC self-renewal and multi-lineage differentiation.89 The HSC 
niche is characterised by the presence of cells and signals which are conducive to the growth and 
development of HSCs, derived in large part, from skeletal or mesenchymal stem cells (MSC).131 132 
Currently there are two recognised populations of skeletal stem cells; the perisinusoidal MSC (PS-
MSC) and the osteochondroreticular stem cells (OCR-SC).133 134 Unlike traditional MSCs, the recently 
described OCR-SC (Figure 1.4A) are localised to regions of the BM that are common sites of MM PC 
metastasis (Figure 1.4B). The OCR-SCs are characterised by their expression of Gremlin1 (Grem1), a 
member of the Dan family of secreted, glycosylated proteins which contain a cysteine knot domain 
shared by the TGF-beta superfamily. 83 
Figure 1.4: Anatomical location of OCR-SC coincides with MM PC growth in the BM. (A) Grem1+ 
OCR-SC (red) line the bone surface in proximity to osteoblasts (OB, green). Modified from Worthley 
et al. 83(B) IHC visualization of actively growing CD138+ MM PC colonies adjacent to the endocortical 
and peritrabecular surfaces of bone. Single “quiescent” MM PC (arrows) are present throughout the 
BM (CB= cortical bone; GP= growth plate; TP= tibial plateau). Modified from Lawson et al.40  
1.3. Grem1  
Grem1 (also known as DRM) is a 184 amino acid protein with primary roles as a  bone morphogenic 
protein (BMP) antagonist (Figure 1.5A), and vascular endothelial growth factor receptor 2 (VEGFR2) 
agonist (Figure 1.5B)135 136. Grem1 exists in both secreted and membrane-bound forms84. 
In normal cellular function, Grem1 is essential for early limb-bud development and organogenesis 
during the early stages of development.137 However, Grem1 has also been identified as one of the most 
highly expressed genes in the tumour microenvironment, and has been implicated in a broad range of 
malignancies.138-141 The role of Grem1 in malignant tissue appears to be complex and is likely mediated 
by a range of interactions with its various binding partners, which include; BMP-2, BMP-4 and BMP-
7, VEGFR2, YWHAH, Slit1 and Slit2.135 142-145  
 














Figure 1.5: Grem1 signaling pathways. (A) Grem1 dimers bind to bone morphogenetic protein 
(BMP) dimers and prevent engagement of BMP receptors, preventing BMP signaling and gene 
expression. (B) Grem1 binds to vascular endothelial growth factor receptor 2 (VEGFR2) and promotes 
downstream angiogenic signaling. Heparin sulphate proteoglycans (HSPGs) and αvβ3 integrin are 
required for this response. (C) Grem1 has been shown to promote cancer cell invasion and proliferation 
via an unidentified mechanism, that is independent of BMP and VEGFR2 signaling. Adapted from 
Brazil et al146. 
1.3.1. Grem1 in early development and homeostasis 
In early stages of development Grem1 is essential in relaying fibroblast growth factor (FGF)-sonic 
hedgehog (SHH) signaling throughout the limb-bud axis, as well as blocking BMP-mediated cell death 
of core mesenchymal cells.137 Early organ patterning is also reliant on Grem1 signaling147. The 
importance of Grem1 can be demonstrated by the fact that loss of Grem1 in the early stages of 
development is largely embryonically lethal148.  
While Grem1 is highly expressed in the early stages of growth, it has a more restricted expression in 
adult tissues, with expression primarily playing a regulatory role in maintaining tissue homeostasis. One 
such role is in bone regeneration and maintenance, which aligns with its known role in BMP 
antagonism. Additionally, Grem1 also identifies a population of intestinal stem cells (intestinal reticular 
stem cells) and plays a key role in maintaining the intestinal crypt stem cell niche. 134 
In a study by Laurila, et al., that aimed to identify expression of BMP antagonists in normal adult tissue, 
Grem1 was found to have negative or weak expression in 76% of the surveyed tissue sites or organs, 
with moderate expression observed in the bone marrow and stomach, and strong, but variable, 
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expression noted in Leydig cells within the testis, lung pneumocytes and all cell types of the nephron 
within the kidney. Only the Leydig cells showed consistently strong Grem1 expression in adult 
tissues149.  
1.3.2. Grem1 and Cancer 
While Grem1 is widely expressed in the early stages of growth, signaling throughout adult tissue is 
largely conserved and restricted primarily to stem cell maintenance and various homeostatic 
functions137. However, in malignant disease, Grem1 has been shown to be one of the most 
overexpressed genes within the tumour microenvironment and is implicated in a range of malignancies, 
with elevated mRNA levels detected in carcinomas of the lung, ovary, kidney, breast, colon and 
pancreas 138 144. The role that Grem1 plays in promoting cancer appears complex and is likely mediated 
by a range of interactions with its various binding partners.  
1.3.2.1. Grem1 promotes tumour cell proliferation 
In colon cancer, Grem1 is reported to act in a largely BMP-dependent manner. Davis, et al., recently 
reported that a genetic duplication of the Grem1 gene in hereditary mixed polyposis syndrome (HMPS) 
resulted in colonic tumourigenesis due to disruption of BMP signaling140. BMP signaling in this setting 
is essential for promoting stem cell differentiation along the colon crypt-villus axis via downstream 
activation of Smads-1/5/9 and allowing the development of post-mitotic specialized cell populations. 
Moreover, the overexpression of Grem1 within the epithelial cells of the colonic crypts was shown to 
disrupt the delicate homeostatic balance of morphogen gradients that maintain the crypt stem cell niche, 
allowing cells to maintain/reacquire a stem cell phenotype, and promote intestinal tumorigenesis140.  In 
malignant mesothelioma, Grem1 is also suggested to promote tumour cell proliferation via BMP 
inhibition150.  
The BMP-dependent roles of Grem1 in cancer provide a potential explanation for the disparity in 
tumour-suppressive and tumour-proliferative roles observed for this protein. While BMP signaling is 
reported to be involved in numerous malignancies, its actions still remain controversial with both 
oncogenic and apoptotic mechanisms reported85 86. This is also true for Grem1, with inhibitory growth 
effects observed in several settings, including in pancreatic neuroendocrine tumours151 152. Like BMP-
signaling, it appears Grem1 may function in a cell-type dependent manner, at least when acting via 
BMP-dependent mechanisms87-89.  
Conversely, Grem1 has also been demonstrated to promote tumour cell proliferation via BMP-
independent mechanisms. For instance, in lung adenocarcinoma, antibody-mediated inhibition of 
Grem1 has been demonstrated to inhibit Grem1-driven tumour growth, despite the fact that the antibody 
did not prevent Grem1 interaction with, or antagonism, of BMP-2, -4 or -7153. Similarly, a study by 
Mulvihill, et al., showed that Grem1-overexpression could promote cancer cell growth, regardless of 




the addition of high concentrations of recombinant BMP protein, suggesting a BMP-independent 
mechanism was responsible for the pro-proliferative role of Grem1139. However, the alternative 
signaling pathways altered by Grem1 have yet to be identified (Figure 1.5C)139 153. Several studies have 
proposed other Grem1 interactions as reasons for its pro-proliferative role, including binding with 14-
3-3 eta (YWHAH) protein, a highly conserved regulatory molecule involved in stabilization of proteins 
in active or inactive states, as well as upregulation of pro-survival pAkt signaling 144 154.  
1.3.2.2. Grem1 promotes angiogenesis 
In keeping with its angiogenic role as a VEGFR2 agonist, Grem1 has been linked to proangiogenic 
functions in cancer. An analysis of human pituitary adenoma patient samples identified a significant 
correlation between Grem1 expression by microarray and CD34 expression (a HSC and endothelial cell 
marker expressed extensively by blood vessels) by immunohistochemistry (IHC)155. Furthermore, 
Grem1 was also shown to be significantly correlated with microvessel density (MVD), determined by 
CD34 positivity in histological slides, in human pancreatic neuroendocrine tumours, whereby 73.3% of 
patients exhibiting high levels of Grem1, also showed high MVD156. In this study, increased Grem1 and 
MVD in patients demonstrated a survival benefit with longer progression-free survival. Notably, 
pancreatic neuroendocrine tumours are unlike most other cancers, as increased MVD has been 
associated with poor outcomes in several malignancies, including multiple myeloma157-159.  
1.3.2.3. Grem1 increases tumour cell migration, invasion and disease spread 
In early development, the expression of Grem1 is essential in initiating the epithelial-mesenchymal 
transition (EMT) signaling required for limb and organ development147. EMT is also an hallmark of 
cancer progression, as cells acquire a less differentiated phenotype that promotes cell migration and 
invasion160. Similarly, aberrant expression of Grem1 has been associated with promoting an EMT 
phenotype in many disease settings, including colorectal cancer, malignant mesothelioma, lung cancer 
and chronic kidney disease, and Grem1 induces tumour cell migration and invasion 141 153 161-163. This is 
highlighted by a study by Karagiannis, et al., that demonstrated that colonic fibroblasts, within the 
tumour supportive microenvironment, overexpress Grem1 and promote the loss of cancer cell 
differentiation via acquisition of prominent markers of epithelial-mesenchymal transition (EMT), 
Vimentin and Snail1141 162. While Grem1 has been reported to promote upregulation of mesenchymal 
proteins such as slug, N-cadherin and alpha-smooth muscle actin, and downregulation of epithelial 
marker E-cadherin in lung cancer and mesothelioma, no mechanism as to how Grem1 regulates these 
EMT-associated proteins has been reported 153 161. Studies of fibrosis suggest that Grem1 may induce 
an EMT via inhibition of BMP-7, in combination with TGF-β and Smad signaling. Whether the same 
mechanism underlies Grem1 stimulation of EMT in cancer remains to be confirmed164 165. Furthermore, 
a large-scale protein interaction screen by Tamminen, et al., demonstrated that Grem1 protein interacts 
with microfibrillar proteins fibrillin-1 and -2. Given that fibrillins have been demonstrated to sequester 




BMP proteins into extracellular matrix structures, this interaction may, in turn, aid in extracellular 
localization of the Grem1 protein and its interactions with BMP isoforms90. Additionally, Grem1 
expression in cancer-associated fibroblasts within breast cancers has been demonstrated to have a 
positive correlation with markers of tumour matrix stiffness, including fibrillin-1, and promote cancer 
cell invasion in zebrafish xenograft models91.  
1.3.3. A role for Grem1 in MM 
Given the co-localisation of the Grem1-expressing OCR-SC population and MM PCs within the 
endosteal niche of BM, an investigation of the role of Grem1 in MM disease is warranted. In addition, 
the mechanisms by which Grem1 has been shown to promote cancer cell growth and disease progression 
in other malignancies closely align to many pathways, well-known to contribute to MM disease 
pathogenesis. The key Grem1 targets BMP-2, -4 and -7 are known to inhibit MM PC proliferation and 
promote apoptosis due to the Smad-dependent repression of key MM mitogen MYC167-169. Furthermore, 
the interaction of Grem1 and VEGFR2 has been shown to have pro-angiogenic functions and increase 
MVD in disease. In keeping with this, high  MVD and increased angiogenic signaling in MM has been 
shown to be an independent factor of poor prognostic factor for MM patients170. Finally, Grem1 has 
been shown to promote the acquisition of an EMT phenotype in cancer cells and promote cancer cells 
invasion and migration141 164 171. MM PC are highly migratory, with multiple MM PC tumours found at 
different skeletal sites at the time of diagnosis11 172. Furthermore, recent studies have demonstrated that 
an EMT-like process may be activated in MM PCs and is associated with a more aggressive and 
migratory phenotype98 173 174. As a disease that is currently incurable, and with poor patient outcomes, 
new therapeutic options are greatly needed in MM, with Grem1 an ideal candidate for further 
investigation.   
1.4. Significance 
MM is a fatal malignancy, which despite recent advances in therapy, has a 10-year survival rate of only 
18%92. In MM disease, the BM microenvironment plays a critical role in MM PC migration, 
proliferation, survival and drug resistance. While recent studies have highlighted the role of the tumour 
microenvironment as a driving force in disease development, to date, the nature and cellular 
composition of the BM tumour microenvironment and the critical factors which drive tumour 
progression remain imprecisely defined. 
Preliminary studies from our laboratory suggest that the recently described OCR-SC are a critical 
component of the “activating niche” within the BM. OCR-SC are concentrated in regions commonly 
associated with MM PC growth and, additionally, these skeletal stem cells are characterised by the 
expression of Grem1, a protein which has been implicated in other cancers including mesothelioma161 
175, pancreatic neuroendocrine tumours156 176, mammary144 177, cervical144 178 and kidney93 tumours and 




sarcoma94. In the context of MM, the Grem1+ OCR-SC population represents a key component of the 
BM microenvironment that may act to promote MM PC disease progression, and Grem1 may represent 
a potential therapeutic target in MM.  
While Grem1 is highly overexpressed in a number of tumour microenvironments, until now, there 
has been little evidence to suggest it plays a role in MM. However, the recent identification of the 
Grem1 expressing OCR-SC population in the bone marrow, and the proximity of these skeletal 
stem cells to sites of MM PC growth raises many questions as to the involvement of Grem1 in 
MM pathogenesis.  
 
1.5. Hypothesis 
Grem1 plays an essential role in promoting MM PC colonization and growth within the bone marrow. 
Furthermore, MM PC stimulate an increase in stromal expression of Grem1, which in turn, promotes 
an increase in MM PC proliferation and disease progression. 
1.6. Aims 
The project aims to: 
(1) Determine whether there is an association between Grem1 expression and MM in vitro and in 
vivo. 
(2) Determine the effects of Grem1 on human and murine MM PC proliferation in vitro.  
(3) Determine the dependency of MM disease development and progression in vivo on Grem1 









































2.1. Molecular Biology 
2.1.1. RNA Techniques 
2.1.1.1.  RNA Isolation 
Total RNA was isolated from purified primary mouse CD138+ PCs using the All Prep DNA/RNA 
Micro Kit (QIAGEN). For isolating total RNA from cell lines, 5-10 x 106 cells were lysed in 1 mL of 
TRIzolTM Reagent (Invitrogen) and 0.2 mL of chloroform was added. Following vigorous shaking and 
a 3-minute incubation, the mixture was centrifuged at 12,000 x g and 4°C for 5 minutes, and the aqueous 
phase was collected. RNA was precipitated by adding 0.5 mL of isopropanol and 2 μL (20µg) of 
ribonuclease-free glycogen (Roche) and incubating at room temperature for 10 minutes. The RNA was 
pelleted by centrifugation at 12,000 x g and 4°C for 15 minutes and then washed with 75% (v/v) ethanol. 
The RNA was resuspended in UltraPureTM DNase/RNase-Free Distilled Water (nucleasefree (NF) 
water; Invitrogen) and incubated at 60°C for 10 minutes to facilitate solubilisation. The concentration 
of RNA in solution was determined by measuring the absorbance at 260 nm on a NanoDropTM 8000 
Spectrophotometer (Thermo Fisher Scientific). RNA was stored at -80°C. For isolating total RNA from 
collagenase treated mouse bone combined with remaining bone fragments, the cell pellet and bone chips 
were lysed in 1mL of TRIzol Reagent on ice for 15mins. Chloroform phase separation and downstream 
extraction was performed as previously described.  
2.1.1.2. RNA DNase Treatment 
RNA underwent DNase treatment with RQ1 DNase prior to cDNA manufacture using SuperScriptTM 
IV (Invitrogen) as per manufacturer’s instructions.  
2.1.1.3.  Reverse Transcription polymerase chain reaction 
To qualitatively assess messenger RNA (mRNA) levels, reverse transcription polymerase chain reaction 
(RT-PCR) was performed. Firstly, total RNA (1 μg) was reverse transcribed into single-stranded 
complementary DNA (cDNA) using SuperScriptTM IV Reverse Transcriptase (Invitrogen). The RNA 
sample was resuspended in a total volume of 11 μL with NF water, and 1 μL each of random hexamers 
(50μM), oligo(dT) (50μM) and deoxyribonucleotide triphosphate (dNTP) mix (10 mM) were added. 
The solution was incubated at 65°C for 5 minutes and immediately chilled on ice for at least 2 minutes. 
A mix containing 5 μL of 5x RT buffer, 1 μL of 0.1 M DTT and 1 μL of SuperScriptTM IV enzyme (200 
U) was then added to the denatured RNA. This reaction mixture was incubated for 10 minutes at 23°C, 
10 minutes at 55°C and 10 minutes at 80°C. It was then diluted to a total volume of 0.1 mL with NF 
water and either used immediately for downstream applications or stored at –20°C. Negative control 
minus reverse transcriptase reactions were performed concurrently for all samples.   





 PCR was then performed using AmpliTaq GoldTM DNA Polymerase (Thermo Fisher Scientific), with 
each 25 µL reaction containing 2 μL of cDNA, 0.2 mM dNTPs, 1.5 mM MgCl2, 0.5 µM forward primer, 
0.5 µM reverse primer, 1x PCR Buffer II and 1.25 U DNA polymerase in NF water. No template control 
(NTC) reactions were performed for each target gene. Reactions were performed on a VeritiTM Thermal 
Cycler (Thermo Fisher Scientific) using the following cycling parameters: 95°C for 10 minutes; 35 
cycles of 95°C for 15 seconds, 55°C for 30 seconds and 72°C for 1 minute; and 72°C for 5 minutes. 
The PCR products were then visualised by agarose gel electrophoresis. A gel was cast containing 2 % 
(w/v) agarose in TAE buffer (40 mM Tris base, 20 mM acetic acid and 1 mM ethylenediamine 
tetraacetic acid (EDTA)) and 1:10,000 GelRed® (Biotium) for DNA visualisation. The PCR products 
(10 µL) were mixed with 6x Gel Loading Dye (New England BioLabs), loaded into the gel, resolved 
by electrophoresis and visualised using a Gel DocTM XR+ Imager (Bio-Rad). 
2.1.1.4. Quantitative polymerase chain reaction 
To quantitatively assess mRNA levels, quantitative reverse transcription polymerase chain reaction 
(RT-qPCR) was performed. Firstly, RT of total RNA was performed as described in section 2.1.1.3. 
Secondly, qPCR was performed, with each 15 μL reaction containing 2 μL of cDNA, 1x RT2 SYBR® 
Green qPCR Mastermix (QIAGEN), 0.5 μM forward primer and 0.5 μM reverse primer in NF water. 
Primer sequences are listed in Table 2.1. All cDNA samples were analysed in triplicate, and minus 
reverse transcriptase and NTC reactions were included for each sample and target gene, respectively. 
Reactions were performed on the CFX ConnectTM Real-Time PCR Detection System (Bio-Rad) using 
the following cycling parameters: 50°C for 2 minutes; 95°C for 15 minutes; 40 cycles of 95°C for 15 
seconds, 60°C for 25 seconds and 72°C for 10 seconds; and 72°C for 3 minutes. A melt curve was then 
performed in which there was an incremental increase of 0.5°C/5 seconds from 65°C to 95°C. Standard 
curves were generated to determine the reaction efficiency of each primer pair. Normalisation and 














Table 2.1: Primer Sequences for PCR 
Gene Primer Sequence 
Human GREM1 forward 5’- AGGCCCAGCACAATGACTCAG-3’ 
reverse 5’- GTCTCGCTTCAGGTATTTGCG-3’ 
Murine Grem1 forward 5’-GCGCAAGTATCTGAAGCGAG-3’ 
reverse 5’-CGGTTGATGATAGTGCGGCT-3’ 
Human IL-6 forward 5’-CCAGTACCAATGCGTCATCCA-3’  
reverse 5’-CTGGGCTCTGCTATCCAAGGAG-3’ 
Murine Il-6 forward 5’-GCACTCCTTGGATAGAGCCC-3’ 
reverse 5’- ACGAGGATTCTTGCACTGGG-3’ 
Murine/human  
Β-Actin/β-ACTIN 
forward 5’- GATCATTGCTCCTCCTGAGC-3’ 
reverse 5’-GTCATAGTCCGCCTAGAAGCAT-3’ 
Grem1-floxed genotyping 
mouse loxP site 
forward 5’-TGGCAGAAAGAATGATACCAGCC-3’ 
reverse 5’- ACAGGTCACACAGTGAATTTGC- 3 
Cre recombinase forward 5’-TGTAGCTGATGATCCGAATA-3’ 
reverse 5’-GCTTGCATGATCTCCGGTAT-3’ 
 
2.1.2. DNA Techniques 
2.1.2.1. Restriction Enzyme Digest 
Restriction digests of DNA were routinely performed by digesting 1 μg of DNA with 10 U of restriction 
enzyme (New England BioLabs) in the supplied digestion buffer and in a total reaction volume of 50 
μL. The reaction was incubated at the optimum temperature for 1 hour. The restriction enzyme was then 
inactivated by heat, where applicable, or the products were immediately resolved by agarose gel 
electrophoresis, as described in section 2.1.1.3, and gel purified using the UltraClean® DNA Purification 
Kit (MO BIO Laboratories), according to the manufacturer’s instructions.  
2.1.2.2. Ligation 
Ligations were routinely carried out in a total volume of 10 µL containing insert and vector DNA (3:1 
molar ratio), 1x T4 DNA Ligase Reaction Buffer and 1 µL (400 U) of T4 DNA ligase (New England 
BioLabs). The ligation reaction mix was incubated at 4°C overnight. A negative control reaction 
containing no insert was also performed to assess the levels of vector re-ligation. 
 
 





2.1.2.3. JM109 E.coli 
Frozen Escherichia coli JM109 cells were streaked onto a LB agar plate, made using Difco LB Broth 
Lennox and BactoTM Agar (BD Biosciences), and incubated at 37°C overnight. A single colony was 
inoculated into 10 mL of LB broth and grown in a 37°C shaking incubator overnight. This starter culture 
was used to inoculate 200 mL of LB broth and was grown in a 37°C shaking incubator until the culture 
reached OD600 = 0.6. The bacteria were incubated on ice for 30 minutes, then pelleted at 3,000 x g and 
4°C for 5 minutes. The cell pellet was resuspended in 25 mL of ice-cold 0.1 M MgCl2 and pelleted 
again. The bacteria were resuspended in 8 mL of ice-cold 0.1 M CaCl2 and 15% (v/v) glycerol. Aliquots 
(0.1 mL) of the competent E. coli JM109 cells were snap frozen on dry ice prior to being stored at -
80°C. 
2.1.2.4. Transformation 
One frozen aliquot of chemically competent E. coli JM109 cells per ligation was incubated on ice for 5 
minutes. The ligation reaction was added to the bacteria, mixed gently and incubated on ice for 30 
minutes. The cells were then heat-shocked at 42°C for 90 seconds and placed back on ice for 5 minutes. 
LB broth (0.2 mL) was added to the cells and incubated for 30 minutes in a 37°C shaking incubator. 
The cells were then spread onto a LB agar plate containing 100 μg/mL ampicillin (Sigma-Aldrich) and 
incubated at 37°C overnight. Transformed colonies were picked and used to inoculate LB broth for 
subsequent plasmid purification.  
 2.1.2.5. Purification of plasmid DNA from bacteria 
For small-scale plasmid DNA extractions from bacteria, buffers P1, P2 and P3 (QIAGEN) were used 
to perform alkaline lysis-based mini-preps, according to the manufacturer’s instructions. For medium-
scale plasmid DNA extractions from bacteria, the PureLinkTM HiPure Plasmid Filter Midiprep Kit 
(Invitrogen) and PureLinkTM HiPure Precipitator Modules (Invitrogen) were used to perform midi-
preps, according to the manufacturer’s instructions. 
2.1.2.6. Sanger Sequencing 
Plasmids/linear DNA fragments and appropriate primers were provided to the Australian Genome 
Research Facility (AGRF), which undertook the Sanger sequencing reactions and generated sequencing 
chromatograms. Analysis of the sequencing data was performed using the publicly available 
chromatogram viewer Chromas v2.6.2 (Technelysium) and the multiple sequence alignment tool 
ClustalX v2.1 (Science Foundation Ireland).   
2.1.2.7. Generation of Grem1-overexpression vector 
The murine cDNA for the Grem1 exon 2 coding sequence was isolated from a pCMV6-KR-Grem1 
vector kindly provided by Dr. Miao Yang, Gastrointestinal Cancer Biology Group, SAHMRI. The 





murine Grem1 sequence was excised by EcoRI and NotI restriction enzyme digest and subcloned into 
the pLeGoiT2 plasmid construct (Addgene, Massachusetts, USA2), as previously described 3.  
2.1.3. Protein Techniques 
2.1.3.1 Lysate Isolation 
Cells were washed in ice-cold 1x phosphate buffered saline (PBS, Sigma-Aldrich) and then resuspended 
in an appropriate volume of radioimmunoprecipitation assay (RIPA) buffer (1% NP-40 (v/v), 20 mM 
HEPES, 150 mM NaCl, 10% glycerol (v/v), 2 mM Na3VO4, 10 mM Na4P2O7, 2 mM NaF, and 1x 
completeTM EDTA-free Protease Inhibitor Cocktail (Roche)) by vortexing. Samples were incubated on 
ice for 30 minutes with occasional vortexing. The lysates were then centrifuged at 20,000 x g at 4°C for 
15 minutes and the supernatant was collected. The protein concentration in the cleared whole cell lysate 
was determined using the RC DCTM Protein Assay Kit (Bio-Rad), according to manufacturer’s 
instructions. Protein lysates were stored at -80°C. 
2.1.3.2. Western Blot 
An appropriate amount of protein lysate was mixed with reducing buffer (50 mM Tris-HCl pH 7.4, 10% 
glycerol (v/v), 2% sodium dodecyl sulphate (SDS) (w/v), 0.02% bromophenol blue (w/v) and 5% β-
mercaptoethanol (v/v)) and denatured by boiling for 4 minutes. Proteins were loaded into 10% SDS-
polyacrylamide gel electrophoresis (PAGE) gels in TrisGlycine-SDS running buffer (0.3% (w/v) Tris-
HCl, 1.44% (w/v) glycine and 0.1% (w/v) SDS). To resolve the proteins, gel electrophoresis was 
performed using the MiniPROTEANTM III System (Bio-Rad). Proteins were transferred from the gel to 
a nitrocellulose 0.45 µm membrane (Bio-Rad) using the Mini Trans-Blot® Electrophoretic Transfer 
Cell (Bio-Rad). The transfer was performed in transfer buffer (192 mM Tris, 25 mM glycine, 20% 
methanol (v/v) and 0.02% (w/v) SDS) at 100 V and 4°C for 1 hour. Following the transfer, the 
membrane was incubated with membrane blocking buffer (5% (w/v) skim milk powder in 1x TBST 
buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl and 0.1% TWEEN 20)) at room temperature for 1 hour. 
The blocked membrane was then probed with primary antibody (Table 2.2) at an optimised 
concentration in membrane blocking buffer with rocking and at 4°C overnight. Following 3 washes in 
TBST, the blot was incubated with an appropriate horseradish peroxidase (HRP)-conjugated secondary 
diluted 1:2,000 in membrane blocking buffer, with rocking and at room temperature for 1 hour. The 
blot was again washed 3 times in TBST. The blot was imaged using AmershamTM Enhanced 
Chemiluminescence (ECL)TM Western Blotting Detection Reagent (VWR International) on the Chemi 









Table 2.2: Primary Antibodies used for western blotting 
Target Source Concentration Company Catalogue # 
Grem1 Polyclonal rabbit 1:250 abcam 140010 
Phospho-Smad-1/5/9 Monoclonal rabbit 1:1,000 Cell Signalling 
Technology 
D5B10 
Hsp90 Polyclonal rabbit 1:2,500 Santa Cruz 7947 
β-Actin Monoclonal mouse 1:2,500 Sigma-Aldrich A1978 
2.2. Cell Culture  
2.2.1. Maintenance of Cell Cultures 
All cell lines were maintained in a humidified environment at 37°C in the presence of 5% CO2 and were 
manipulated within a class II biological safety cabinet. Unless otherwise specified, all cell culture 
reagents were sourced from Sigma-Aldrich and all media were supplemented with 2 mM L-glutamine, 
100 U/mL penicillin, 100 µg/mL streptomycin, 1 mM sodium pyruvate, and 10 mM HEPES buffer. All 
cell lines were tested for mycoplasma infection using a MycoAlertTM Mycoplasma Detection Kit 
(Lonza) prior to use. 
2.2.1.1. Mouse myeloma 5TGM1 cell line 
The murine MM 5TGM1 PC line was originally kindly provided by Assoc Prof Claire Edwards 
(University of Oxford, UK). 5TGM1 cells expressing both GFP and luciferase were previously 
generated using the retroviral expression vector NES‐TGL4 5. To generate a basal 5TGM1 cell line with 
enhanced BM tropism, 5TGM1 cells were previously injected i.v. into C57BL/KaLwRij (KaLwRij) 
mice (section 2.3.1.1.) and those present in the long bones of the hind limbs were purified and expanded. 
5TGM1 cells were maintained in Iscove’s Modified Dulbecco’s Medium (IMDM) with 20% fetal calf 
serum (FCS, Thermo Fisher Scientific). The cells were subcultured every 2-3 days to maintain a 
concentration of 0.2-2 x 106 cells/mL.  
2.2.1.2. Mouse BM stromal OP9 cell line 
The mouse BM stromal cell (BMSC) line OP9 was obtained from the American Type Culture Collection 
(ATCC) (Manassas, VA, USA) and was maintained in Dulbecco's Modified Eagle Medium (DMEM) 
with 10% FCS (complete DMEM). Medium was renewed every 2-3 days and confluent monolayers 
were split at a subcultivation ratio of 1:5. Briefly, cells were harvested by rinsing with Hanks’s Balanced 
Salt Solution (HBSS) and adding 0.05% (v/v) trypsin-EDTA. Cells were incubated at 37°C for 5-10 
minutes, depending on the time taken to detach from the culture flask. Trypsin activity was then 
neutralised by the addition of FCS-containing medium and detached cells were pelleted at 1400 x g for 





5 minutes. The cell pellet was resuspended in fresh complete DMEM and an appropriate aliquot of the 
cell suspension was added to a new culture flask. 
2.2.1.3. Human myeloma cell lines 
Human myeloma cell line (HMCL) RPMI-8226 was purchased from the ATCC, while the HMCLs LP-
1, OPM2 and JJN3 were a kind gift from Prof Andrew Spencer (Monash University, Australia). All 
HMCLs were maintained in Roswell Park Memorial Institute 1640 (RPMI-1640) medium with 10% 
FCS (complete RPMI-1640 medium) and subcultured every 2-3 days to maintain a concentration of 
0.2-1 x 106 cells/mL. 
2.2.1.4. Primary human BM trephine-derived stromal cells 
Iliac crest trephines were collected from randomly selected patients with newly diagnosed, symptomatic 
MM who presented at the Royal Adelaide Hospital (Adelaide, Australia), and from haematologically 
normal age-matched controls (MM; n=15, Normal; n=17, age-range=44-78 years, mean age=61.9 
years). All patients provided informed consent in accordance with the Declaration of Helsinki. Bone 
marrow (BM) mononuclear cells were prepared from BM trephines by density gradient isolation, as 
previously described6 and cryopreserved by the South Australian Cancer Research Biobank (SACRB) 
at SA Pathology. The studies were approved by the Central Adelaide Local Health Network Human 
Research Ethics Committee (CALHN HREC) (HREC/13/RAH/569 No:131133). Samples were 
collected from patients prior to treatment. Stromal cell cultures were grown out from the BM 
mononuclear cells by plastic adherence culture as previously described1 and expanded prior to 
cryopreservation. Stromal cell cultures were retrieved from storage in liquid nitrogen and cultured in 
alpha-MEM culture medium supplemented with 100µM L-ascorbate-2-phosphate for 24 hours prior to 
RNA extraction using TRIzolTM Reagent (Thermo Fisher Scientific) for downstream RNA extraction 
as described in section 2.1.1.1. 
2.2.1.5. Human embryonic kidney (HEK) 293T cell line  
HEK293T cells were cultured in complete DMEM and cells were subcultured every 2-3 days by 
trypsinisation, as described in section 2.2.1.2. 
2.2.1.6. Mouse breast cancer PyMT-B01 cell line 
The PyMT-B01 mouse-derived breast cancer cell was kindly donated by Professor Sheila Stewart (St 
Louis, MO, USA) and the MDA-MB-231 human breast cancer cell line was kindly provided by Dr 
Toshiyuki Yoneda (formerly at University of Texas Health Sciences Centre, San Antonio, TX). PyMT-
B01 cells express luciferase produced by retroviral expression of the SFG-NES-TGL vector 5. Breast 
cancer cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM, Life Technologies, 
Australia) with 10% FCS. 





2.2.1.7. Human prostate cancer PC-3 cell line 
The PC-3 human prostate cancer cell lines were obtained from ATCC. PC-3 cells express luciferase 
produced by retroviral expression of the SFG-NES-TGL vector 5. Cancer cells were cultured in 
RPMI1640 (Life Technologies, Australia) supplemented with 10% FCS. 
2.2.1.8. Human osteosarcoma K-HOS cell line 
The K-HOS human osteosarcoma cancer cell line was obtained from ATCC. K-HOS cells express 
luciferase produced by retroviral expression of the SFG-NES-TGL vector 5. Cancer cells were cultured 
in Dulbecco's Modified Eagle's Medium (DMEM, Life Technologies, Australia) supplemented with 
10% FCS.  
2.2.2. Generation of genetically modified cells 
2.2.2.1. Grem1 overexpression in murine OP9 BM stromal cells 
HEK293T cells (1.5 x 106 cells/transfection) were seeded in 6 cm culture dishes in complete DMEM 
24 hours prior to transfection. The cells were then transfected with 5 μg of the gene-encoding or empty 
pLegoiT2 plasmid and 5 μg each of the murine psPAX2 lentiviral packaging plasmid and the pVSVG 
envelope protein-expressing plasmid using Lipofectamine 2000 (Invitrogen), according to the 
manufacturer’s instructions. After 48 hours, medium containing the lentivirus was collected from the 
transfected HEK293T cells and added dropwise through a 0.45 µm surfactant-free cellulose acetate 
membrane filter onto OP9 cells (70% confluent) in complete DMEM containing polybrene (final 
concentration of 8 µg/mL) in a 6cm dish. Cells were incubated at 37°C with 5% CO2 overnight. The 
cells were washed with complete DMEM and expanded in culture. Following another wash, the OP9 
cells underwent fluorescence activated cell sorting (FACS) for TdTomato protein expression, which 
indicated successful transduction of the pLegoiT2 plasmid, on a FACSAriaTM Fusion (BD Biosciences). 
Subsequent sorts were conducted, where appropriate, until a pooled cell line consisting of > 99% 
TdTomato+ OP9 cells was obtained. 
2.2.2.2. GFP/Luciferase expression in Vk*MYC MM PCs 
Lentiviral particles were produced using the NES-TGL-SFG plasmid with psPAX2 lentiviral packaging 
plasmid and the pVSVG envelope protein-expressing plasmids, as described in section 2.2.2.1. 
Vk*MYC cells grown attached to an OP9.pLegoiT2 stromal feeder layer (Section 2.2.3.4.)  were then 
transduced with NES-TGL-SFG containing viral particles. Successfully transduced GFP+ cells were 
isolated by FACS from GFP- and GFP+TdTomato+ populations and expanded on fresh OP9.pLegoiT2 
stromal feeder layers. Cryopreservation of modified Vk*MYC cells was performed as a whole co-
culture.  
 





2.2.3. In vitro cell culture assays 
2.2.3.1. Co-culture of MM PC and BM stroma 
OP9 stromal cells were seeded in both a 6cm TC dish and 24-well plate at 5x104 and 2x104, respectively 
and allowed to adhere for 5 hours. 5TGM1 MM PC were suspended at 1x105 cells/ml and added to the 
stromal cell cultures. Stromal cells were collected at 24, 48 and 72 hours post co-culture initiation. For 
contact co-culture the GFP+OP9 cells were isolated by flow cytometry from the GFP negative 5TGM1-
parental MM PCs to obtain a pure stromal population for analysis. For non-contact co-culture, 
5TGM1.Bmx1 PCs were separated from the OP9 cells using a 3 m Transwell for the duration of the 
co-culture. Human MM cell lines RPMI-8226, U266, KMS-11 and H929 were each cultured with 3 
primary human BM stromal samples isolated from haematopoietically-healthy individuals for 72hours. 
Human MM cell lines were washed thoroughly from the adherent stroma twice with 1xPBS. For IL-6 
experiments, recombinant mouse Il-6 protein (R&D systems) was used at 20ng/mL and neutralising 
anti-mouse Il-6 antibody (R&D systems) was used at 0.05µg/mL. Stromal cells were lysed in TRIzol 
and processed by chloroform/isopropanol isolation. RNA underwent DNase treatment with RQ1 DNase 
prior to cDNA manufacture using SuperScriptIV (Invitrogen). GREM1/Grem1 expression was assessed 
by quantitative-PCR using the primers sequences stated in Table 2.1.  
2.2.3.2. Co-culture luciferase proliferation assay  
5TGM1 cells were seeded in triplicate at 1 × 105 cells/mL in complete IMDM with, or without, a 
confluent layer of OP9 cells. After 72 hours of co-culture at 37°C with 5% CO2, the 5TGM1 cells were 
enumerated by measuring luciferase activity. Briefly, cells were collected with the aid of trypsin, 
washed in PBS and lysed in 40 L of 1x Luciferase Cell Culture Lysis Reagent (Promega). The lysates 
were vortexed for 10 seconds, centrifuged at 12,000 x g and 4°C for 2 minutes and then 20 μL of 
supernatant was transferred into an opaque 96-well plate. Bioluminescence was measured by adding 
100 μL of luciferase reaction buffer (5 mM MgCl2, 30 mM HEPES, 150 μg/mL D-luciferin (Biosynth) 
and 150 μM ATP) per well and reading the signal on a luminometer (Wallac 3000).  
2.2.3.3. WST-1 proliferation assay 
HMCLs were plated at 1 x 105 cells/mL in triplicate in 100 μL of complete RPMI-1640 medium in 
replicate 96-well plates with increasing concentrations of recombinant GREM1 protein (UCB-Pharma) 
and incubated at 37°C with 5% CO2. 72 hours post, 10 μL of WST-1 Reagent (Roche) was added to all 
the relevant wells of each plate, which was then returned to the incubator for 2 hours. Following this 
incubation, the absorbance of each well at 450 nm was measured using the iMarkTM Microplate 
Absorbance Reader (Bio-Rad). The background was subtracted from the absorbance values and the 
foldchange in absorbance was calculated relative to no recombinant GREM1 controls. 





2.2.3.4. Ex vivo culture of primary Vk*MYC PCs on stromal cell feeder layer 
A single vial of Vk*MYC 4929 whole splenic sample obtained from serial passage (section 2.3.1.6.) 
was thawed and sorted for CD138+/B220- PCs on a FACSAriaTM Fusion (BD Biosciences), cells were 
stained as detailed in section 2.3.7.2. using the antibodies listed in Table 2.3. Sorted cells were seeded 
on a confluent layer of OP9.pLegoiT2.Grem1 stromal cells in α-MEM culture medium supplemented 
with 100µM L-ascorbate-2-phosphate and 20% FCS in a 10cm dish. Cells were monitored daily for 
outgrowth of PCs (as determined by the presence of bright, grape-like clusters on top of the stromal 
layer). Vk*MYC stromal cells were expanded and maintained on an OP9.pLeogiT2.Grem1 stromal 
feeder layer for the duration of the study.  
Table 2.3: Primary Antibodies for fluorescent-activated cell sorting murine PCs 
Target Conjugate Host/Isotype Dilution Company Cat# 
CD138 PE Rat/IgG2aK 1:100 Biolegend 142503 
B220 PeCy7 Rat/IgG2aK 1:100 eBioscience 25-0452-82 
 
2.3. Animal Techniques 
2.3.1. In vivo models of cancer 
KalwRij mice, originally kindly provided by Prof Andrew Spencer (Monash University, Australia) were 
rederived, bred and housed at the SAHMRI Bioresources Facility. NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ (NSG) and C57BL/6 mice were purchased from the SAHMRI Bioresources 
Facility. All procedures were performed with the approval of the SAHMRI Animal Ethics Committee. 
In all studies, the mice in different experimental groups were age- and sex-matched.  
2.3.1.1. 5TGM1 MM cells in KaLwRij mice intravenous model 
For i.v. delivery, 5TGM1 cells were washed and resuspended in sterile PBS at a concentration of 5 x 
106 cells/mL. KaLwRij or NSG mice between 6 and 8 weeks old were injected with 0.1 mL of 5TGM1 
cell suspension (5 × 105 cells) via the tail vein. The injected mice underwent in vivo bioluminescence 
imaging (BLI, section 2.3.3.) 2-, 3- and 4-weeks post-tumour cell injection and were humanely 
euthanised after 4 weeks.  
Various treatment regimens with the anti-Grem1 antibody treatment were assessed for this model, see 
section 2.3.2.  
 





2.3.1.2. K-HOS osteosarcoma cells in NSG mice intra-tibial model  
5-week old NSG immunocompromised mice were subcutaneously (s.c.) administered two 30mg/kg 
doses of anti-Grem1 antibody UCB6114 (UCB-Pharma) or IgG control, AbA33 (UCB-Pharma), the 
week prior to tumour cell inoculation. 5x104 luciferase expressing K-HOS human osteosarcoma cells 
were orthotopically injected into the intra-tibial space of the left tibia in each mouse. Briefly, K-HOS 
cells were washed and resuspended in sterile PBS at a concentration of 5 x 106 cells/mL. NSG mice 
between 5 and 6 weeks old were anaesthetised by isoflurane inhalation for the duration of the procedure. 
A gas-sterilised 25 µL Hamilton syringe with a 27-gauge needle and containing 10 µL of cell suspension 
was inserted through the cortex of the anterior tuberosity of the left tibia. Once the bone cortex was 
traversed, the needle was inserted 3 to 5 mm down the diaphysis of the tibia, and the cell suspension (1 
x 105 cells per inoculum) was injected into the marrow space.  Antibody treatment continued twice 
weekly for the duration of the study. At weekly intervals, mice were administered 150 mg/kg luciferin 
intraperitoneally (i.p.) and imaged using the Xenogen IVIS Bioluminescence Imaging System, and 
tumour burden was quantitated using Living Image software. The study ended on day 18 post-tumour 
cell injection due to high tumour burden. Organs were dissected upon culling animals and BLI imaged 
ex vivo for analysis of tumour metastasis.  
2.3.1.3. PC-3 prostate cancer cells in NSG mice intra-arterial model 
5-week old NSG immunocompromised mice were subcutaneously (s.c.) administered two 30mg/kg 
doses of anti-Grem1 antibody UCB6114 or IgG control, AbA33, the week prior to tumour cell 
inoculation. 5x105 luciferase expressing PC-3 mouse prostate cancer cells were injected systemically 
via the caudal artery (CA). Antibody treatment continued twice weekly for the duration of the study. At 
weekly intervals, mice were administered 150 mg/kg luciferin intraperitoneally (i.p.) and imaged using 
the Xenogen IVIS Bioluminescence Imaging System, and tumour burden was quantitated using Living 
Image software (PerkinElmer, MA, USA). At the end of the study, organs were dissected upon culling 
animals and BLI imaged ex vivo to quantify the extent of tumour metastasis.  
2.3.1.4. PyMT-B01 breast cancer cells in C57BL6 intra-arterial model 
5-week old C57BL6 immunocompetent mice were subcutaneously (s.c.) administered two 30mg/kg 
doses of anti-Grem1 antibody Ab7326 or IgG control, Ab101.4, the week prior to tumour cell 
inoculation. 1x105 luciferase expressing PyMT-B01 mouse breast cancer cells were injected 
systemically via the CA. Treatment continued twice weekly for the duration of the study. At weekly 
intervals, mice were administered 150 mg/kg luciferin intraperitoneally (i.p.) and imaged using the 
Xenogen IVIS Bioluminescence Imaging System, and tumour burden was quantitated using Living 
Image software. The study ended on day 13 due to high tumour burdens. At the end of the study, organs 
were dissected upon culling animals and BLI imaged ex vivo to quantify the extent of tumour metastasis.  





2.3.1.6. Vk*MYC MM cells in C57BL6 mice intravenous and intra-tibial models 
Vk*MYC 4929 and 3596 whole splenic samples were kindly obtained from Prof Ricky Johnstone (Peter 
MacCallum Cancer Centre, VIC, Aus). Vk*MYC cell stocks were expanded by serial passage in vivo. 
Frozen 2x107 cell aliquots were thawed and immediately washed twice with sterile 1xPBS. Cells were 
resuspended at 1x107 cells per mL in sterile 1xPBS. 100µL of cell suspension was injected systemically 
via i.v. injection into C57BL6 mice. Tumours were allowed to develop over 12 weeks and monitored 
by weekly tail bleeding for serum protein electrophoresis (SPEP, section 2.3.4.). Whole spleens from 
mice with detectable tumour burden via SPEP were collected at 12 weeks post tumour cell 
administration and stored in 2x107 cells per mL aliquots for subsequent experiments.  
For experimental studies 6-8 week old C57BL6 mice were subcutaneously (s.c.) administered two 
30mg/kg doses of anti-Grem1 antibody Ab7326 (UCB-Pharma) or IgG control, Ab101.4 (UCB-
Pharma), the week prior to tumour cell inoculation mice. Frozen splenic cells were thawed and prepared 
as described above. For i.v. studies 100µL of whole splenic cell suspension was injected i.v. into 6-8 
week-old C57BL6 mice. For i.t. studies 10µL of freshly thawed and GFP+ sorted Vk*MYC.SFG cell 
suspension (section 2.2.2.2) was injected into the intra-tibial space of the left tibia in each mouse, as 
earlier described. Mice were tail bled weekly to monitor tumour burden via SPEP. Livers and spleens 
were dissected at the conclusion of the study for physiological and histological analysis (section 
2.3.10.).  
2.3.2. Therapeutic Treatment Regimens 
The dosing regimen for the anti-Grem1 antibody was decided in consultation with collaborator and 
pharmaceutical drug supplier UCB Pharma based on previous pre-clinical testing with this compound 
that demonstrated antibody efficacy.  
2.3.2.1. Anti-Grem1 antibody treatment in established disease 
Mice were injected i.v. with 5TGM1 cells as per previously described, and MM disease was allowed to 
establish for 2-weeks. Mice were randomly assigned to one of two treatment groups of even tumour 
burden based on BLI, and were then administered s.c. either 30mg/kg anti-Grem1 antibody Ab7326 
(UCB-Pharma) or IgG control antibody Ab101.4 (UCB-Pharma). Mice received one further dose of 
anti-Grem1 antibody at week 3 post-tumour cell inoculation, before ending the study at week 4. 
2.3.2.2. Anti-Grem1 antibody treatment in early-stage disease 
Mice were s.c. administered either 30mg/kg of anti-Grem1 antibody Ab7326 (UCB-Pharma) or IgG 
control antibody, Ab101.4 (UCB-Pharma) 3-days post-tumour cell inoculation. Treatment was 
maintained twice weekly for the remainder of the study. 
 





2.3.2.3. Anti-Grem1 antibody pre-treatment prior to tumour cell inoculation 
Mice were s.c. administered two 30mg/kg doses of either anti-Grem1 antibody Ab7326 (UCB-Pharma) 
or IgG control antibody, Ab101.4 (UCB-Pharma) one week prior to tumour cell inoculation. Treatment 
was maintained twice weekly for the remainder of the study. 
2.3.2.4. Anti-Grem1 antibody and Bortezomib combination therapy in established disease 
Mice were injected i.v. with 5TGM1 cells as per previously described, and MM disease was allowed to 
establish for 2-weeks. Mice were randomly assigned to one of four treatment groups of even tumour 
burden based on BLI. Treatment regimens consisted of twice weekly doses of one of the following:  
(1) 30mg/kg IgG control antibody, Ab101.4 + 1.33% DMSO/saline vehicle control 
(2) 30mg/kg IgG control antibody, Ab101.4 + 0.5mg/kg bortezomib resuspended in 1.33% 
DMSO/saline vehicle 
(3) 30mg/kg anti-Grem1 antibody, Ab7326 + DMSO/saline vehicle control 
(4) 30mg/kg anti-Grem1 antibody, Ab7326 + 0.5mg/kg bortezomib resuspended in DMSO/saline 
vehicle 
2.3.3. Bioluminescent Imaging 
Mice injected with luciferase-expressing 5TGM1 cells were shaved under anaesthesia prior to in vivo 
BLI. To measure tumour burden, the mice were administered firefly D-Luciferin substrate (30 mg/mL 
in PBS, Biosynth) by intraperitoneal injection at a concentration of 150 mg/kg. After 10 minutes, during 
which time the mice were anaesthetised by isoflurane inhalation, the dorsal, ventral and/or lateral 
aspects of the mice were scanned using the IVIS® Spectrum In Vivo Imaging System and Living 
Image® Software v4.5.5 (PerkinElmer), which was also used to quantitate the bioluminescence signal 
in the mice. 
2.3.4. Serum Protein Electrophoresis 
Peripheral blood was collected weekly from week 2 for 5TGM1 or Vk*MYC injected mice by tail 
bleed. The blood was allowed to clot at room temperature and then centrifuged at 2,000 x g and 4°C for 
10 minutes. The serum supernatant was collected and stored at -20°C. Subsequently, the serum samples 
were thawed and the levels of M protein/paraprotein were assessed by performing serum protein 
electrophoresis (SPEP) using the Hydragel Protein β1/β2 Kit (Sebia), according to the manufacturer’s 
instructions. The stained SPEP gels were imaged on a Gel DocTM XR+ Imager (Bio-Rad), and the 
intensity of the paraprotein band/M-spike was quantitated and normalised to the albumin band using 
Image Lab Software v6.0.1 (Bio-Rad) 





2.3.5. 24-hour BM homing 
5TGM1 cells (5 x 106 in 0.2 mL of PBS) were injected i.v. into 6-8 week old KaLwRij mice via the tail 
vein. After 24 hours, the mice were culled and both femora and tibiae from each mouse were collected 
and cleaned. These bones were flushed with PFE buffer (1xPBS, 2% FCS, 2mM EDTA) and the marrow 
was collected. While in chilled PFE buffer, the bones were cut longitudinally, scraped and minced with 
a scalpel blade. All the cells were then filtered through a 70-µm cell strainer, pelleted and resuspended 
in PFE buffer. The samples were immediately analysed for the presence of GFP+ tumour cells by flow 
cytometry on a FACSCantoTM II (BD Biosciences) using FACSDivaTM software v8.0 (BD 
Biosciences). 
2.3.6. Detection of GFP+ cells by flow cytometry in mouse tissues 
Single cell suspensions of BM, spleen and PB from tumour cell-injected mice were obtained, as 
described in section 2.3.7.1. Cells from a mouse not injected with tumour cells were also analysed to 
act as a negative control for gating cell populations. The cells were pelleted, resuspended in PFE buffer 
and immediately analysed for the presence of GFP+ tumour cells by flow cytometry on the 
FACSCantoTM II (BD Biosciences) using FACSDivaTM software v8.0 (BD Biosciences). 
2.3.7. Multi-colour flow cytometry for analysis of primary mouse cells 
2.3.7.1. Preparation of cells 
BM was collected from cleaned femora and tibiae by repeatedly flushing the bones with 5 mL of chilled 
PFE buffer using a 10 mL syringe and 21 G needle or crushing the bones in PFE buffer using a mortar 
and pestle. The BM cell-containing solution was then homogenised and passed through a 70 µm filter. 
Spleens were excised and cleaned of any connective tissue prior to being pushed through a pre-wet 70 
µm filter using the plunger of a 3 mL syringe. To generate a splenic single cell suspension, the filter 
was then washed with 5 mL of chilled PFE buffer. PB was collected by a terminal cardiac bleed using 
a 25 G needle and a 1 mL syringe containing 0.05 mL of 50 mM EDTA. The PB was then twice 
incubated with 9 mL of ACK red blood cell lysis buffer (150 mM NH4Cl, 10 mM KHCO3 and 0.1 mM 
EDTA in milli-Q water) at room temperature for 10 minutes, followed by washing in 10 mL of chilled 
PFE buffer. 
2.3.7.2. Antibody staining and flow cytometry 
A defined number of cells (1-2 million depending on the tissue source) was stained with Fixable 
Viability Stain 700 (BD Biosciences), according to the manufacturer’s instructions. These cells were 
incubated in FC blocking buffer on ice for 30 minutes and then stained with the relevant panel of 
fluorochrome-conjugated antibodies on ice and in the dark for 30 minutes (Table 2.4). Staining with 
Strepavidin-APC conjugated secondary antibody (Life Technologies) was used for all biotin-





conjugated primary antibodies. Unstained, single-colour and fluorescence minus one (FMO) controls 
were also prepared for each panel to assist with gating cell populations. All antibody cocktails were 
comprised of rat anti-mouse antibodies. Following staining, the cells were washed twice with 2 mL of 
PFE buffer and stored in FACS fixation buffer prior to analysis. Typically, at least 100,000 events per 
sample were run on a LSRFortessaTM X-20 flow cytometer using FACSDivaTM software v8.0 (BD 
Biosciences) and the data was analysed, including calculating compensation, using FlowJo v10.0.8 
software (FlowJo, LLC). 
 
Table 2.4: Primary Antibodies used for flow cytometry 
Panel Target Conjugate Concentration Company Catalogue # 
Lineage B220 Biotin 1:200 BioLegend 103204 
CD3 Biotin 1:200 BioLegend 100304 
CD4 Biotin 1:200 BioLegend 100404 
CD5 Biotin 1:200 BioLegend 100604 
CD8 Biotin 1:200 BioLegend 100704 
Gr1 Biotin 1:200 BioLegend 108404 
Ter119 Biotin 1:200 BioLegend 116204 
CD11b Biotin 1:200 eBioscience 13-0112-82 
HSC Sca1 Brilliant Violet-786 1:100 BD Biosciences 563991 
cKit PE-Cy7 1:100 BD Biosciences 558163 
CD135 PE-CF594 1:200 BD Biosciences 562537 
CD34 Brilliant Violet-421 1:100 BD Biosciences 562608 
MSC CD45 APC-eFluor780 1:200 eBioscience 47-0451-82 
CD31 PerCP/Cy5.5 1:100 BioLegend 563356 
Sca1 PE-Cy7 1:100 BD Biosciences 558162 
CD51 PE 1:200 BioLegend 104106 
Macrophage F4/80 Pacific Blue 1:100 Bio-Rad MCA497PB 
CD11b APC/Cy7 1:100 BioLegend 557657 
 
 





2.3.8. Peripheral blood counts 
Peripheral blood samples were collected from mice by a tail bleed into EDTA-coated microvette tubes 
(Sarstedt). Complete blood counts were performed using a HEMAVET950 automated blood analyser 
(Drew Scientific), according to the manufacturer’s instructions. 
2.3.9. MicroCT analysis of bone composition 
6-week old KaLwRij mice were treated with either anti-Grem1 antibody, Ab7326 or IgG control 
antibody, Ab101.4 twice weekly over four weeks. At the end of the study, mice were humanely 
euthanized. The left leg (femur and tibia combined) was excised from each mouse and stored in 10% 
neutral-buffered formalin for at least 48 hours. Limbs were wrapped in 70% EtOH-soaked gauze, cling 
film within the bulb of a transfer pipette and imaged on the SkyScan 1176 microtomograph (Bruker).  
Samples were scanned at 74kv/100mA with an isometric resolution of 8.7µm/pixel using a 0.8 
aluminium filter and 2 frame averaging. Scan data was reconstructed using NRecon reconstruction 
software (SkyScan) and analysed using CTAn software (SkyScan). Analysis of trabecular bone volume 
and number of the secondary spongiosa of the tibia in each mouse was determined by  analysis of a 
region with a height of 65 slices, 25 slices from a reference slice (reference slice manually determined 
as the slice showing the seam between the growth plate and primary spongiosa).  
2.3.10. Morphological analysis of spleens and livers 
2.3.10.1. Spleen lengths 
Spleens were isolated from animals and assessed for length on a glass slide by ruler to the closest 
millimetre.  
2.3.10.2. Liver macrolesions 
Livers were isolated from animals and visually inspected for the presence of extramedullary tumour 
growth and/or lesions. A liver was classified to have liver macrolesions if the presence of white nodular 
tumour growth and/or discoloured circular lesions could be seen by eye on the surface of the liver. Liver 
lesions were confirmed to be PCs by histomorphometric analysis.  
2.3.11. Immunohistochemistry 
Livers excised from tumour-bearing Vk*MYC 4929 mice were collected from C57BL6 mice at the 
experimental endpoint (week 12) and fixed in 10% (v/v) buffered formalin. Fixed-livers were then 
paraffin-embedded and 5 µm longitudinal sections were prepared. Sections were deparaffinised and 
stained with hematoxylin and eosin (H&E) and mounted with DePex. Slides were imaged on a BX53 
microscope (Olympus). 
 





2.3.12. Serial passage of bone-tropic MM PCs 
Vk*MYC.SFG cells grown ex vivo on an OP9.pLegoiT2.Grem1 stromal feeder layer were washed twice 
with HBSS and detached with 0.5% trypsin treatment. All cells (including washes) were centrifuged at 
1400 x g for 5mins at 4°C. Cells were resuspended in PFE buffer and sorted for GFP+ only cells from 
GFP+TdTomato+ stromal cells on the FACSAriaTM Fusion (BD Biosciences). GFP+ cells were 
resuspended in sterile 1xPBS and injected systemically i.v. into recipient C57BL6 mice. Disease was 
allowed to develop over 20 weeks, and BM was isolated from tumour-bearing mice. Pooled BM was 
re-sorted for GFP+ cells and subsequently re-injected into new recipient mice. Serial passages were 
performed over three cycles of BM isolation/re-injection to obtain a bone-tropic Vk*MYC.SFG subline. 
2.3.13. Generation of Grem1 knockout mice 
2.3.13.1. Mouse breeding 
Grem1-floxed mice (Regeneron Pharmaceuticals, New York, USA) were kindly obtained from Prof 
Simon Leedham (Gastrointestinal Stem cell Biology Laboratory, Wellcome Trust Centre for Human 
Genetics) and re-derived into the SAHMRI Bioresources facility. UBC-cre ERT2 mice were kindly 
obtained from Stuart Reed (Australian National University) with permission from The Jackson 
Laboratory (JAX® Mice) and re-derived into the SAHMRI Bioresources facility. Mice were intercrossed 
to obtain experimental animals of the correct genotype (Figure 2.1). To confirm the correct genotype, 
genomic DNA samples were generated from ear notches and qualitative PCR was performed, as 
described in section 2.1.1.3. Separate primers were used to detect the presence of loxP in Grem1-floxed 
mice and the presence of cre in UBC-CreERT2 mice (Table 2.1).  
  
Figure 2.1: Mouse breeding strategy for Grem1 knockout mice 





2.3.13.3. Tamoxifen-induction of cre-recombinase mediated gene knockout 
2.3.13.3.1. In vitro 
UBC-cre ERT2, Grem1 floxed experimental mice were culled at 8 weeks of age and tibias and femurs 
were collected for tissue extraction, as described in section 2.3.7.1. BM and compact bone were isolated 
from the long bones as previously described and cultured for 24 hours in alpha-MEM complete medium. 
Subsequently, 1 µM of 4-hydroxytamoxifen (OHT) or 95% ethanol vehicle control (for a final 
concentration of 0.001% ethanol in cell cultures) was added to the cell cultures and incubated at 37°C 
and 5% CO2 for 48 hours. After tamoxifen treatment, cells were lysed with 1mL TRIzol reagent and 
RNA collected as previously described, for downstream RT-PCR analysis. 
2.3.13.3.2. In vivo 
UBC-cre ERT2, Grem1 floxed and UBC-cre ERT2, Grem1 wildtype experimental mice were placed 
on a tamoxifen-chow diet (400mg Tamoxifen/kg chow, Speciality Feeds, WA, Australia) 2 weeks prior 
to Vk*MYC tumour cell inoculation. Mice were maintained on tamoxifen-chow for the duration of the 
study.  
2.4. Statistics 
Unless otherwise described, statistical analysis was performed using GraphPad Prism v8.0.0 (GraphPad 
Software). The Fisher’s exact test was used to determine whether the proportions of one categorical 
variable were different depending on the value of the other categorical variable. When three or more 
groups were being compared for a single variable, a parametric one-way ANOVA with Tukey’s post-
hoc multiple comparisons test or a non-parametric Kruskal-Wallis test with Dunn’s multiple 
comparisons test was used. For time-course experiments, groups were compared using a two-way 
ANOVA with Sidak’s or Tukey’s multiple comparisons test. When two groups were being compared 
for a single variable, a parametric paired t test, a parametric unpaired t test or a non-parametric Mann-

















3 THE ASSOCIATION BETWEEN 




























Multiple Myeloma (MM) is a malignancy characterised by the uncontrolled proliferation of antibody 
producing MM plasma cells (PCs) within the bone marrow (BM), accumulation of monoclonal 
immunoglobulin (paraprotein) and end organ damage defined by the CRAB criteria (CRAB: 
hypercalcaemia, renal insufficiency, anaemia and bone lesions)12. MM accounts for approximately 10% 
of all haematological malignancies, with over 100 000 new diagnoses each year95. Almost all MM cases 
are preceded by monoclonal gammopathy of undetermined significance (MGUS), a benign clonal PC 
proliferation characterised by less than 10% PCs within the BM and no end organ damage1 8.  
The disease initiating events for MGUS occur in the post-germinal centre B cell by a primary 
cytogenetic event, such as a  chromosomal translocation involving the immunoglobulin heavy chain 
gene1. While it has long been accepted that the malignant transformation of MGUS to MM has been 
due to the accumulation of secondary “genetic hits”, recent studies from our laboratory96 and others97-
99 have demonstrated that many chromosomal abnormalities and genetic lesions identified in MM PCs 
are also present at the MGUS stage. Furthermore, Das, et al., demonstrated that patient-derived MGUS 
cells were capable of progressive growth in a humanized mouse model, despite patient disease 
remaining stable over long-periods of time without progression. This study highlights the importance 
of extrinsic control of tumour growth in MM disease100 and suggest that MM disease progression does 
not solely rely on the acquisition of additional intrinsic mutations in PC, but can often be driven by PC-
extrinsic factors derived from the BM microenvironment. The ability of bone marrow 
microenvironmental changes to drive cancer has also been exemplified by a study from Kode, et al.,  In 
this study, generation of an activating mutation of β-catenin in mouse osteoblasts (a component of the 
BM microenvironment) altered the differentiation potential of haematopoietic stem cells (HSC) and 
promoted the development of the malignancy acute myeloid leukaemia41. Collectively, these findings 
suggest that non-cancer cells within the tumour microenvironment can govern the course of tumour 
growth and can actively promote the progression of disease.  
While the exact composition of the MM BM microenvironment remains unknown, MM PCs are thought 
to colonize areas that normally support HSC self-renewal and multi-lineage differentiation37. The HSC 
niche is characterised by the presence of cells and signals which are conducive to the growth and 
development of HSCs, derived in large part, from skeletal or mesenchymal stem cells (MSC)101 102. 
Currently there are two recognised populations of skeletal stem cells: the perisinusoidal MSC (PS-
MSC), and the osteochondroreticular stem cells (OCR-SC)83 103. Unlike traditional MSCs, the recently 
described OCR-SC are predominantly found within the metaphyseal and endosteal regions of bone, 
sites commonly associated with MM PC metastasis40. These cells are characterised by their expression 







Grem1 is a highly conserved, 184 amino acid cysteine knot-secreted protein and has primary functions 
as a potent BMP-2, -4, -7 antagonist and VEGF-R2 agonist104-107. Grem1 is also expressed by cells of 
the periepithelial intestinal mesenchymal sheath83 and studies show that Grem1 is functionally 
implicated in driving gastrointestinal carcinogenesis108-111. Grem1 has also been implicated in other 
cancers including mesothelioma90 112, pancreatic neuroendocrine tumours113 114, mammary94 115, 
cervical94 116 and kidney93 tumours and sarcoma94.  Furthermore, Grem1 has been found to be one of the 
most upregulated genes in the tumour microenvironment117. Additionally, in keeping with its pro-
angiogenic properties (i.e. via binding to VEGF-R2), Chen, et al., have shown that Grem1 expression 
is associated with increased microvessel density (MVD), a marker of angiogenesis, in patients with 
pancreatic neuroendocrine tumours113. Notably, increased MVD is associated with poor outcomes in 
patients with MM118.  
While Grem1 is highly overexpressed in numerous tumour microenvironments, until now, there has 
been little evidence to suggest it plays a role in MM. However, the recent identification of the Grem1 
expressing OCR-SC population in the BM, and the proximity of these skeletal stem cells to sites of MM 
metastasis raises many questions as to the involvement of Grem1 in MM pathogenesis. In this chapter, 
human patient and mouse BM stromal samples were assessed for any association between 
GREM1/Grem1 expression and MM tumour burden. Furthermore, in vitro cell culture techniques were 
utilized to determine a role for Grem1 in MM. Lastly, the studies presented here investigate a 
mechanism for Grem1 upregulation in MM, and the identification of a novel feed-forward loop.  
3.2. Results 
3.2.1. Grem1 expression is elevated in the bone marrow stroma in MM 
In order to determine a role for Grem1 in MM, the expression of GREM1 was analysed in mRNA 
samples obtained from normal- and MM patient- derived BM stroma. MM patient BM stroma (n=15) 
had significantly higher expression of GREM1 compared to BM stroma from age-matched 
haematopoietically normal donors (n=17) (Mann-Whitney test, P=0.0004, Figure 3.1).  Grem1 
expression was also investigated in the 5TGM1/KaLwRij.Hsd mouse model of myeloma. In this model, 
injection of the 5TGM1 murine MM cell line intravenously into young syngeneic KaLwRij mice results 
in the development of disease that recapitulates many features of human disease, including PC growth 
within the BM, lytic bone disease and paraprotein production119 120. Compact bone was isolated from 
healthy- and MM tumour bearing- C57BL/KaLwRij.Hsd mice (Figure 3.2A) and analysed for 
differences in Grem1 expression. BM stroma from tumour-bearing mice demonstrated a significant 
increased Grem1 expression compared to the stroma from healthy controls (Mann-Whitney, P=0.0056, 
Figure 3.2B). Importantly, the mice with the greatest tumour burden, as determined by bioluminescent 
imaging, displayed the greatest expression of Grem1, with a significant positive correlation between 







Collectively, these studies show that BM stroma display a cancer associated increase in GREM1/Grem1 
expression in both primary MM patient samples and a murine model of MM.  
Figure 3.1: GREM1 expression is elevated in primary stromal cultures from MM patients. RNA 
was extracted from ex vivo cultured BM trephine samples from age and gender matched normal donors 
and MM patients and the expression of GREM1 was analysed by real-time PCR. Data presented as 
mRNA expression normalised to β-ACTIN (ACTB), mean ± SD, Normal; n=17 and MM; n=15, 



















Figure 3.2: Grem1 expression correlates with MM tumour burden in the compact bone of tumour-
bearing KaLwRij mice. Grem1 expression in compact bone isolated from the long bones of non-
tumour and tumour-bearing KaLwRij mice was analysed by real-time PCR. (A) Representative BLI 
images of control and 5TGM1-tumour bearing KaLwRij mice. (B) Grem1 expression was compared 
between the compact bone of control KaLwRij mice and mice injected with 5TGM1.Bmx1 MM PCs 
with disease detectable via BLI. Graph depicts Grem1 expression relative to β-actin (ActB), mean ± 
SD, Normal; n=11 and Tumour-bearing; n=16, **P<0.01, Mann-Whitney test. (C) Grem1 expression 
in the BM stroma isolated from the hindlimbs of tumour-bearing mice was correlated with the tumour 
burden in the respective limbs, as detected by BLI. Graph depicts Grem1 expression (y-axis) vs tumour 
burden (x-axis), n=10, Pearson Correlation, p<0.05, R=0.64. 
3.2.2. MM PC promote increased GREM1 expression in BM stroma via an IL-6 dependent 
mechanism 
In order to determine the effect of MM PCs on GREM1 expression within stromal cells of the BM 
microenvironment, co-culture experiments utilizing primary human bone marrow stromal cells 
derived from haematopoietically normal individuals with the human MM cell lines KMS-11, 
RPMI.8226, H929 and U266 were performed. The KMS-11 (P=0.0343) and U266 (P=0.0013) cell 
lines demonstrated an ability to induce an increase in GREM1 expression in BM stroma after 72 hours 
of co-culture, while co-culture with the cell lines RPMI.8226 (P>0.05) and H929 (P>0.05)  did not 
result in significant changes in GREM1 expression in the stroma (One-way ANOVA, Fig 3.3). In 
addition, co-culture of the murine MM cell line 5TGM1 in direct contact with the BM-derived stromal 
cell line, OP9 was performed. Following 72 hours of co-culture, expression of Grem1 was 
significantly greater in the OP9 stromal cells cultured in the presence of the 5TGM1 cells, compared 
with those that were cultured alone (One-way ANOVA, 72hrs; P=0.0200, Figure 3.4A). Co-culture 
was also performed in Transwell conditions, however under these conditions there were no statistically 
significant changes in stromal Grem1 expression within 72 hr (One-way ANOVA, P>0.05, Figure 










RNAseq data and RT-PCR from this cell line. Furthermore, while the Grem1 expression in the human 
myeloma cell lines is not demonstrated in this thesis, evidence from the extensive RNAseq database 
from human myeloma cell lines collected by the Keats Laboratory (www.keatslab.org) demonstrates 
that Grem1 is minimally expressed in the human myeloma cell lines tested, if at all.  
To explore the potential mechanism underlying the increased stromal Grem1 expression driven by 
exposure to MM cells, we investigated the role of Il-6 in regulating Grem1. Previous studies have 
reported that IL-6 may regulate GREM1 in fibrosis121, and it is well-established that MM PCs upregulate 
IL-6 in the MSC population51 122. However, no direct link between the cytokine and Grem1 has been 
reported in MM. Consistent with published findings, we observed an increase in IL-6 expression upon 
exposure of stromal cells to MM cells. OP9 BM stromal cells cultured in the presence of 5TGM1 MM 
PCs for 72 hours displayed a significant increase in Il-6 expression compared to a monoculture of OP9 
cells (t-test, P=0.0313, Figure 3.5A). To investigate if this increase in Il-6 could directly influence 
stromal Grem1 expression, OP9 cells were subsequently cultured with 20ng/mL recombinant Il-6 
protein for 72 hours, with a significant increase in Grem1 expression observed in the Il-6 treated cells 
(t-test, P=0.0086, Figure 3.5B). To confirm the involvement of Il-6 in the upregulation of Grem1 in 
stromal cells cultured in the presence of MM PCs, an Il-6 neutralising antibody was added to the co-
cultures. As demonstrated previously, OP9 cells cultured with 5TGM1 tumour cells showed a 
significant increase in Grem1 expression, however the addition of an Il-6 neutralising antibody to the 
culture abrogated the increase in stromal Grem1 expression (One-way ANOVA, P<0.05, Figure 3.5C).  
The expression of IL-6 and GREM1 in mRNA samples obtained from normal- and MM patient- derived 
BM stroma was also examined. No significant correlation was observed between IL-6 and GREM1 
expression in the trephine-derived BM stromal cells (Pearson Correlation, P=0.5203, r=0.3, Figure 
3.6A). Further investigation of this patient cohort also demonstrated that, in contrast to published 
findings49 56 123 124, there was no significant difference in IL-6 expression between the normal- and MM- 
patient BM stroma (T-test, P=0.4711, Figure 3.6B). Given that stromal cells from these BM trephine 
samples have been cultured ex vivo in the absence of MM PC and other microenvironmental conditions, 
IL-6 expression observed in the BM stroma isolated from these MM patients may no longer be 
representative of the expression of IL-6 that would be observed in intact MM BM microenvironment.  
MM is primarily a disease of older adults, with an average age of diagnosis of 71.5 years old92. Recent 
studies have indicated that there are distinct changes in the gene expression profiles of aging or 
senescent cells, and that these changes may create a more inflammatory and tumour permissive 
microenvironment125-129. As such, we sought to determine whether there was any association between 
IL-6 and GREM1 in aging and/or senescent BM stromal cells, given that IL-6 is one of the primary 







increasing evidence to suggest that this phenotype also plays an important role in MM132-134. Analysis 
of IL-6 expression in primary human normal donor BM stromal cells cultured at early passages (<2) 
compared to late stage passages (>8) (by when  cells have demonstrated senescence, as determined by 
a substantial slowing in growth) demonstrated a significant increase in IL-6 expression in the late-stage 
cultures (T-test, P=0.0433, Figure 3.7A). Furthermore, this observation was upheld when expression of 
GREM1 was analysed within the same donor BM samples, with a significant increase in GREM1 











Figure 3.3: Human MM PC lines co-cultured with BM stroma results in differential upregulation 
of stromal-derived GREM1. GREM1 expression was analysed in primary, non-disease human stroma 
co-cultured with KMS-11, RPMI.8226, H929 and U266 human MM cell lines for 72hrs. Graph depicts 
data from three-independent replicate experiments from co-culture with three normal stroma donors, 
GREM1 expression relative to β-ACTIN (ACTB) and normalised to media only control. Mean ± SEM, 









Figure 3.4: Murine 5TGM1 PCs upregulated stromal-derived Grem1 in adherent co-culture. 
Grem1 expression was analysed in the murine, BM derived stromal OP9 cell lines following 24, 48 and 
72 hr co-culture with 5TGM1 MM PCs either (A) plated directly onto the adherent stromal cells, or (B) 
co-cultured in the upper 3µm Transwell. For contact culture, OP9.GFP+ cells were sorted by FACS 
from the 5TGM1.parental MM PCs for analysis of stromal-Grem1 expression via real-time PCR. Data 
presented as mRNA expression relative to β-Actin (ActB) and normalised to media only control. Graph 
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Figure 3.5: Stromal Il-6 is upregulated by MM PC co-culture and drives stromal-Grem1 
expression. (A) Il-6 expression was analysed in the murine, BM derived stromal OP9 cell lines 
following 72hr co-culture either with 5TGM1.Bmx1 MM PCs or with media only. Graph depicts Il-6 
mRNA expression relative to β-actin (ActB). (B) OP9 cells were cultured in the presence of either 
20ng/mL recombinant Il-6 (r.Il-6) or PBS for 72hrs and analysed for Grem1 expression. Graph depicts 
Grem1 mRNA expression relative to β-actin (ActB). (C) OP9 stromal cells were cultured in media only, 
in co-culture with 5TGM1 MM PCs in the absence/presence of 20ng/mL anti-Il-6 neutralising antibody 
and analysed for Grem1 expression. Graph depicts Grem1 mRNA expression relative to β-actin (ActB). 
(A)(B) Data represented as Mean ± SD of 3 replicate experiments, * P<0.05, **P<0.01, t-test. (C) Data 















Figure 3.6: IL-6 expression is not increased in MM stroma and does not correlate with GREM1 
expression. RNA was extracted from ex vivo cultured BM trephine samples from age and gender 
matched normal donors and MM patients, and IL-6 and GREM1 gene expression was analysed by 
quantitative PCR.  (A) IL-6 expression in all BM trephine samples (normal and MM) was correlated 
with GREM1 for each sample, as determined by quantitative PCR. Graph depicts GREM1 expression 
(y-axis) vs IL-6 expression (x-axis), n=32, Pearson Correlation, p>0.05, r=0.30. (B) Expression of IL-6 
in normal donors and MM patients.  Data presented as mRNA expression normalised to β-ACTIN 





Figure 3.7: IL-6 and GREM1 expression increases in aging human BM-stromal cells. BM trephine 
derived stromal cells from haematopoietically normal donors were cultured ex vivo for up to 8 rounds 
of cell passaging. RNA was extracted from cultured cells at passage 2 (Early) and passage 8 (Late) and 
analysed by quantitative PCR. Expression of (A) IL-6 and (B) GREM1 was analysed by real-time PCR. 
Data presented as fold-change relative to the Early passage, mRNA expression normalised to β-ACTIN 









3.2.3. Stromal-derived Grem1 promotes increased MM PC proliferation 
In order to determine the significance of the observed increase in stromal Grem1 expression levels on 
MM disease course, human MM cell lines KMS-11, RPMI.8226, JJN3 and U266 were cultured in the 
presence of recombinant human GREM1 protein for 72hrs and their proliferation measured via WST-1 
assay. Using this approach, no significant increase in the proliferation of any human MM cell line in 
response to recombinant GREM1 was observed (one-way ANOVA, Tukey Multiple Comparisons, 
P>0.05, Figure 3.8A-D). In fact, the RPMI.8226 cell line demonstrated a subtle, but statistically 
significant, decrease in proliferation when cultured in the presence of the highest concentration of 
recombinant GREM1, 5µg/mL (one-way ANOVA, Tukey Multiple Comparisons, P=0.0222, Figure 
3.8B). To further validate these results, a secondary independent assay of proliferation was utilized. The 
proliferation of luciferase-expressing U266 and RPMI.8226 MM cell lines cultured in the presence of 
recombinant GREM1 was examined by using direct measurement of luciferase activity as a measure of 
relative cell number. Consistent with the findings observed in the WST-1 analysis of proliferation, 
neither MM cell line demonstrated a significant difference in proliferation in response to recombinant 
GREM1 by luciferase assay (one-way ANOVA, Tukey Multiple Comparisons, P>0.05, Figure 3.9A 
and B).  
Despite these findings, the potential role for Grem1 in MM disease progression was further investigated 
in a more biologically relevant setting, given that the monoculture of MM cell lines does not recapitulate 
the complexities of the interactions between the BM cell populations and MM PCs. In order to address 
this, OP9 stromal cells overexpressing Grem1 were generated (Figure 3.10A-D) and used in co-culture 
experiments with 5TGM1 MM PCs. The increase in Grem1 mRNA in Grem1-overexpressing OP9 
stromal cells was thousands-fold (Figure 3.10C), compared to an average of 5-fold increase based on 
protein densitometry from two independent western blots (Figure 3.10D). It is likely that the translation 
from mRNA to protein is a rate-limiting step in the production of Grem1 protein135. 5TGM1 cells 
demonstrated a significant increase in proliferation when co-cultured with the Grem1-overexpressing 
OP9 stromal cells, both in cell-contact (t-test, P=0.0023, Figure 3.11A) and Transwell (t-test, P=0.0003, 
Figure 3.11B) culture settings. Thus, these findings suggest that Grem1 does indeed play a role in 
promoting the growth of MM PC within the BM microenvironment. Given that Grem1 has a primary 
role as a BMP-antagonist104 136, we hypothesized that the pro-proliferative role of Grem1 in MM 
occurred through antagonism of the BMP pathway, as the BM stromal cell compartment is a rich source 
of the Grem1-targets, BMP -2, -4 and -7137 138. The BMP pathway is known to inhibit MM PC 
proliferation and promote apoptosis and its inhibition by Grem1 represents a potential mechanism for 
the increase in MM PC proliferation observed 139 140. Consistent with this proposed mechanism, MM 













Figure 3.8: Recombinant Grem1 did not increase human MM PC proliferation in monoculture 
as measured by WST-1 assay. Human MM PC lines; (A) KMS-11  (B) RPMI.8226, (C) JJN3 and (D) 
U266, were cultured in the presence of 500ng/mL, 1µg/mL and 5µg/mL recombinant human GREM1 
(rh.GREM1) for 72hrs. Cell proliferation was measured by WST-1 assay. Data presented as fold-change 
relative to media-only control for three replicate experiments, mean ± SEM, *P<0.05, One-way 


















Figure 3.9: Recombinant Grem1 does not increase human MM PC proliferation in monoculture 
as measured by luciferase assay. Luciferase expressing, human MM PC lines; (A) U266 and (B) 
RPMI.8226 were cultured in the presence of 5ng/mL, 10ng/mL 50ng/mL, 100ng/mL and 1g/mL 
recombinant human GREM1 (rh.GREM1) for 72hrs. Luciferase activity in cells was used as a direct 
measure of cell proliferation. Data presented as fold-change relative to media-only control for three 


































Figure 3.10: Generation of a Grem1 lentiviral construct and confirmation of overexpression in 
OP9 cells. Grem1 was overexpressed in the murine BM stromal cell line, OP9. (A) Schematic 
illustrating the Grem1 overexpression construct with the NotI and EcoRI restriction sites used for 
insertion of Grem1 cDNA into the pLegoiT2 plasmid backbone. (B) Flow plots depicting the GFP 
positive OP9 stromal cells population before and after lentiviral transfection with the Tomato positive 
Grem1 overexpression construct. Grem1 transgene expression in OP9 stromal cells was confirmed by 
(C) quantitative PCR and (D) western blot. Western blot Grem1 protein expression levels displayed 




















Figure 3.11: Stromal-derived Grem1 promoted an increase in 5TGM1 MM PC proliferation. 
Proliferation of 5TGM1 MM PCs in (A) cell-cell contact, and (B) Transwell co-cultures with OP9 
empty vector and OP9 stromal cells modified to overexpress Grem1 (OP9.Grem1) was measured by 
luciferase after 72 hours of culture. Graphs depict mean ± SEM of 3 replicate experiments normalized 











Figure 3.12: BMP-signalling is downregulated in 5TGM1 MM PC cultured with Grem1-
overexpressing stromal cells. 5TGM1 MM PCs cells were cultured in Transwell in the presence of 
OP9 empty vector, or Grem1 overexpressing OP9 stromal cells for 24 hours. Protein was immediately 
isolated from 5TGM1 cells and analysed by western blot. BMP signalling was indicated by the amount 























The importance of the tumour microenvironment in the development of malignant cell growth is 
becoming increasingly clear, with many studies highlighting the crosstalk between the tumour cells and 
the microenvironment resulting in the continued growth, survival and spread of disease141-143. However, 
there remains an incomplete understanding of the factors that contribute to MM cell growth in the BM. 
To our knowledge, the studies presented here demonstrate, for the first time, a novel positive feedback 
loop between MM PCs and BM stroma that works to promote the proliferation of MM PCs and may 
represent a new option for future therapeutic targeting.  
It has previously been reported that Grem1 is overexpressed in the tumour supportive tissue of basal 
cell carcinoma, as well as carcinomas of the bladder, breast, lung, colon and pancreas144 145. In addition, 
Grem1 has been shown to be upregulated in cancerous tissues of the lung, mesothelium, brain and gut90 
109 110 146 147. Our findings are consistent with previous studies that report upregulation of Grem1 within 
the tumour microenvironment, demonstrating for the first time that Grem1 is upregulated in the BM 
stroma of MM patients. In addition, a significant increase in Grem1 expression in the bones of mice 
with MM-like tumours was observed. Furthermore, previous studies performed by our laboratory, have 
demonstrated that the composition of the BM is different in MM patients, compared to healthy 
controls49. These studies highlighted that there are elevated total numbers of bone marrow MSCs in 
MM patients compared to healthy individuals, and therefore the total Grem1 expression in the MM BM 
microenvironment may in fact be higher than we report due to a combination of both an increase in the 
number of Grem1-expressing cells within the bone and an increase in the expression of Grem1 by these 
cells.  In keeping with these findings, our studies show that culture of mouse MM PC directly with a 
BM-derived stromal cells resulted in an increase in Grem1 expression in the stroma. These findings 
suggest that the increase in BM-derived Grem1 expression in MM is directly driven by MM PC. 
However, this finding was not replicated when the MM PCs were not in direct cell-to-cell contact with 
the stromal cells, although a trend toward increased Grem1 expression was observed. This indicates 
that the MM-driving factors responsible for the increased Grem1 expression from the stroma may rely 
on cell contact for maximal induction of expression. Consistent findings were also observed in two of 
four human MM cell lines cultured in direct contact with primary donor human BM stroma. The MM 
cell lines KMS-11 and U266 induced a greater than 3-fold increase in stromal GREM1 expression, 
whereas the RPMI.8226 and H929 cell lines did not. The ability of some human MM cell lines to induce 
a change in GREM1 expression, but not others, may indicate that there are fundamental differences in 
the expression of key factors responsible for the regulation of GREM1 between these cell lines.  
The role of IL-6 in MM is well-established, and it has been previously demonstrated that IL-6 is 







MM tumour cells49. IL-6 has a multitude of roles in the MM BM microenvironment, with key roles in 
mediating pro-osteoclast signalling pathways124 148 and upregulation of angiogenesis through VEGF149, 
both pathways that support the growth of MM PC. Importantly, it has also been reported in the disease 
setting of fibrosis, that IL-6 plays a role in the regulation of Grem1 through STAT3-dependent 
mechanisms121. This prompted us to investigate the role of IL-6 in regulating Grem1 in MM. This is the 
first study to demonstrate that Il-6 may play an important role in regulating the BM-derived Grem1 in 
MM. In keeping with this, according to the Keats Laboratory RNAseq database of HMCL gene 
expression (www.keatslab.org), the U266 HMCL has the highest expression of IL-6 of all surveyed 
HMCLs, and subsequently displayed the greatest ability to induce stromal GREM1 expression in the 
studies presented here (Figure 3.3). The ability of Il-6 to upregulate Grem1 may also explain the 
differences between Grem1 expression in stromal cells in contact and non-contact co-cultures with MM 
PCs. Previous studies have shown IL-6 is upregulated in paracrine signalling between MM PCs and the 
BM, with adhesion of MM PCs to the stroma previously reported as inducing greater IL-6 expression 
than without150. Given that these present studies support a role for Il-6 in promoting increased stromal-
Grem1 expression, it was expected that there would be an increase in IL-6 expression observed in 
patient BM trephine-derived stroma compared to stroma from healthy patients, as well as an association 
between stromal IL-6 and GREM1 expression levels. However, the results presented here do not support 
this. Despite this, subsequent studies performed by other members of the laboratory have demonstrated 
a correlation between IL-6 and Grem1 expression in both MGUS and MM BM stromal samples151. In 
addition, there is a breadth of MM studies that report an increase in IL-6 within MM BM stroma49 52 150. 
As such, the lack of the increased IL-6 expression observed in primary MM patient BM trephines may 
be a result of their ex vivo culture and subsequent passaging and thus unrepresentative of their true 
expression profiles in vivo. While it is well established that IL-6 plays an important role in MM disease 
progression, therapeutically targeting IL-6 in the clinic has failed to demonstrate a significant effect on 
patient progression free- and overall- survival rates152 153. Given the lack of clinical impact in targeting 
IL-6, these studies which show an association between Il-6 and Grem1 within the MM BM 
microenvironment may allow for the development of an effective combination therapy which targets 
both IL-6 and GREM1.    
Previous studies have identified pro-tumorigenic roles for Grem1 in lung and colorectal cancers and 
malignant mesothelioma, with pro-proliferative and pro-angiogenic roles reported 90 107 110 154 155. 
However, the role of Grem1 in oncogenesis is conflicting, with Grem1 reported to be predictor of 
positive outcomes and have inhibitory growth effects in pancreatic neuroendocrine tumours 156 157. To 
examine the role of Grem1 in MM in a biologically relevant setting, Grem1-overexpressing BM stromal 
cells were generated and co-cultured with MM PCs in order to partially replicate the crosstalk between 







proliferation after just 3 days of contact co-culture with Grem1-overexpressing stromal cells. While no 
previous studies have described a role for Grem1 in promoting MM growth, the inhibitory role of BMPs 
in MM disease is well documented139 158-160. While BMP signalling is reported to be involved in 
numerous malignancies, its actions are context-dependent with both oncogenic and apoptotic 
mechanisms reported85 86. This is also true for Grem1. Like BMP-signalling, it appears Grem1 may 
function in a cell-type dependent manner, at least when acting via BMP-dependent mechanisms.  In 
relation to MM, many studies have highlighted the anti-proliferative and pro-apoptotic functions of 
BMPs, especially the Grem1 targets, BMP-2 and BMP-4. Therefore, it is not surprising that an increase 
in MM cell proliferation was observed when the BMP-antagonist Grem1 was overexpressed by stromal 
cells, and that a decrease in the downstream activation of BMP signalling was also observed in response 
to increased Grem1. The stromal cell overexpression of Grem1 provides a cellular source of BMPs and 
other signalling pathways that inhibition of Grem1 acts upon to increase MM PC proliferation, and may 
provide reasoning for the effect of Grem1 on MM PC proliferation observed in MM PC/stromal cell 
co-cultures, but not in MM PC monocultures.  
MM PCs are reliant upon the BM for their continued growth, survival and spread. However, the exact 
composition of the MM tumour supportive microenvironment is incompletely understood. Collectively, 
our data suggests that Grem1 is a key BM stroma-derived factor that promotes MM disease initiation 
and progression. Furthermore, MM PCs mediate the increased expression of stromal Grem1 expression 
within the MM BM microenvironment through an Il-6 dependent mechanism, representing a novel 
positive feedback loop. To the best of our knowledge this study demonstrates for the first time that 
Grem1 is a critical BM-derived factor in MM that supports MM tumour growth and as such represents 

























4 TARGETING GREMLIN1 LIMITS TUMOUR 
GROWTH IN THE 5TGM1/KaLwRij MOUSE 























Multiple Myeloma (MM) is a haematological malignancy of plasma cells (PCs) within the bone marrow 
(BM). MM is the second most common haematological malignancy in adults, and accounts for 
approximately 1000 deaths in Australia each year92. Despite significant advances in the treatment 
modalities for MM, which have resulted in improved patient outcomes over the past 20 years, MM 
remains a largely incurable disease in which relapse is inevitable92 161 162. As such, there is a need to 
identify new therapeutic targets in MM that provide new treatment options and better patient outcomes.  
MM is a progressive disease with almost all cases preceded by the indolent, asymptomatic condition, 
referred to as monoclonal gammopathy of undetermined significance (MGUS). MGUS is a common, 
largely benign disorder, present in approximately 3% of the population over 60 years of age. Individuals 
with MGUS are at continuous risk of progression to MM at a rate of 1% per year10 13. The initiating 
events responsible for the development of the MGUS and MM are thought to relate to intrinsic genetic 
changes within the PC; commonly involving hyperdiploidy or a translocation involving the heavy chain 
locus1. The progression from the benign MGUS to symptomatic MM was previously thought to be 
driven by the acquisition of further genetic mutations, however recent studies from our laboratory, and 
those of others, have highlighted that little change is evident in the genetic landscape of PCs recovered 
from the patients at the pre-malignant and malignant stages of disease96 97. This highlights the potential 
role of PC-extrinsic factors within the tumour microenvironment as promoters of disease progression. 
Further evidence of this notion, is provided by studies from our laboratory which have shown that MM 
PCs that are genetically identical, have vastly different proliferative fates depending on where, within 
the BM microenvironment, they “land”39. 
Like normal PCs, MM PCs home to CXCL12-rich regions of the BM microenvironment and adhere to 
extracellular matrix, BM stromal cells and other juxtaposed cells46. Once there, the complex mix of 
cellular and non-cellular factors within the BM microenvironment contribute to the continued growth, 
survival and drug resistance of the MM PC163. While our knowledge of the importance of the BM in 
MM disease progression is improving, the critical factors that promote disease progression are still 
incompletely understood. These, yet to be determined factors, may represent ideal targets to which 
therapies can be generated to drastically improve patient outcomes. 
Recent studies have demonstrated that MM PCs co-localise to regions of the BM that are synonymous 
with the rare osteochondroreticular stem cell (OCR-SC) population83 164. This stem cell population is 
characterised by high expression of Gremlin1 (Grem1). Grem1 encodes a highly conserved 184 amino 
acid cysteine knot, secreted protein belonging to the DAN family of glycoproteins104 136. Grem1 is a 
bone morphogenic protein (BMP)-2, -4, -7 antagonist, and vascular endothelial growth factor receptor 
2 (VEGFR2) agonist104 155. During early development, Grem1 is essential for limb-bud formation and 
organogenesis, while in adults, it has a regulatory role in maintaining tissue homeostasis165 166. In 





disease, Grem1 is one of the most upregulated genes within the tumour microenvironment in numerous 
solid cancers and has been identified as promoting tumour growth and spread in colorectal cancer, lung 
cancer, cervical cancer, pancreatic cancer, mesothelioma and glioma88 90 109 110 112 114 116 117 167.  
Studies presented in this thesis demonstrate that Grem1 is overexpressed in the BM stroma of MM 
patients, and that this increase is driven by MM PC-BM stromal cell interactions. Furthermore, Grem1 
overexpression in BM stromal cells promotes an increase in MM PC proliferation, representing a 
positive feedback loop. As such, MM presents an ideal cancer setting in which to evaluate the use of a 
targeted Grem1 reagent as an anti-cancer therapeutic. In this chapter, the 5TGM1/KaLwRij murine 
model of MM was utilized to study the efficacy of an anti-Grem1 therapeutic in reducing MM tumour 
burden. In addition, this pre-clinical model was used to investigate the broader effects of anti-Grem1 
neutralising antibody on the composition of the BM microenvironment, through use of flow cytometry 
and microCT analysis.  
4.2 Results 
4.2.1. Anti-Grem1 neutralising antibody is effective in restoring BMP signalling and limiting 
MM PC growth in vitro 
Given that Grem1 expression is increased in the MM BM microenvironment and acts to promote MM 
PC proliferation in vitro, it was hypothesized that functional blocking of Grem1 activity may reduce 
MM tumour growth.  To assess the effects of targeting Grem1 in the context of MM, a Grem1-
neutralising antibody, Ab7326 (referred to as anti-Grem1 antibody from here on), was obtained through 
a collaboration with UCB Pharma, UK. The  anti-Grem1 antibody is comprised of a human-mouse 
variable region with a mouse IgG1 backbone, blocks both human and mouse Grem1, and has been 
shown to effectively reverse Grem1-mediated inhibition of BMP signalling in an ID1 reporter assay 168. 
The ability of the anti-Grem1 antibody to restore Grem1-blocked BMP signalling was independently 
confirmed by western blot detection of a restoration of phospho-SMAD levels (Figure 4.1, performed 
by Alanah Bradey in our laboratory as part of her Honours degree studies). The 4T1 breast cancer cell 
line was used in these studies, as previous studies have shown it to be highly sensitive to BMP 
stimulation169.  
To investigate the potential for targeting Grem1 in MM, the proliferation rate of the 5TGM1 murine 
MM PC line was compared in the presence of either the anti-Grem1 antibody or the IgG isotype control 
antibody. The proliferation of 5TGM1 tumour cells was assessed in both MM PC-only cell suspensions 
and in cultures where MM-PC were co-cultured with the OP9-stromal cell line. No significant 
difference in MM PC proliferation was observed in MM PC monocultures (Figure 4.2A).  However, 
5TGM1 MM PC growth in co-culture with stroma was significantly reduced by 17% in the presence of 
anti-Grem1 antibody compared to IgG control (t-test, P<0.0001, Figure 4.2B). The ability of the anti-





Grem1 antibody to reduce MM PC proliferation in stromal co-culture supports further investigation in 








Figure 4.1: Anti-Grem1 antibody restores BMP signalling in the presence of recombinant Grem1. 
Murine 4T1 cells were serum starved for 6hours, before stimulation for 2 hours with combinations of 
rhBMP2, rhGrem1, anti-Grem1 antibody and IgG isotype control antibody. Protein was immediately 
isolated from cells and analysed by western blot. BMP signalling was indicated by the amount of 






Figure 4.2: Blocking Grem1 activity with an anti-Grem1 neutralising antibody significantly 
reduces MM PC proliferation in co-culture with BM stroma but not in monocultures of MM PCs 
in vitro. 5TGM1.BMx1 MM PCs were cultured in the presence of either 1µg/mL anti-Grem1 antibody 
or IgG isotype control antibody in either the (A) absence or (B) presence of OP9 BM stromal cells and 
allowed to grow for 72hours. 5TGM1 proliferation was assessed by luciferase activity and results were 
normalised to the IgG control for replicate experiments. Mean ± SEM of n=3 replicate experiments. 
****P<0.0001, paired t-test. 
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4.2.2. Treatment of MM with a Grem1-neutralising antibody reduces MM tumour growth in 
vivo  
In order to assess the efficacy of anti-Grem1 antibody treatment in reducing MM tumour burden, the 
5TGM1/KaLwRij pre-clinical MM model was utilized39 170. The 5TGM1.BMx1 (5TGM1) MM PC line 
was previously established from a spontaneous C57BL6/KaLwRij/Hsd (KaLwRij) mouse PC tumour 
and was subsequently passaged through the BM to produce a bone-tropic MM PC line that produces 
MM-like disease with clinically relevant symptoms over 4 weeks. Additionally, the 5TGM1 PC line 
has been modified to express GFP and luciferase171, enabling both ex vivo flow cytometric analysis of 
tissue samples and in vivo  bioluminescent imaging (BLI) to track tumour burden throughout the 
study170. In addition, whole mouse tumour burden can be measured by quantitation of the monoclonal 
antibody (paraprotein) secreted by 5TGM1 cells, detected following serum protein electrophoresis 
(SPEP). In this study, KaLwRij mice were inoculated with 5TGM1 MM PCs and disease was 
established over two weeks. Mice were then randomly assigned to two groups which displayed 
comparable tumour burden and received two doses of either anti-Grem1 antibody or IgG isotype control 
antibody, the first dose at week 2 and the second dose at week 3, prior to ending the experiment at week 
4 (Figure 4.3A). At the conclusion of the study there was no significant difference in tumour burden 
observed between treatment groups as measured by BLI (ANOVA, Sidak’s multiple comparisons, 
P=0.4399, Figure 4.3B) or serum paraprotein levels measured by SPEP (t-test, P=0.1218, Figure 4.3C). 
While no statistically significant differences were observed in this study, there was a trend toward a 
reduction in tumour burden in the anti-Grem1 antibody treatment group by both BLI and SPEP (Figure 
4.3B-C) that warranted further investigation. 
When the first treatment was administered at the half-way point of the 4-week MM model, the tumour 
growth had reached an exponential growth phase and it was hypothesised that the growth was less likely 
to be influenced by modulation of BM microenvironmental pro-tumorigenic factors. Furthermore, as a 
monotherapy, targeting only a single BM-derived factor, it was anticipated that it was unlikely to have 
a significant effect on reducing and/or slowing tumour growth. Given that anti-Grem1 antibody 
treatment was not effective in reducing MM tumour burden in the later stages of disease, a more 
aggressive treatment regime starting at an earlier timepoint was evaluated. KaLwRij mice were 
inoculated with 5TGM1 MM PCs and treatment was initiated three days later. Mice then received 
treatment with the anti-Grem1 antibody or isotype control antibody, twice weekly, for the duration of 
the study (Figure 4.4A). Notably, a 54% reduction in MM tumour burden (as measured by BLI) was 
observed in mice treated with anti-Grem1 antibody compared to that observed in mice treated with the 
isotype control antibody (ANOVA, Sidak’s multiple comparisons, P=0.0012, Figure 4.4B) and SPEP 
(t-test, P=0.0034, Figure 4.4C).  





Furthermore, when anti-Grem1 antibody treatment was initiated one week prior to tumour cell 
inoculation, an even greater reduction in MM tumour burden was observed. Specifically, mice treated 
with the anti-Grem1 neutralising antibody had an 85% reduction in tumour burden compared to mice 
treated with an isotype control antibody, as measured by both BLI (ANOVA, Sidak’s multiple 
comparisons, P=0.0496, Figure 4.5B) and SPEP (t-test, P<0.0001, Figure 4.5C). When combined with 
the results from treatment started at day 3 (Figure 4.4), these results suggest that Grem1 does play a 
role in both disease establishment and progression, and represents a viable therapeutic target in MM. 
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Figure 4.3: Anti-Grem1 antibody treatment does not reduce 5TGM1 tumour growth in 
established, late stage disease in vivo. (A) Schematic illustrating the experimental design for testing 
the effect of anti-Grem1 antibody on 5TGM1 tumour burden. At timepoint 0, KaLwRij mice were 
inoculated with 5x105 5TGM1 MM PCs. At week two post-tumour cell inoculation, mice were treated 
with 30mg/kg anti-Grem1 antibody or IgG isotype control. A second treatment was administered at 
week three. Tumour burden was measured throughout the study by BLI, and at the endpoint by SPEP. 
(B) Graph depicts whole-body ventral BLI quantitation at weeks 2, 3 and 4 for anti-Grem1 antibody 
and isotype control treated mice. Representative BLI images for the final timepoint at week 4 are shown. 
(C) A secondary, independent measure of tumour burden was also used. Graph depicts level of 
paraprotein detected in serum following tail bleeds at week 4 (normalised to internal albumin control). 
Representative electrophoretic images of paraprotein (>) and other serum proteins are shown on the 
right. Graphs depict mean ± SEM of n=10 mice per treatment group. P>0.05, (B) two-way ANOVA, 
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Figure 4.4: Anti-Grem1 antibody treatment reduces 5TGM1 tumour growth in established, early 
stage disease in vivo. (A) Schematic illustrating the experimental design for testing the effect of anti-
Grem1 antibody on 5TGM1 tumour burden. At timepoint 0, KaLwRij mice were inoculated with 5x105 
5TGM1 MM PCs. Three days post-tumour cell inoculation, mice were treated with 30mg/kg anti-
Grem1 antibody or IgG isotype control, with treatment continued twice weekly. Tumour burden was 
measured throughout the study by BLI and at the endpoint by SPEP. (B) Graph depicts whole-body 
ventral BLI quantitation at weeks 2, 3 and 4 for anti-Grem1 antibody and isotype control treated mice. 
Representative BLI images for the final timepoint at week 4 are shown. (C) A secondary, independent 
measure of tumour burden was also used. Graph depicts level of paraprotein detected in serum following 
tail bleeds at week 4 (normalised to internal albumin control). Representative electrophoretic images of 
paraprotein (>) and other serum proteins are shown on the right. Graphs depict mean ± SEM of n=11 
mice per treatment group. *P<0.05, **P<0.01 (B) two-way ANOVA, Sidak’s multiple comparisons or 
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Figure 4.5: Pre-treatment with anti-Grem1 antibody reduces 5TGM1 tumour growth in vivo. (A) 
Schematic illustrating the experimental design for testing the effect of anti-Grem1 antibody on 5TGM1 
tumour burden.  KaLwRij mice received two doses of either 30mg/kg anti-Grem1 antibody or IgG 
control antibody treatment prior inoculation with 5x105 5TGM1 MM PCs at timepoint 0. Treatment 
continued twice weekly for the duration of the tumour model. Tumour burden was measured throughout 
the study by BLI, and at the endpoint by SPEP.  (B) Graph depicts whole-body ventral BLI quantitation 
at weeks 2, 3 and 4 for anti-Grem1 antibody and isotype control treated mice. Representative BLI 
images for the final timepoint at week 4 are shown. (C) SPEP was also used as a secondary, independent 
measure of tumour burden. Graph depicts level of paraprotein detected in serum following tail bleeds 
at week 4 (normalised to internal albumin control). Representative electrophoretic images of 
paraprotein (>) and other serum proteins are shown on the right. Graphs depict mean ± SEM of n=7; 
IgG control and n=8; anti-Grem1 Ab mice per treatment group. *P<0.05, ****P<0.0001 (B) two-way 
ANOVA, Sidak’s multiple comparisons or (C) unpaired t-test. 
 
4.2.3. Anti-Grem1 antibody mediated reduction in MM tumour burden is specific to sites of  
Grem1 expression 
Given that GREM1 expression is widely restricted in adult tissues172, we hypothesized that the 
effect of anti-Grem1 antibody treatment would be specific to sites of highest Grem1 expression. In the 
5TGM1/KaLwRij model, tumour growth is commonly restricted to the skeleton and the spleen. The 
skeleton is reported to have moderate to high GREM1 expression, while the spleen is reported to be 
negative for GREM1 expression172, expression36 an observation that we have independently verified by 
RT-PCR of splenic and compact bone RNA (Figure 4.6A).. To this end, examination of the spatial 
distribution of tumour burden in KaLwRij mice treated with anti-Grem1 antibody, demonstrated that 
the antibody-mediated reduction in tumour burden appeared to be  specific to the Grem1-positive site 
of the long bones, compared to the Grem1-negative/low site of the spleen. To determine if the anti-
Grem1 antibody anti-tumour effects were localised to sites of higher Grem1 expression, the BLI of anti-
Grem1 antibody and IgG control treated mice was re-analysed for spatially-restricted BLI signal arising 
from either the long bones of the hindlimbs or the spleen. Examination of the tumour burden in the 
control and treatment groups using whole animal BLI (Figure 4.4B-C and 4.5B-C), showed that the 
differences in the skeletal BLI signals was significant (t-test, P<0.05, Figure 4.6C-Day 3 and Pre-
treatment).  However, no significant differences in mean splenic tumour burden were observed (Day 14 
and Day 3 treatment, P>0.05; Figure 4.6C). While the mean reduction in splenic tumour burden was 
reduced (Pre-treatment, P=0.0012; Figure 4.6C), it was reduced far less than the mean reduction in 
hindlimb skeletal tumour burden. 
 






Figure 4.6: Anti-Grem1 antibody treatment in 5TGM1-tumour bearing mice specifically reduces 
skeletal tumour burden, but not splenic tumour. (A) RNA from whole cell suspensions of the spleen 
and compact bone of KaLwRij mice (n=9) was analysed by RT-PCR for Grem1 mRNA expression. 
PCR products were visualized on a 2% agarose gel. (B) Schematic illustrating the detection of splenic 
tumour signal by BLI. (C) Final BLI scans for anti-Grem1 treatment regimens started: prior to 5TGM1 
tumour (pre-treatment) cell inoculation, three days post-tumour cell inoculation (day 3), and 14 days 
post-tumour cell inoculation (day 14) measuring BLI tumour signal from the splenic region and skeletal 


















4.2.4. Bortezomib and anti-Grem1 antibody combination therapy does not reduce MM tumour 
burden 
In most instances,  MM patients are only diagnosed when the disease has spread to multiple sites 
throughout the body173 174. Given that the pre-clinical studies trialling the efficacy of anti-Grem1 
antibody only showed an ability to reduce MM tumour burden in early stages of disease, we 
hypothesized that the anti-Grem1 antibody would show a greater effect in more advanced disease when 
used in combination with a current standard-of-care therapy that acts directly upon the MM PCs 
themselves. This would therefore provide a double-edged approach to limit MM disease burden by 
targeting both the MM PCs and the MM-supportive microenvironment. KaLwRij mice, with established 
5TGM1 tumour burden, were treated with one of four treatment combinations; (1) 30mg/kg IgG control 
antibody and DMSO vehicle control, (2) 30mg/kg anti-Grem1 antibody and DMSO control (3) 
0.5mg/kg Bortezomib (Btz) and 30 mg/kg IgG control antibody or (4) a combination of 30mg/kg anti-
Grem1 antibody and 0.5mg/kg Btz. (Figure 4.7A). The sub-optimal dose of bortezomib was used in 
order to identify any additive or synergistic effects of anti-Grem1 antibody. As shown in Figure 4.7., 
there were no significant differences in the rate or extent of tumour progression between any of the 
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Figure 4.7: Anti-Grem1 antibody treatment in combination with sub-optimal Bortezomib does 
not reduce 5TGM1 tumour burden in vivo. (A) Schematic illustrating the experimental design for 
testing the effect of anti-Grem1 antibody in combination with the standard-of-care therapeutic 
bortezomib on 5TGM1 tumour burden.  At timepoint 0, KaLwRij mice were inoculated with 5x105 
5TGM1 MM PCs. At week two post-tumour cell inoculation, mice started treatment with (1) 30mg/kg 
IgG control and DMSO vehicle control, (2) 30mg/kg anti-Grem1 antibody and DMSO control (3) 
0.5mg/kg Bortezomib (Btz) and 30 mg/kg IgG control or (4) a combination of 30mg/kg anti-Grem1 
antibody and 0.5mg/kg Btz. Mice received a further three treatments over the final two weeks of the 
model. Tumour burden was measured throughout the study by BLI, and at the study endpoint by SPEP. 
(B) Graph depicts whole-body ventral BLI quantitation at weeks 2, 3 and 4 for IgG antibody and DMSO 
control, anti-Grem1 antibody and DMSO control, Btz and IgG antibody control and anti-Grem1 
antibody and Btz combination treated mice. (C) Final, week 4 BLI scans for each treatment group 
depicted in graph with representative BLI images. (D) SPEP was also used as a secondary, independent 
measure of tumour. Graph depicts level of paraprotein detected in serum following tail bleeds at week 
4 (normalised to internal albumin control). Representative electrophoretic images of paraprotein (>) 
and other serum proteins are shown on the right. Graphs depict mean ± SEM of n=5; mice per treatment 
group. P>0.05 (B) two-way ANOVA, Sidak’s multiple comparisons or (C) and (D) unpaired t-test. 
 
4.2.5. Anti-Grem1 antibody does not affect the ability of MM PC to home to the BM in vivo 
Given that a greater reduction in tumour burden was observed in mice that were treated with anti-Grem1 
antibody prior to tumour cell inoculation compared to those where treatment started after tumour cell 
inoculation, we hypothesized that Grem1 may play a role in the homing of MM PCs to the BM 
microenvironment. To investigate this, a 24-hour in vivo homing assay was performed. KaLwRij mice 
were treated twice weekly with the anti-Grem1 neutralising antibody or isotype control and 
subsequently systemically injected with 5TGM1 MM PCs. 24 hours following cell injection, mice were 
culled, and the BM was isolated from the hindlimbs of each mouse. The BM was isolated and analysed 
for the presence of GFP-positive 5TGM1 cells. There was no significant difference in the numbers of 
GFP-positive cells detectable in the BM of anti-Grem1 antibody treated mice compared to isotype 
control treated mice (t-test, p=0.1804, Figure 4.8A). Additionally, there was no significant difference 
in the number of GFP positive cells in the peripheral blood circulation (t-test, p=0.8498, Figure 4.8B) 
between the two treatment groups. Together, these results demonstrate that anti-Grem1 treatment does 
not affect the ability of MM PCs to home to the BM.  
 
 












Figure 4.8: Anti-Grem1 antibody treatment does not alter the ability of 5TGM1 MM PCs to home 
to the BM in vivo. KaLwRij mice were treated with 30mg/kg anti-Grem1 antibody or IgG control 
antibody twice over one week and subsequently injected with 5TGM1 MM PCs. GFP+ 5TGM1 MM 
PC within the (A) BM or (B) in the circulation 24 hours after tumour cell inoculation were analyzed by 
flow cytometry from IgG control or anti-Grem1 antibody treated mice. Graphs depict mean ± SEM of 
n=8 per treatment group from two independent replicate experiments, P>0.05, unpaired t-test. 
 
4.2.6. Anti-Grem1 antibody does not change the cellular composition of the BM 
microenvironment  
The cellular compartment of the BM microenvironment plays an essential role in supporting the 
continued growth and survival of MM PCs49. Given that Grem1 has previously been implicated in the 
maintenance of stem cell populations, namely in the regulation of HSC differentiation and osteoblast 
numbers and function175-178, there was a need to determine if the anti-tumorigenic effects of the anti-
Grem1 antibody could be attributed to changes in the cellular composition of the BM 
microenvironment. To investigate this, 6-8 week old tumour-naïve KaLwRij mice were treated with 
30mg/kg anti-Grem1 antibody or IgG control antibody twice weekly for two weeks. Three days 
following the last treatment, mice were culled, and the long bones were collected for compact bone and 
BM isolation. A panel of fluorescently-labelled antibodies to lineage-specific cell surface markers was 
used to identify the different cell populations present in these bone compartments. Compact bone was 
analysed for MSC populations, while the BM was assessed for HSC, macrophage and endothelial 
populations. There were no significant differences in the proportions of any of the cell populations 
within the BM microenvironment between anti-Grem1 antibody treated and isotype control treated mice 
(t-test, P>0.05, Figure 4.9A-D). 
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Furthermore, cardiac blood was sampled at the end of the study and analysed for any changes in 
haematological parameters between treatment groups to provide insight into any changes in mature 
myeloid and erythroid populations with anti-Grem1 antibody treatment. No significant differences were 
observed in any parameters (t-test, P>0.05, Figure 4.10A-O).  
Finally, the bone composition of tumour-bearing anti-Grem1 antibody and control treated mice was 
analysed by x-ray micro computed tomography (microCT), as the loss of Grem1 has previously been 
associated with increased bone volume and trabecular thickness in adult mice175 179. Whole tibiae were 
scanned using the SkyScan 1176 and images reconstructed using NRecon software. CTAn analysis was 
subsequently performed on reconstructed images to determine differences in bone composition. Bone 
volume, trabecular number and trabecular thickness were all unchanged between treatment groups (t-
test, P>0.05, Figure 4.11A-C).  
Taken together, these results indicate that anti-Grem1 antibody treatment does not overtly alter the 
cellular composition of the BM microenvironment. As such the putative mode of action whereby the 
anti-Grem1Ab exerts an anti-tumour effect in MM is likely to result from a direct neutralization of 
Grem1-mediated autocrine and paracrine signalling pathways, rather than an indirect effect on cellular 
architecture of the BM niche.  
 
 











Figure 4.9: Anti-Grem1 antibody treatment does not alter the cellular composition of the BM in 
vivo. KaLwRij mice were treated with 30mg/kg anti-Grem1 antibody or IgG control antibody twice 
weekly for two weeks. Mice were culled three days after the final treatment and BM and compact bone 
were collected from the long bones for flow cytometric analysis. Compact bone was analysed for (A) 
MSC lineage populations; OB, OP and MSCs. BM was analysed for (B) HSC lineage populations; 
progenitors, short-term and long-term HSC, and (C) mature (CD31+CD144+) and immature 
(CD31+CD144-) endothelial lineages. Graphs depict mean ± SEM from n=6 mice per treatment group 
from two independent experiments. Representative flow plots indicate the gating strategy used for each 
cell population. P>0.05, unpaired t-test. OB=osteoblast, OP=osteoprogenitor, MSC= mesenchymal 
stem cell, HSC-P= haematopoietic stem cell progenitors, ST-HSC= short-term haematopoietic stem 
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Figure 4.10: Anti-Grem1 treatment does not alter any haematological parameters in vivo. 
KaLwRij mice were treated with 30mg/kg anti-Grem1 antibody or IgG control twice weekly for two 
weeks. Peripheral blood was collected by cardiac puncture three days after the final treatment and was 
analysed on a HEMAVET analyser. Graphs depict mean ± SEM from n=6 mice per treatment group 
from two independent experiments. P>0.05, unpaired t-test. WBC=white blood cell, RBC=red blood 
cell, HB=haemoglobin, HCT=haematocrit, MCV=mean corpuscular volume, MCH=mean corpuscular 
haemoglobin, MCHC=mean corpuscular haemoglobin concentration, RDW=red blood cell distribution 
width, PLT=platelet, MPV=mean platelet volume.  
 
 
Figure 4.11: Anti-Grem1 antibody treatment does not alter trabecular bone volume, number or 
thickness in vivo. Micro CT analysis of (A) trabecular bone volume, (B) trabecular number and (C) 
trabecular thickness of the secondary spongiosa of the tibia in 10-week old KaLwRij mice injected 
with 5TGM1 myeloma plasma cells and treated with either IgG control or anti-Grem1-neutralising 
antibody. (A) Trabecular bone volume as a percentage of total bone (BV/TV%), (B) trabecular number 
(Tb. N./mm-1) and (C) trabecular thickness (Tb.Th. (mm)) of MM-tumour bearing KaLwRij mice 
treated with IgG control (n=4) or anti-Grem1 antibody (n=3). Graphs depict mean ± SEM. P>0.05, 
unpaired t-test. (C) Representative binary images of trabeculae in the proximal tibia of sample mice 
(Green represents bone). 
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4.2.7. There is a heterogenous response to anti-Grem1 treatment in other cancer settings 
Grem1 is one of the most overexpressed genes within the tumour microenvironment117 and has 
demonstrated mitogenic effects in colorectal cancer, non-small cell lung cancer, lung adenocarcinoma 
and glioma88 110 147 167. As such, further study of the use of the anti-Grem1 antibody in other cancers was 
evaluated. Given that the studies presented here demonstrated an effect in reducing MM skeletal tumour 
growth, the models chosen were those in which there is significant primary or secondary skeletal tumour 
involvement. To this end, osteosarcoma, a primary bone malignancy, as well as, prostate and breast 
cancer, where the bone is a common site of metastasis; were chosen to investigate this further. 
The K-HOS human osteosarcoma cells were injected directly into the tibia of 4-6 week old NSG mice. 
The direct administration into the BM microenvironment was required as the K-HOS line does not 
metastasize readily to the bone from systemic tumour cell inoculation. A pre-treatment protocol was 
utilized as this achieved the greatest reduction in tumour growth in the 5TGM1/KaLwRij MM model. 
Following three weeks of tumour growth there was no significant difference in tumour burden between 
mice pre-treated with anti-Grem1 antibody and those pre-treated with an IgG control antibody (Figure 
4.12A). As intra-tibial administration of tumour cells within the BM has the potential to overwhelm the 
microenvironment and bypass the reliance on the microenvironment for tumour growth, a systemic 
injection route was utilized for the breast and prostate cancer models. Previous studies have highlighted 
that injection via the caudal artery (CA) is most effective in achieving skeletal tumour growth from 
solid tumours that regularly metastasize there180. C57BL6 mice inoculated with PyMT-B01 murine 
breast cancer cells via the CA rapidly developed skeletal tumours localised in the long bones of the 
hindlimbs over a 2-week disease time course. A significant reduction of 35% in PyMT-B01 tumour 
burden was observed in anti-Grem1 antibody pre-treated mice compared to IgG control pre-treated mice 
(Figure 4.12B). In contrast, this anti-tumour effect was not observed in the PC-3 prostate cancer model. 
NSG mice, in which PC-3 human prostate cancer were CA injected cells, developed tumours within the 
skeleton and the liver over the 4-week disease time course. No difference in PC-3 prostate cancer 
tumour burden was observed between anti-Grem1 antibody and IgG control treated mice (Figure 
4.12C). Subsequent ex vivo analysis of the liver, lungs and bones also showed no significant difference 
in PC-3 tumour burden within the long bones when analysed in isolation from the liver (data not shown). 
A contributing factor to the lack of antibody effect on prostate cancer tumour burden may have been 
the unexpected level of liver tumour growth observed in this model compared to previous studies180. 
This may have limited the ability to observe any difference in skeletal tumour burden, with tumour cells 
readily able to recirculate from the liver, supporting continued skeletal tumour development. The 
combined results of these solid tumour studies demonstrate that anti-Grem1 antibody treatment has a 
mixed effect in limiting skeletal tumour burden in different cancer settings. This highlights the context-
dependent role for Grem1 in cancer, and as such the wider use of anti-Grem1 therapies in cancer needs 
to be assessed individually on a case-by-case basis.  
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Figure 4.12: Anti-Grem1 antibody treatment has a mixed response in other skeletal cancer 
models. Investigation of the efficacy of anti-Grem1 antibody treatment in three models of skeletal 
tumour growth. Mice received two treatments with either 30mg/kg anti-Grem1 antibody or IgG control 
antibody over one week and were subsequently inoculated with tumour cells. Treatment was continued 
twice weekly for the duration of each study and tumour burden was monitored by weekly BLI. (A) NSG 
mice were inoculated with K-HOS human-derived osteosarcoma tumour cells via intra-tibial (IT) 
injection. Graph depicts the final BLI scan at day 18 post-tumour cell inoculation for anti-Grem1 
antibody (n=11) and IgG control antibody treated (n=9) mice. Representative BLI images for day 18 
are shown.  (B) C57BL6 mice were injected with PyMT-B01 murine breast cancer cells via the caudal 
artery (CA). Graph depicts the final BLI scan at day 13 post-tumour cell injection for anti-Grem1 
antibody (n=13) and IgG control antibody treated (n=12) mice. Representative BLI images for day 13 
are shown. (C) NSG mice were injected with PC-3 human prostate cancer cells via the CA. Graph 
depicts the final BLI scan at day 28 post-tumour cell injection for anti-Grem1 antibody (n=8) and IgG 
control antibody treated (n=8) mice. Representative BLI images for day 28 are shown. Graphs depict 




It has previously been demonstrated that Grem1 is overexpressed within the MM BM 
microenvironment and promotes the proliferation of MM PC and as such, represents a therapeutic target 
in MM (Chapter 3). The studies presented in this Chapter aimed to determine whether Grem1 is a viable 
therapeutic target in the MM BM microenvironment, and specifically whether MM tumour growth 
could be limited through the use of an anti-Grem1 neutralising antibody (UCB Pharma, UK). Previous 
studies have demonstrated effective targeting of Grem1 using neutralising antibodies. For example, 
Kim, et al., developed the anti-Grem1 neutralising antibody GRE1, and demonstrated that GRE1 
treatment resulted in a significant reduction in lung adenocarcinoma cell proliferation and migration in 
vitro, however no studies were performed to test the effect on lung adenocarcinoma growth in vivo 181. 
Moreover, in vivo use of anti-Grem1 antibody, 16E3-2-1, has been shown to effectively prevent the 
disease pathology of vascular remodelling in pulmonary arterial hypertension 182. These studies 
demonstrate that Grem1 can be neutralised through antibody targeting and supports the use of blocking 
Grem1 as a treatment strategy. However, to date there have been no additional studies exploring the use 
of anti-Grem1 antibody-based therapy as a cancer therapeutic, despite the large body of evidence 
implicating Grem1 in cancer progression. 





Through a collaboration with UCB Pharma, UK, a Grem1-neutralising antibody was obtained for trial 
in pre-clinical models of MM. Initial in vitro testing of the antibody demonstrated an ability to 
significantly reduce MM PC growth, although this effect was limited to a reduction of only 17% in the 
rate of MM PC proliferation. Given the inability to fully recapitulate the complexities of the MM BM 
microenvironment in vitro, the 5TGM1/KaLwRij preclinical mouse model of MM was used to further 
investigate a role for Grem1 in disease development and determine whether therapeutically targeting 
Grem1 represents a viable treatment option. Subsequent studies in the KaLwRij/5TGM1 MM model 
demonstrated increased effectiveness when the anti-Grem1 antibody treatment was initiated earlier in 
the disease course, with an 85% reduction in tumour burden observed in anti-Grem1 antibody treated 
mice. These findings suggest Grem1 plays a role in both disease establishment and early tumour growth, 
and that targeting Grem1 within the tumour microenvironment represents a viable therapeutic option to 
reduce disease burden. While earlier treatment demonstrated the greatest reductions in tumour burden, 
there was a lack of any significant effect on tumour burden when antibody treatment was started in late 
stage, established disease.  This may suggest that there is a threshold limit of tumour burden whereby 
there is limited effectiveness of a therapy solely targeted at the tumour microenvironment when the 
disease burden is high. Considering that it has also been shown that MM PC can induce Grem1 
expression within the BM stroma (see Chapter 3), this may be a factor in the lack of therapeutic effect, 
as the large number of MM PCs may be stimulating an increase in Grem1 expression that is simply 
beyond the capacity for the anti-Grem1 antibody to neutralize with the antibody dosing strategy used 
in this study.  
Given that MM is usually diagnosed when the disease has progressed, and that the studies presented 
here show that anti-Grem1 antibody treatment does not significantly reduce MM tumour burden in the 
established disease setting, these in vivo studies highlight the limited clinical potential for anti-Grem1 
antibody treatment as an upfront monotherapy. Furthermore, the frontline standard-of-care treatment 
regimens in MM always require a combination therapy approach2. As such, anti-Grem1 antibody 
treatment was trialled in combination with the standard-of-care therapeutic bortezomib (VelcadeTM). A 
sub-optimal dose of bortezomib was employed to target the MM PC specifically, while the anti-Grem1 
antibody was concurrently used to target BM stromal-derived Grem1. There was a lack of any additive 
or synergistic effects of the bortezomib/anti-Grem1 antibody dual therapy on tumour growth in this 
study. However, as the KaLwRij/5TGM1 model of MM is particularly aggressive, a modified dosing 
regimen with increased frequency or concentration of treatments may allow for an anti-tumour effect 
to be observed. Furthermore, future studies may benefit from investigating whether upfront bortezomib 
treatment, followed by the inclusion of anti-Grem1 antibody as a maintenance therapy can prevent or 
reduce time to relapse, given that reductions in MM tumour growth of 85% and 54% are observed when 
treatment is started prior to, or in the early stages following tumour cell inoculation, respectively. Given 
that the cytokine interleukin-6 (IL-6) has been demonstrated to upregulate Grem1 in MM (Chapter 3), 





combination targeting of Grem1 and IL-6 may also be beneficial. The anti-IL-6 antibody, Siltuximab, 
has previously shown great promise in MM pre-clinical studies, however failed to have a significant 
effect in the clinic153 183 184. It remains to be determined whether IL-6 inhibitory agents, used in 
combination with anti-Grem1 antibody treatment, would show an additive or synergistic anti-MM 
effect. 
As a greater reduction in tumour burden was observed when treatment started prior to tumour cell 
inoculation, it raises the question as to whether Grem1 plays a role in the homing to and retention of 
MM PCs to the BM. A 24-hour homing assay was used to investigate this, with no significant difference 
observed in the number of GFP positive 5TGM1 MM PCs within the BM or remaining in circulation. 
Previous studies have suggested a role for Grem1 in cell migration with involvement in promoting an 
EMT phenotype110 185. While EMT is traditionally characteristic of solid malignancies, it is well-
documented that MM PC can also undergo an EMT-like transition to enable migration to distal BM 
sites186 187. However, the studies presented here suggest that treatment of mice with anti-Grem1 in vivo 
immediately prior to tumour cell inoculation, does not limit the ability of MM PCs to reach the BM. 
However, further investigation is warranted to determine if there may be an effect on the migratory 
ability of cells once established within the BM to reach other sites. This could be investigated using an 
intra-tibial tumour model, where the number of MM PCs that reach the contralateral leg can be analysed 
to determine the effect on migration75. However, as there is a known role for Grem1 in MM PC 
proliferation, it may be difficult to ascertain whether any differences in the number of cells migrating 
to other bone sites are truly reflective of a migratory defect or whether such differences are due to 
altered responses to proliferative/quiescent signals of MM PCs once they reach the new BM location.  
It has previously been reported that Grem1 is a key factor in stem cell maintenance116 176 188 and skeletal 
homeostasis178 189. Shekels, et al., reported that Grem1 skews HSC differentiation toward B cell 
development, while reducing mature myeloid populations177, which in the context of MM may suggest 
a supportive role for B cells and their PC progeny. Furthermore, Grem1 has been associated with 
limiting osteoblast number and activity175 178, and a reduction in osteoblasts is  commonly associated 
with the proliferative MM BM niche40 49. These Grem1-induced cellular changes in normal tissues 
support the notion that Grem1’s mitogenic role in MM may be due to Grem1-mediated changes to the 
composition of the cellular compartment of the BM microenvironment in MM. As such, any cellular 
changes that occur as a result of anti-Grem1 antibody treatment in the absence of tumour were 
investigated. The results presented here demonstrate that anti-Grem1 antibody treatment does not 
significantly alter the cellular composition of the BM microenvironment. Furthermore, HEMAVET 
analysis of mature myeloid populations, within peripheral circulation, also demonstrated no change 
between control and antibody treated mice.  





In addition to changes in cell populations and cell signalling, Grem1 has been shown to influence the 
development of bone, with loss of Grem1 associated with increased bone formation and subsequently 
increased bone volume and trabecular thickness178 179. Conversely, the overexpression of Grem1 impairs 
bone formation190. Therefore, this study also investigated how anti-Grem1 antibody treatment affects 
these bone parameters. MicroCT was used to analyse trabecular bone volume, trabecular number and 
trabecular thickness in anti-Grem1 antibody and isotype control antibody treated mice. No differences 
in bone composition were observed between treatment groups. While these results differ to previously 
reported findings for the role of Grem1 in bone, previous studies utilized genetic knockout models, 
whereby Grem1 expression was removed at the neonatal and pre-weaning stages. The studies presented 
here utilized mice at 6 weeks of age, where the mice were substantially older and more developed at 
the time of Grem1 inhibition than those used in knockout studies178 179. Furthermore, it is conceivable 
that the levels of BM Grem1 cannot be effectively neutralised by the administration of a single anti-
Grem1 agent.  
Grem1 is widely reported to promote tumour cell proliferation, invasion and spread in many cancer 
settings. As such, an anti-Grem1 therapeutic may not only benefit MM patients, but also individuals 
with other cancers94 117. Due to the role of Grem1 in maintaining bone homeostasis and its effect in MM 
within bone, this study investigated several other malignancies that were known to grow within the 
skeletal microenvironment. In the context of breast cancer, tumour growth was significantly reduced 
with anti-Grem1 antibody treatment, while prostate cancer and osteosarcoma tumour growth were 
unchanged. As a BMP-antagonist, the BMP-dependent roles of Grem1 in cancer provide a potential 
explanation for the disparity in the results observed. Previous studies utilizing the PyMt breast cancer 
cell line showed that disruption of BMP-signalling promotes tumour cell proliferation and metastasis191, 
providing a rationale as to why restoration of BMP-signalling, via blockade of  Grem1, resulted in 
reduced PyMt tumour burden. Conversely, BMP-signalling in the K-HOS osteosarcoma and PC-3 
prostate cancer lines has been shown to have no, or pro-tumorigenic effects, respectively192 193. 
However, it is important to note that the actions of BMP in malignant tissue remains controversial, with 
contradictory oncogenic and apoptotic mechanisms for each of these cancer cell lines also reported194-
198. Therefore, further investigation is required to elucidate the specific activity of BMPs in each 
individual cancer setting, and how this may contribute to the differences in response to the anti-Grem1 
neutralising antibody. Moreover, other non-canonical effects of Grem1 and additional influences such 
as the disease stage and tumour microenvironment are likely to contribute to the differences in tumour 
responses observed across studies, and warrant further study85.  
In summary, advances in MM therapy over the past 20 years have resulted in an overall improved 
survival. Despite this, patients inevitably become refractory to treatment and the disease relapses199. 
While the BM is known to support MM PC proliferation, survival and drug resistance, there has been 
limited success and there are few therapies targeting the MM BM microenvironment that have made it 





into standard clinical practice199 200. Therefore, there remains a need to identify new BM therapeutic 
targets that could effectively reduce MM tumour burden. In vitro studies investigating a role for Grem1 
in MM highlighted that stromal-derived Grem1 promotes MM PC proliferation and as such represented 
a viable therapeutic target for treating MM. In this study, anti-Grem1 antibody therapy was shown to 
significantly reduce MM tumour burden in early stages of disease in vivo. Further investigation of the 
mode of action showed that it is likely that anti-Grem1 antibody works by blocking signalling pathways 
that prevent MM PC proliferation and survival, as no changes in the cellular composition of the BM 
were observed following antibody treatment. Future studies analysing other treatment combinations 
including anti-Grem1 antibody treatment would prove beneficial to the clinical translation of targeting 
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Multiple Myeloma (MM) patient outcomes have vastly improved in the past 20 years, yet the 5-year 
survival rate for MM remains less than 50%, below the average Australian 5-year survival rate of 68.9% 
for all cancers92. Despite numerous, ongoing studies demonstrating the activity of novel MM therapeutic 
agents in cell line and in vivo models of MM, few of these agents have made an impact in clinical 
trials201. Furthermore, excluding Daratumumab and derivatives of existing drugs, all of the therapeutic 
agents recommended in the International Myeloma Working Group management guidelines have been 
known to have anti-MM activity for over 20-years202-210. This highlights a need for more rigorous pre-
clinical investigations of novel therapeutic agents, that utilise multiple and/or improved strategies to 
identify new therapeutic targets and treatment modalities for MM.  
MM plasma cells (PCs) are reliant upon the bone marrow (BM) microenvironment for their continued 
growth and survival49. As such, it is essential that the interactions between MM PCs and the BM 
microenvironment are considered during the development of therapeutic strategies for MM. However, 
due to the complexity of the BM microenvironment, with a multitude of cell types and interactions 
involved, it is difficult to replicate this environment for study in vitro211. This necessitates the use of in 
vivo pre-clinical models of MM, that effectively model the interactions between the MM PC and BM 
microenvironment, to increase the understanding of MM disease development and for the discovery of 
new therapies 211 212. Studies presented as part of this thesis have demonstrated that the BM stromal-
derived protein Gremlin1 (Grem1) promotes the growth of MM PC and can be effectively targeted in a 
commonly used pre-clinical mouse model of MM (Chapter 3 and 4, respectively). Given the failure of 
many novel therapeutics to progress from pre-clinical models to success in the clinic213, further 
confirmation of the efficacy of targeting Grem1 in MM was needed.  
Murine models of MM are critical in the development of new therapeutic strategies in MM. Although 
there are a numerous murine pre-clinical MM models that are commonly used, there are few that reliably 
reproduce the pathophysiology of MM disease. Xenogenic models, such as the severe combined 
immunodeficient (SCID)-xenograft and SCID-hu models, utilize the inoculation of human MM cell 
lines and primary MM cells in order to produce growth of human MM cells in vivo214-216. However, due 
to cross-species differences between the human MM PC and mouse BM, these models are limited in 
their ability to replicate the BM interactions observed in disease211. Furthermore, as these models often 
lack of a fully functioning immune system, they cannot replicate the important role of the immune 
response in disease211.  
In contrast to the use of immunodeficient-human implant models, syngeneic murine models of MM can 
more effectively replicate the interactions between MM PC and BM. The systemic murine 5TMM 
models are derived from spontaneously occurring PC tumours in the KaLwRij strain of mouse, and 
different clones have been established to develop a range of sub-lines that replicate the clinical signs of 
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MM to varying degrees120. However, due to the specific genetic background of the KaLwRij mouse, 
this model cannot easily be used to modify the host environment through transgenic alterations, as the 
requisite knockout/transgenic mice are in mouse strains with different genetic backgrounds217. The 
5TGM1/KaLwRij model was previously utilized to demonstrate an anti-tumour effect of an anti-Grem1 
antibody (Chapter 4), however given the heterogenous nature of the genetic mutations observed in the 
PCs of patients with MM, it would be ideal to further validate these results in an additional MM model 
with a different genetic aetiology.  
The Vk*MYC murine model of MM was developed through induced activating mutations in the MYC 
gene, which encodes for a protein known to be involved in MM disease initiation34. The genetically 
modified mice consistently develop MM-like disease over a long disease time course. Furthermore, 
upon transplantation of Vk*Myc-derived cancer cells into recipient mice, tumours develop over 10 -26 
weeks. As the MM PCs in this model are still reliant on the BM and have a relatively long latency 
period of disease, this model presents an ideal tool for further analysis of potential therapeutic targets. 
Furthermore, studies investigating the effectiveness of the Vk*MYC model in replicating clinical 
response to MM therapeutics have shown that this model is a good predictor of clinical outcome201 218. 
A key benefit of the Vk*MYC transplant models is the ability to use these cells in a range of genetically 
modified hosts due to sharing a background with the commonly used C57BL/6 mouse strain.  
In this chapter, the Vk*MYC pre-clinical MM model was utilized as a secondary tool to study the 
efficacy of an anti-Grem1 therapeutic in reducing MM tumour burden. In addition, this chapter details 
the first successful ex vivo growth and genetic modification of Vk*MYC cells, and the subsequent 
utilization of these novel cells in a transgenic Grem1 knockout mouse model.  
5.2. Results 
5.2.1. Anti-Grem1 antibody treatment showed no effect on tumour burden in the Vk*MYC 4929 
tumour model  
Anti-Grem1 antibody treatment in the 5TGM1/KaLwRij pre-clinical MM model has previously 
demonstrated a significant reduction in tumour burden of up to 80% (Chapter 4). The significant 
reduction in tumour burden upon antibody treatment provided promise that the anti-Grem1 antibody 
represents an effective therapeutic strategy in MM. However, validation of this response in an 
independent, secondary in vivo model of MM would provide increased evidence for the clinical use of 
this therapeutic approach. The fully syngeneic and immunocompetent Vk*MYC model represented a 
suitable model for secondary analysis of the use of the anti-Grem1 antibody in MM. Vk*MYC 
transplant lines are derived from spontaneous PC tumours in the transgenic Vk*MYC mouse.  These 
lines can only be maintained through serial in vivo transplantation of cryopreserved cells from the spleen 
or BM of Vk*MYC tumour-bearing mice34. The Vk*MYC 4929 line is one of the more commonly used 
clones and results in disease development in 12-16 weeks, with evidence of end-organ damage, bone 
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lytic lesions and splenomegaly219. Given the widely reported use of this Vk*MYC line, it was utilized 
to further investigate the effect of the anti-Grem1 antibody on MM tumour burden. Initial establishment 
of Vk*MYC 4929 transplants in C57BL6 mice resulted in development of detectable MM by 
paraprotein at 10 weeks post-transplant (4/10 mice developed detectable paraprotein, Figure 5.1A). 
Additionally, there was a significant increase in spleen length, indicative of splenomegaly, in Vk*MYC 
4929 transplant mice with detectable tumour burden by SPEP compared to mice with no detectable 
paraprotein (t-test, P=0.0456, Figure 5.1B). Furthermore, as it has previously been shown that there is 
an association between MM tumour burden and BM stromal expression of Grem1, this was also 
investigated in the Vk*MYC model. Analysis of Grem1 expression in whole bone of Vk*MYC 4929 
tumour-bearing mice compared to non-tumour control animals demonstrated a significant increase  in 
Grem1 expression is also observed in Vk*MYC 4929 tumour-bearing mice compared to healthy 
C57BL6 controls (Mann-Whitney, P<0.0001, Figure 5.1C).  
Given that establishment of the Vk*MYC 4929 line showed reliable reproduction of the clinical signs 
of MM and evidence of increased Grem1 expression in the BM, this model was ideal for further testing 
of the anti-Grem1 antibody on MM disease development. C57BL6 mice were pre-treated with anti-
Grem1 antibody or isotype control antibody and subsequently inoculated with whole spleen transplants 
from Vk*MYC 4929 tumour-bearing mice. Treatment was continued twice weekly for the duration of 
the study (Figure 5.2A). As the Vk*MYC line can only be maintained by serial transplantation, disease 
monitoring throughout the study was performed via measurement of serum paraprotein. Serum 
paraprotein levels of anti-Grem1 antibody and control antibody treated mice were not significantly 
different at any timepoint throughout the study (two-way ANOVA, Sidak’s multiple comparisons, 
P>0.05, Figure 5.2B). Furthermore, there appeared to be an increase in tumour burden in male mice 
compared to female mice, however no significant differences between sex-specific treatment groups 
was observed (one-way ANOVA, Tukey multiple comparisons, P>0.05, Figure 5.2C). Importantly, the 
apparent sex-bias was not a phenomenon observed in the 5TGM1/KaLwRij murine MM model 
(Chapter 4). 
While SPEP is a reliable method of analysis to determine global tumour burden in this model, it does 
not provide any indication of the spatial distribution of tumours throughout the body. In order to analyse 
this further, flow cytometric analysis of cell surface markers to identify the CD138+/B220- PC 
population was performed from samples of the BM, spleen and peripheral blood of each mouse. In 
agreement with the SPEP results, no significant differences in the number of PCs were observed 
between treatment groups, with male mice maintaining a trend of increased tumour burden compared 
to females (ANOVA, Sidak’s multiple comparisons and t-test, P>0.05, Figure 5.3A-C). Flow 
cytometric analysis of PC burden in the BM demonstrated that despite 13 out of 20 mice displaying 
intense paraprotein bands, there was minimal BM involvement in this model, with these 13 mice having 
less than 1% clonal PC burden in the BM. Further investigation of tumour-bearing mice in this study 
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revealed extensive extramedullary tumour growth with the Vk*MYC 4929 MM model. Many of the 
mice were observed to have splenomegaly, however there was no statistically significant difference in 
the size of spleens between treatment groups (T-test and One-way ANOVA, Tukey Multiple 
comparisons, P>0.05, Figure 5.4A). Additionally, 75% of mice in the study were observed to have MM 
macrolesions in the liver, as evidenced by large nodular liver metastases (Figure 5.4B). There was no 




Figure 5.1: Vk*MYC clone 4929 produces MM-like disease within 10-weeks. C57BL6 mice were 
inoculated with 1x106 pooled splenic cells derived from Vk*MYC 4929 tumour-bearing mice. MM-
like disease developed over a 10-week disease time course, with MM tumour burden in mice confirmed 
by SPEP. (A) Representative electrophoretic image of paraprotein (>) and other serum proteins at 10 
weeks post-tumour cell inoculation. (B) Evidence of extramedullary disease was assessed by the 
presence of splenomegaly. Comparison of spleen lengths of mice with detectable paraprotein (M-spike) 
or without (no M-spike). Graph depicts mean ± SEM of n=6; no M-spike, and n=4; M-spike. *P<0.05, 
t-test. (C) Grem1 expression in the compact bone of control, non-tumour mice and Vk*MYC 4929 
tumour-bearing mice relative to β-actin reference gene expression. Graph depicts mean ± SEM of n=10 
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Figure 5.2: Anti-Grem1 antibody treatment does not reduce global Vk*MYC 4929 tumour 
burden by SPEP. (A) Schematic illustrating the experimental design for testing the effect of anti-
Grem1 antibody on Vk*MYC 4929 tumour burden. C57BL6 mice received two doses of 30mg/kg anti-
Grem1 antibody or IgG control antibody treatment prior to inoculation with 1x106 pooled splenic cells 
from Vk*MYC 4929 tumour-bearing mice at timepoint 0. Treatment continued twice weekly for the 
duration of the tumour model. Tumour burden was measured throughout the study by SPEP.  (B) Graphs 
depict levels of paraprotein detected in serum following weekly tail bleeds over the duration of the 
study (normalised to internal albumin control). (C) Graphs depict level of paraprotein detected in serum 
following tail bleeds at the conclusion of the study, week 10. Graphs depict mean ± SEM of n=10 mice 
per treatment group. P>0.05, (B) two-way ANOVA, Sidak’s multiple comparisons or (C) unpaired t-
test. (D) Representative electrophoretic images of paraprotein (>) and other serum proteins are shown 
on the right.  
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Figure 5.3: Anti-Grem1 antibody treatment does not reduce Vk*MYC 4929 tumour burden in 
the BM, circulation or spleen by flow cytometry. C57BL6 mice treated with 30mg/kg anti-Grem1 
antibody or IgG control antibody and subsequently injected with 1x106 pooled splenic cells from 
Vk*MYC 4929 tumour-bearing mice. 10-weeks post-tumour cell inoculation CD138+/B220- Vk*MYC 
4929 MM PCs within the (A) BM, (B) PB circulation, and (C) spleen were analysed by flow cytometry 
from IgG control and anti-Grem1 antibody treated mice. Graphs depict mean ± SEM of n=10 per 
treatment group, P>0.05, comparison of two-variables; unpaired t-test, comparison of more than two 
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Figure 5.4: Anti-Grem1 antibody treatment does not reduce the incidence of splenomegaly or 
liver macro-lesions in Vk*MYC 4929 tumour-bearing mice. C57BL6 mice were treated with 
30mg/kg anti-Grem1 antibody or IgG control antibody and subsequently injected with 1x106 pooled 
splenic cells from Vk*MYC 4929 tumour-bearing mice. At the conclusion of the study, 10-weeks post-
tumour cell inoculation, the (A) length of spleens was assessed in mice treated with IgG control or anti-
Grem1 antibody. Graphs depict mean ± SEM of n=10 per treatment group. P>0.05, 2 variables; t-test, 
>2 variables; one-way ANOVA, Tukey’s multiple comparisons. Representative images of spleens at 
the conclusion of the study are shown. (B) The number of Vk*MYC tumour-bearing mice treated with 
IgG control antibody or anti-Grem1 antibody with overt liver metastases, defined as visible liver 
nodules upon dissection. Graphs depict n=5-10 per treatment group. P>0.05, 2 variables; Fisher’s exact 
test, >2 variables; Chi-square test for trend. Representative images of normal livers and livers with 
nodular liver lesions are shown. (C) Paraffin-embedded liver tissue sections were stained for H&E 
cytoplasmic (pink) and nuclear (purple/blue) staining to confirm the presence of MM PC tumours. 
5.2.2. Anti-Grem1 antibody treatment showed no effect on tumour burden in the Vk*MYC 3596 
tumour model   
Due to the limitations associated with the disease presentation of MM in the Vk*MYC 4929 model, an 
alternative Vk*MYC clone was established in order to test the effects of anti-Grem1 antibody on MM 
tumour growth. Similar to the Vk*MYC 4929 transplantable line, the Vk*MYC 3596 line is splenic-
derived, however the MM tumours from this line developed at a slower and less intense rate, as 
measured by serum paraprotein from 12-weeks post-tumour cell inoculation (Figure 5.5A). In contrast 
to mice injected with the Vk*MYC 4929 line, the mice injected with the Vk*MYC 3596 line did not 
show signs of extramedullary disease, with no significant difference in spleen length between mice with 
detectable paraprotein (M-spike) and those without (t-test, P=0.1630, Figure 5.5B). Neither was there 
any evidence of nodular liver lesions upon post-mortem examination. Despite the lack of significantly 
increased Grem1 expression in the BM of Vk*MYC 3596 tumour-bearing mice bone (t-test, P=0.6656, 
Figure 5.5C), the Vk*MYC 3596 transplant line had detectable paraprotein in 6/10 mice and clonal 
MM PC growth within the BM as determined by analysis of H&E stained BM sections (Figure 5.5D). 
Therefore, the Vk*MYC 3596 transplant line still represented a suitable secondary option for further 
testing the effects of anti-Grem1 antibody treatment on MM tumour burden. 
C57BL6 mice were pre-treated with either anti-Grem1 antibody or isotype control antibody and 
subsequently inoculated with whole spleen transplants from Vk*MYC 3596 tumour-bearing mice. 
Antibody treatment was continued twice weekly for the duration of the study (Figure 5.6A). Tumour 
burden was not detected by serum paraprotein until the later stages of this study. At the conclusion of 
the study there was no significant difference in tumour burden by serum paraprotein levels between 
mice treated with either an anti-Grem1 antibody or IgG isotype control antibody (t-test, P=0.9293, 
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Figure 5.6B). While no difference in tumour burden was observed between treatment groups, the uptake 
of tumour among the experimental cohorts was variable, with approximately 45% of mice displaying 
no or low detectable paraprotein by the conclusion of the study, irrespective of the treatment group. 
Furthermore, examination of tumour burden specifically within the BM of this cohort was not possible 
as the expression of the CD138-PC marker was not readily detectable by flow cytometry within these 
samples, despite the confirmation of the presence of PCs within the BM of Vk*MYC 3596 tumour-
bearing mice by histomorphometric analysis in initial pilot studies (data not shown).  
 
Figure 5.5: Vk*MYC clone 3596 produces MM-like disease within 12-weeks, in the absence of 
splenomegaly. C57BL6 mice were inoculated with 1x106 pooled splenic cells derived from Vk*MYC 
3596 tumour-bearing mice. MM-like disease developed over a 12-week disease time course, with MM 
tumour burden in mice confirmed by SPEP. (A) Representative electrophoretic image of paraprotein 
(>) and other serum proteins at 12 weeks post-tumour cell inoculation. (B) Evidence of extramedullary 
disease was assessed by the presence of splenomegaly. Comparison of spleen lengths of mice with 
detectable paraprotein (M-spike) or without (no M-spike). Graph depicts mean ± SEM of n=4; no M-
spike, and n=6; M-spike. P=0.1630, t-test. (C) Grem1 expression in the compact bone of control, non-
tumour mice and Vk*MYC 3596 tumour-bearing mice relative to β-actin reference gene expression. 
Graph depicts mean ± SEM of n= 16: non-tumour and n=15: Vk*Myc per group. P=0.6656, t-test. (D) 
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Figure 5.6: Anti-Grem1 antibody treatment does not reduce global Vk*MYC 3596 tumour 
burden by SPEP. (A) Schematic illustrating the experimental design for testing the effect of anti-
Grem1 antibody on Vk*MYC 3596 tumour burden. C57BL6 mice received two doses of 30mg/kg anti-
Grem1 antibody or IgG control antibody treatment prior to inoculation with 1x106 pooled splenic cells 
from Vk*MYC 3596 tumour-bearing mice at timepoint 0. Treatment continued twice weekly for the 
duration of the tumour model. Tumour burden was measured throughout the study by SPEP.  (B)  Graph 
depicts level of paraprotein detected in serum following tail bleeds at the conclusion of the study, week 
12. Graphs depict mean ± SEM of n=10 mice per treatment group. P=0.9293, unpaired t-test. 
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5.2.3. Establishment of a bone tropic, GFP and luciferase expressing Vk*MYC cell line through 
ex vivo culture  
The existing Vk*MYC transplant models are limited by their inability to grow ex vivo and hence, to be 
readily genetically modified. This study aimed to establish the growth of Vk*MYC ex vivo by utilizing 
the Grem1-overexpressing OP9-BM stromal cell line as a feeder-layer. OP9 stromal cells were seeded 
in a 3cm tissue culture dish and allowed to establish a monolayer. Cryopreserved Vk*MYC 4929 
splenic-derived cells were thawed and fluorescently labelled with antibodies to CD138 and B220 cell 
surface markers to enable subsequent isolation of a pure PC population by fluorescent activated cell 
sorting (FACS). The splenic-derived Vk*MYC 4929 cells were chosen based on a faster growth rate 
observed in vivo from published studies that frequently use splenic-propagated Vk*MYC cells34 201 220 
221. The sorted CD138+/B220- PC population was cultured upon the stromal-feeder layer (Figure 5.7A-
B). Given the reliance of Vk*MYC cells on the BM microenvironment, it was thought that culture with 
a BM stromal feeder layer would continue to provide the necessary interactions and factors to support 
their ongoing growth. As Grem1 has been demonstrated to support increased MM PC proliferation the 
OP9-Grem1 overexpressing stromal cell line was utilized as a feeder layer and it was hypothesized that 
this would also help with the propagation the Vk*MYC MM PCs ex vivo. While most Vk*MYC PCs 
died in the days following the initiation of ex vivo culture, solitary cells survived while attached to the 
stromal layer. 2-3 weeks following the start of culture, the presence of bright, grape-like clusters of cells 
upon the stromal-layer were observed under light microscopy (Figure 5.7B). The expanded PC 
populations, in culture with the stromal-feeder layer, were transfected with the SFG-NES-TGL 
construct171, a triple reporter retroviral vector that has previously been used in the 5TGM1.Bmx1 cell 
line to allow for fluorescent sorting by GFP and in vivo bioluminescent imaging (BLI) due to the 
expression of firefly luciferase170 222.  Transfected cells (referred to as Vk*MYC.SFG from hereon) were 
assessed for luciferase (Figure 5.7C) and GFP (Figure 5.7D) expression by luciferase assay and 
fluorescent microscopy, respectively.  
The establishment of the Vk*MYC.SFG line provides many advantages to the existing Vk*MYC pre-
clinical model, including efficient isolation of pure PC populations due to the expression of GFP and 
ease of monitoring the spatial-distribution of tumour growth throughout the study by live BLI due to 
luciferase expression. However, these changes did not overcome the main limitation of the original 
Vk*MYC 4929 population: the occurrence of substantial extramedullary disease with minimal BM 
involvement. In order to improve this, Vk*MYC.SFG cells were passaged in vivo through bone to 
generate a bone-tropic line more representative of the pattern of tumour growth observed in MM (Figure 
5.8A). Initial in vivo tumour spread of the Vk*MYC.SFG cells, as determined by BLI, was concentrated 
throughout the abdominal cavity, supportive of the spleen and liver contribution observed in the initial 
Vk*MYC 4929 study (Figure 5.8B-1st BM passage). GFP+ PCs were isolated by flow cytometry from 
the BM of 20-week-old tumour-bearing mice (now called the Vk*MYC.SFG.BMx1 line), and 
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subsequently re-injected into C57BL6 recipient mice. In this second group of C57BL6 mice, the 
Vk*MYC.SFG.BMx1 cells produced an increase in tumour burden concentrated within the BM, as 
demonstrated by BLI (Figure 5.8B-2nd BM passage). This serial sorting and in vivo passaging was 
repeated an additional time to further increase the bone tropism of these cells. This study has 
demonstrated the ex vivo expansion and genetic modification of Vk*MYC cells for the first time. Future 
work will further expand and characterise this cell population to enable its wide-spread use as a pre-




Figure 5.7: Generation of a GFP positive, luciferase positive Vk*MYC.4929 cell line for use in 
vivo. (A) Schematic illustrating the experimental design for ex vivo culture and modification of 
Vk*MYC MM PCs. CD138+/B220- Vk*MYC 4929 PCs were isolated by FACS and cultured on a 
feeder-layer of Grem1-overexpressing OP9 BM stromal cells. The pooled PC and stromal cell 
population was transfected with the SFG-NES-TGL reporter construct. GFP+ Vk*MYC PCs were 
isolated from the GFP+, TdTomato+ OP9 stromal cells and used for subsequent in vivo injection. (B) 
CD138+/B220- Vk*MYC 4929 PCs were isolated from cryopreserved pooled splenic samples from 
tumour-bearing Vk*MYC 4929 mice by FACS. Representative image of Vk*MYC MM PC outgrowth 
on stromal cells as determined by the presence of grape-like clusters of bright, circular cells under light 
microscopy. (C) Luciferase expression in transfected Vk*MYC cells was assessed by luciferase assay. 
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luciferin. Representative BLI image from serially diluted cells shown below. (D) Representative image 














Figure 5.8: Passaging Vk*MYC.SFG through BM in vivo produces a bone tropic MM line. (A) 
Schematic illustrating the experimental design for BM passage of Vk*MYC.SFG MM PCs. C57BL6 
mice were systemically inoculated with Vk*MYC.SFG cells. Following 20-weeks of tumour 
establishment, BM from the long bones from injected mice were isolated and GFP+ MM PC cells were 
selected by FACS. The sorted GFP+ cells were injected into another population of C57BL6 mice. This 
process was repeated an additional time. (B) Representative BLI images for mice at week 20 post-
Vk*MYC.SFG MM PC inoculation for each subsequent BM passage are shown.  
 
5.2.4. Grem1 genetic knockout mice do not demonstrate a reduction in intra-tibial 
Vk*MYC.SFG tumour growth  
Previous studies have demonstrated that many therapeutic agents have unintended off-target effects223 
224.  Therefore, it was important to confirm that the anti-tumour effect of the anti-Grem1 antibody, as 
demonstrated in the 5TGM1/KaLwRij model (Chapter 4), was attributable to specific targeting of 
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tumour burden in vivo was utilized: a Grem1 genetic knockout model. Grem1 plays an essential role in 
early skeletal and organ development, and the constitutive loss of Grem1 is largely embryonically lethal, 
as such Grem1 genetic ablation must be induced post-birth. To generate a Grem1 knockout mouse 
model, mice homozygous for loxP-flanked Grem1 (Grem1-floxed; Grem1fl/fl)179 were crossed with the 
B6.Cg-Ndor1Tg(UBC-cre/ERT2)1Ejb/1J (UBC-Cre) inducible-cre mouse strain225 (Figure 5.9A-B). The UBC-
Cre mouse contains the Cre-ERT2 fusion gene under the control of the ubiquitin C (UBC) promoter 
sequence (Figure 5.9A), enabling widespread activation of cre-recombinase upon exposure to the 
estrogen receptor ligand, tamoxifen. Upon tamoxifen induction, cre-mediated recombination resulted 
in deletion of the loxP flanked Grem1 (Figure 5.9B). To ensure that effective knockout of Grem1 could 
be achieved in these mice, compact bone and BM was isolated from the long bones of UBC-
cre/Grem1fl/fl mice. Subsequently, these cells were cultured ex vivo and treated with the synthetic 
tamoxifen-derivative, 4-hydroxytamoxifen (OHT). Tamoxifen-induced loxP recombination resulted in 
a reduction in Grem1 expression of approximately 98% within compact bone (t-test, P=0.2762, Figure 
5.9C), and >99% reduction within the BM (t-test, P=0.0288, Figure 5.9D), although the results in 
compact bone did not reach statistical significance. Furthermore, RNA in situ hybridization for 
detection of Grem1 RNA in the BM of tamoxifen-treated Grem1fl/fl mice (performed by Hiroki 
Kobayashi and Jia Ng, Gastrointestinal Cancer Biology Group, SAHMRI) demonstrated an almost 
complete lack of Grem1-positive staining compared to tamoxifen treated-Grem1wt/wt controls that 
maintained evident Grem1 expression (Figure 5.9E).   
The inducible UBC-Cre, Grem1fl/fl knockout model demonstrated great ability to eliminate Grem1 
expression in mice, and as such, represented an ideal model to further investigate the role of Grem1 in 
MM disease development. As Vk*MYC cells share the same C57BL6 genetic background as the Grem1 
knockout mice, these transplantable MM cells were used to model myeloma in these mice. However, 
given the considerable extramedullary disease, and limited BM tumour growth observed following the 
systemic injection of Vk*MYC transplants (Figure 5.4A-C), a modified approach was needed. Hence, 
the novel Vk*MYC.SFG cell line generated in this study (Figure 5.7) was utilized. The GFP expression 
in this cell line enabled isolation of a pure MM PC population that could be directly injected into the 
BM space of the tibia in tamoxifen-treated Grem1-wildtype and -knockout mice. Intra-tibial injection 
of tumour cells limits their dissemination to other organs that may result in extra-medullary disease. 
Intra-tibial tumour models have not previously been demonstrated with Vk*MYC cells, as injection of 
heterogenous-splenic populations into the tibia may introduce an array of other cell types into the BM 
and produce an environment not representative of MM. The ability to isolate Vk*MYC.SFG MM PCs 
based on GFP expression circumvents the complication of whole spleen injection into the BM. 
Furthermore, the expression of luciferase by these cells enabled BLI tumour monitoring in live mice. 
MM PCs were readily detectable in the injected hindlimbs of mice at week 2 (t-test, P=0.3368, Figure 
5.10D) and week 3 (t-test, P=0.3166, Figure 5.10D) post-tumour cell inoculation and showed a trend 
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toward decreased tumour burden in Grem1-knockout mice (UBC-cre, Grem1fl/fl) compared to the 
Grem1-wildtype (UBC-cre, Grem1wt/wt) controls. However, the BLI signal in mice declined in the later 
phases of the study, until it was no longer detectable most mice. This made it difficult to determine any 
true significant difference in tumour burden between Grem1-wildtype (UBC-cre, Grem1wt/wt) and -
knockout mice (UBC-cre, Grem1fl/fl) at the conclusion of the study. Furthermore, flow cytometric 
analysis for V*MYC.SFG cells demonstrated that approximately 70% of mice displayed less than 1% 
BM PC tumour burden by GFP+ at the conclusion of the study (Figure 5.10E). In combination, the BLI 
and GFP analysis suggests that these cells may not achieve sustained in vivo growth long-term, or that 
there is loss of luciferase and GFP expression in these cells over the course of this study. Of note, Grem1 
knockout was not formally demonstrated in this particular experiment (Figure 5.10), however the pilot 
experiment (Figure 5.9) suggests that Grem1 would have been deleted appropriately. Further 
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Figure 5.9: Generation of Grem1 KO mice. (A) Representative images display genotype confirmation 
of homozygous Grem1fl/fl and hemizygous Grem1fl/wt-UBC-CreERT2 genetically modified mice by 
PCR. Schematic representation of (top) the Grem1 locus and addition of loxP sites in relation to the 
open reading frame (ORF) contained in exon 2 of Grem1. The second, downstream loxP site was 
inserted as part of a flippase recombinase target (FRT)- neomycin (Neo) cassette. Image modified from 
Gazzerro et al179. (Bottom) The lentiviral construct used to generate Cre-ERT2 fusion protein-
expressing lentivirus under the control of ubiquitin C (UBC) promoter region. Image modified from 
Ruzankina et al225. (B) Confirmation of Grem1 knockout was assessed by PCR analysis of genomic 
DNA isolated from compact bone of tamoxifen-treated control UBC-cre, Grem1wt/wt mice and UBC-
cre, Grem1fl/fl mice. PCR primers span a 100 base pair region between the loxP flanked regions of 
Grem1 gene exon 2.  Representative image of agarose gel shown. Ex vivo culture of (C) compact bone 
and (D) BM isolated from the long bones of Grem1fl/fl, UBC-cre mice in the absence (-) or presence (+) 
of the tamoxifen-derivation 4-OHT (TAM) was performed. Graphs depict mean ± SEM of n=2 
individual donor mice, *P<0.05, t-test. (E) RNA in situ hybridisation for Grem1 was assessed in tissue 
sections of tamoxifen-treated control UBC-cre, Grem1wt/wt mice and UBC-cre, Grem1fl/fl mice. 
Representative images display tibia BM-tissue sections with intracellular staining for Grem1 RNA 
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Figure 5.10: Grem1 knockout in vivo does not reduce Vk*MYC.SFG MM PC growth. (A) 
Schematic illustrating the experimental design for induction of Grem1 knockout by tamoxifen-chow 
diet and subsequent Vk*MYC SFG tumour cell inoculation. UBC-Cre, Grem1wt/wt and UBC-Cre, 
Grem1fl/fl mice were administered a tamoxifen-chow diet 2-weeks prior to intra-tibial inoculation of 
1x105 Vk*MYC.SFG MM PCs. Tamoxifen-chow was continued for the duration of the study. Tumour 
burden was monitored weekly throughout the study by BLI. (B) Knockout of Grem1 expression in 
compact bone was confirmed by RT-PCR at the conclusion of the study. Graph displays mean ± SEM, 
n=5-6, P>0.05, t-test. (C) Representative BLI images at week 3 post-tumour cell inoculation in UBC-
cre, Grem1wt/wt and UBC-cre, Grem1fl/fl mice. (D) Tumour burden at week 2 and week 3 post-tumour 
cell inoculation assessed by BLI. Graphs display mean ± SEM, n=6, P>0.05, t-test. (E) At the 
conclusion of the study, week 10, BM was isolated from the injected and contralateral tibias of UBC-
cre, Grem1wt/wt and UBC-cre, Grem1fl/fl mice. BM was analysed by flow cytometry for the presence of 
GFP+ Vk*MYC.SFG MM PCs. Graphs display mean ± SEM, n=3-4, P>0.05, t-test.  
 
5.3. Discussion 
Grem1 is widely reported to promote the progression of cancers of the gastrointestinal tract, lung and 
brain110 147 181 188. Furthermore, the studies presented in this thesis demonstrate, for the first time, that 
increased stromal-Grem1 expression promotes MM PC proliferation (Chapter 3) and that use of a novel 
Grem1-neutralising antibody significantly reduces MM tumour burden in the 5TGM1/KaLwRij mouse 
model of MM (Chapter 4).  However, in vivo studies investigating the efficacy of anti-Grem1 antibody 
treatment in MM have only been demonstrated in a single pre-clinical animal model. Given that MM is 
a genetically heterogenous disease, with great inter-patient variability, there was a need to further 
investigate the use of Grem1-targeted therapy in disease with a secondary pre-clinical model and a 
complementary Grem1 genetic knockout approach. Furthermore, using a complementary Grem1 
genetic knockout approach to ablate Grem1 in a mouse model of MM would provide extra evidence 
that the anti-cancer effects of the antibody therapy were due to specific neutralisation of Grem1. 
The translation of pre-clinical findings into the clinic relies on the use of in vivo models that effectively 
recapitulate human disease. In recent years, a variety of pre-clinical models have been generated to 
reproduce the biological features of MM, these include; human-xenograft and bone transplant models 
that allow the use of human primary MM PCs or MM cell lines, and spontaneous or transgenic mouse 
models of MM211. While models that enable the utilization of human MM samples have the advantage 
of mimicking the specific genomic profiles of the MM PCs within human disease, these models are 
often limited by their ability to completely reproduce the homing to and/or the interaction with the BM 
microenvironment. This is largely due to the need to use severe immunocompromised mice in these 
studies and the potential for human-mouse species differences to prevent the accurate capture of the 
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MM BM microenvironment interactions. Hence, fully immunocompetent syngeneic mouse models are 
more suited for the study of the BM microenvironment in MM disease progression and establishment, 
and for validation of BM-targeted therapeutics. The previously described 5TGM1/KaLwRij model39 75 
170 utilizes the KaLwRij-tumour-derived 5TGM1 cell line that can be efficiently transplanted into 
syngeneic mice to reproduce disease. This model replicates the clinical symptoms of MM, with 
osteolytic bone lesions and high levels of serum paraprotein. Alternatively, the genetically engineered 
Vk*MYC mouse model34 and Vk*MYC transplant models34 201 rely on upregulation of the MYC gene, 
a common genetic abnormality in MM226 227, as the driver of disease. The Vk*MYC model is considered 
to accurately replicate MM-like disease, with high dependence on the BM microenvironment, low 
proliferative index and secretion of high levels of serum monoclonal Ig34 201 219. Additionally, like 
primary MM PCs, MM PCs derived from this model consistently do not grow in vitro. This model has 
demonstrated success in determining positive drug response, with in vivo results proving to be a good 
indicator of clinical efficacy for existing and new therapeutics201. Therefore, establishment of this model 
within the laboratory provided an ideal tool for validation of the anti-tumour results observed in the 
5TGM1/KaLwRij model. Furthermore, given that this model has a longer disease timeframe, is less 
aggressive and has a higher dependence on the BM, it was hypothesized that targeting the BM-derived 
Grem1 may result in an even greater anti-tumour effect. 
Multiple transplant lines of the Vk*MYC model have been isolated, each varying in disease time course 
and severity. The Vk*MYC 4929 line is one of the most widely used, in part due to its shorter time of 
disease development, with paraprotein detectable by SPEP between 12-16 weeks compared to 
>16weeks in other lines34 75 201 218 219 228. Additionally, the 4929 line reproduces the clinical signs of MM 
disease with evidence of end-organ damage, bone lytic lesions and splenomegaly219. Establishment of 
the Vk*MYC 4929 line in this study confirmed the previously reported disease characteristics with a 
similar disease time course and presentation of clinical signs observed (Figure 5A-B).  A significant 
increase in stromal Grem1 expression within the bones of Vk*MYC 4929 tumour-bearing mice also 
lent credence to the potential of anti-Grem1 antibody treatment as a therapeutic option. However, 
Vk*MYC 4929 tumour growth was not significantly altered following anti-Grem1 antibody treatment, 
as determined by SPEP, in contrast to the results in the 5TGM1/KaLwRij model (Chapter 4). These 
conflicting results warrant a more in-depth investigation into the presentation of MM disease between 
these models.  
While the 5TGM1/KaLwRij model can utilise the expression of luciferase by 5TGM1 MM PCs to 
monitor the spatial distribution of disease throughout studies, the Vk*MYC model relies primarily on 
weekly blood collection to track whole body tumour burden via serum paraprotein levels. Therefore, 
flow cytometric analysis of Vk*MYC MM PCs based on the expression of cell surface markers CD138 
and B220 was performed in various tissues, including the BM, spleen and peripheral circulation. MM 
tumour growth is characterised by its BM involvement, however, in this study most mice displayed 
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negligible BM involvement (Figure 5.3A), not representative of >10% PC burden of diagnostic MM 
disease. This suggests that this model is not ideal for determining any effect of anti-Grem1 antibody 
treatment on MM tumour burden, especially considering the primary effect of the anti-Grem1 antibody 
to date has been specifically in reducing skeletal tumour burden (Figure 4.6B, Chapter 4). 
Furthermore, post-mortem examination of mice revealed a large degree of nodal liver tumour growth, 
confirmed to be MM PCs by histomorphometric analysis. In MM, liver metastases are largely reported 
in single case studies229-234, however wider cohort studies have also demonstrated varying reports of the 
incidence of liver involvement in MM234. A retrospective study examining a database of 2584 MM 
patients, determined that only 9 presented with macroscopic MM liver lesions, or approximately 0.3% 
of patients235. In contrast, two separate studies of autopsied patients with MM have reported much 
higher rates of hepatic involvement, with 13% and 32% of cases displaying MM liver nodes236 or liver 
involvement237, respectively. The large variation in reports of MM liver involvement can be partially 
attributed to the methods used to identify patients in these studies, with a reliance on case files 
accurately recording the presence of liver involvement in these retrospective studies, with tissue 
biopsies from these sites often unavailable for secondary analysis. While the introduction of positron 
emission tomography (PET) and whole-body low-dose computerised tomography (CT) imaging 
techniques in recent years may allow for the extent of soft-tissue metastasis, such as liver tumour nodes, 
in MM to be identified more readily238, and as such allow for a more accurate representation of the 
degree of liver involvement in MM to be determined, liver metastasis is not currently considered a 
feature characteristic of MM.  
Given the concerns regarding the extent of liver tumour growth in the Vk*MYC 4929 tumour-bearing 
mice, this study was repeated with a secondary Vk*MYC line, 3596, that did not display overt evidence 
of tumour growth in the liver. However, the Vk*MYC 3596 model also demonstrated no effect of anti-
Grem1 antibody treatment on tumour burden (Figure 5.6). The lack of anti-Grem1 antibody effect was 
not consistent with the results observed in the 5TGM1/KaLwRij model. The lack of antibody affect 
may be due to the unexpectedly large degree of variability in tumour uptake seen in this model, with 
only 40% of mice developing detectable paraprotein levels, preventing the study from being 
appropriately powered to determine a significant difference in tumour burden.  
The uncharacteristic presentation of MM disease following systemic injection of the Vk*MYC 4929 
and 3596 lines warranted a more detailed investigation of previous studies that have utilized Vk*MYC 
transplant models. Of the 13 published studies that have utilized Vk*MYC transplant models since the 
establishment of this model, over 60% of studies primarily rely on detection of M-spike by SPEP75 201 
218-221 239-246. Only 5 studies have reported flow cytometric analysis of PC surface markers to quantify 
the plasma cell burden within the BM201 220 239 246, and only 1 study performed further post-mortem 
analysis of Vk*MYC tumour-bearing mice, although there is no further mention of their findings in this 
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study221. This highlights a need to be wary of disease spread in long-standing clonal lines and for more 
rigorous post-mortem analysis of animals to be conducted, especially when SPEP is the primary method 
of quantifying tumour burden, as this does not provide details of tumour burden location. This is 
particularly necessary in studies that focus on the involvement of the BM microenvironment in disease 
progression.  While studies may demonstrate an anti-tumour effect of cytotoxic agents regardless of the 
tumour location, pharmacological agents specifically targeting microenvironmental interactions, such 
as the anti-Grem1 antibody, are less likely to demonstrate an anti-tumour response when the bulk of 
tumour growth occurs in extramedullary sites.  
Given the minimal BM involvement and the extent of extramedullary soft tissue involvement in the 
Vk*MYC models, there was a need to further optimise this model for future experimental use. 
Additionally, a considerable limitation to the current Vk*MYC model systems is the inability to monitor 
tumour distribution using live imaging techniques throughout the study, relying only on end-of-study 
analyses. However, as all previous reports with the Vk*MYC model demonstrate that Vk*MYC MM 
PCs consistently do not grow in vitro34, genetic modification of the Vk*MYC MM PCs has not been an 
achievable option. The studies presented here demonstrate for the very first time, long-term ex vivo 
growth of Vk*MYC MM PCs and the subsequent genetic modification of these cells to express GFP 
and luciferase (Vk*MYC.SFG). Subsequent systemic in vivo injection of Vk*MYC.SFG MM PCs was 
performed, with initial spatial distribution of tumour growth, as determined by live BLI, displaying little 
BM involvement. Two further passages of the genetically modified Vk*MYC.SFG MM PCs through 
the BM generated a more bone tropic subline. The generation of a bone tropic, GFP+ and luciferase+ 
Vk*MYC subline provides an essential tool for future in vivo studies, with expansion of this line for 
wide-spread use in pre-clinical MM models ongoing.  
While the use of a Grem1-neutralising antibody in the 5TGM1/KaLwRij pre-clinical MM model 
demonstrated a significant reduction in tumour burden (Chapter 4), there is potential for this therapeutic 
to have multiple targets and/or non-specific side effects that mediate its anti-tumour effects. As such, a 
complementary genetic knockout approach was needed to validate the role of Grem1 in MM disease 
progression. Due to the key roles of Grem1 in early development in controlling limb-bud development 
and organogenesis, constitutive genetic knockout is not an option. Previous studies have demonstrated 
the use of Grem1 knockout models to study its roles during early development and bone formation. 
Studies that have utilized a constitutive knockout approach to Grem1 have consistently reported that 
mice are rarely viable for more than 24-48 hours post birth and suffer from poorly developed or even 
absent kidneys, and underdeveloped limb extremities166 178 247 248. However, it is important to note that 
there are rare reports of mice surviving to adulthood, although often with decreased weight, body length 
and altered bone formation compared to their wildtype counterparts178 247. Given the substantial effects 
of constitutive Grem1 knockout in pre-clinical mouse models, conditional deletion of Grem1 is a 
favoured approach. Gazzerro, et al., established a conditional Grem1 knockout model with the use of 
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osteocalcin-cre recombinase-mediated gene excision of loxP-flanked Grem1. Transient changes in bone 
formation and bone mass were reported, but animals were otherwise healthy and viable following 
knockout179. While the studies presented by Gazzerro, et al., demonstrated effective knockout of Grem1, 
the use of osteocalcin-driven cre recombinase limits gene excision solely to osteoblasts. As Grem1 is 
also expressed by other cell populations within the BM, including stromal cells83 249 and macrophages250, 
a more global knockout approach was needed. Instead, the studies presented here utilized the UBC-
cre/ERT2 mouse strain, whereby the Cre-ERT2 fusion gene is under the control of the widely expressed 
human ubiquitin C promoter to enable Grem1 knockout in all body tissues. Crossbreeding of the UBC-
cre/ERT2 strain with mice containing the loxP-flanked Grem1 sequence resulted in viable offspring, 
with effective induction of Grem1 knockout following tamoxifen administration.  
Therapeutically targeting Grem1 in the 5TGM1/KaLwRij mouse MM model significantly reduced MM 
tumour burden (Chapter 4). However, the specific genetic background of the KaLwRij mice does not 
readily allow for crossing with other genetically modified strains, unlike more commonly used strains 
such as C57BL6, and as such this model was not suitable for investigating Grem1 knockout within the 
BM microenvironment. Given that the UBC-Cre, Grem1-floxed mouse model was on a fully 
immunocompetent C57BL6 background, any alternate MM models also needed to be of this C57BL6 
genetic background to avoid immune rejection. Therefore, the Vk*MYC.SFG MM PCs generated as 
part of this study provided a suitable secondary option. Nevertheless, as the bone-tropic subline had yet 
to expand sufficiently for use in this study, a strategy was required to bypass the extensive 
extramedullary disease otherwise observed with this transplant line.  
In order to circumvent the need for tumour cells to disseminate and colonise the BM, Vk*MYC.SFG 
tumour cells were injected intra-tibially into the BM space of Grem1-knockout and Grem1-wildtype 
mice. Injection directly into the tibial space also minimises the initial likelihood of cells colonising 
extramedullary sites that would readily occur upon systemic tumour cell injection. Tumour uptake in 
the BM following intra-tibial injection was variable, with less than 50% of Vk*MYC tumour cell 
injections resulting in colonization of the BM, as determined by BLI, regardless of mouse genotype. 
Notably, a trend toward reduced MM tumour burden was observed in the Grem1-knockout mice 
compared to Grem1-wildtype controls by both BLI (Figure 5.10D) and flow cytometry (Figure 5.10E), 
however this was not statistically significantly. This result warrants further investigation of the role of 
Grem1 in MM through the utilization of the Grem1-KO mouse model. Future studies will aim to use 
the bone tropic Vk*MYC.SFG subline established as part of these studies. The modified Vk*MYC.SFG 
line would allow for the systemic injection of cells that have a preference to disseminate to and colonise 
the BM, without the need to inject cells directly into the bone. While direct injection of MM PCs into 
the BM is a useful technique, it poses the risk of damaging and/or modifying the natural state of the 
BM microenvironment upon injection. Furthermore, injection of a bolus of cells directly into the BM 
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space may overwhelm the BM microenvironment and reduce the reliance of these cells on 
microenvironmental signals for survival.  
In summary, anti-Grem1 antibody treatment in two separate Vk*MYC pre-clinical MM models failed 
to significantly alter MM tumour burden. However, these studies highlighted substantial limitations to 
these models, primarily a lack of preferential seeding of the BM microenvironment by MM PCs. As 
such, a more bone tropic Vk*MYC subline was generated harbouring luciferase and GFP to provide a 
better cancer model. Use of the newly generated Vk*MYC.SFG cells in an inducible Grem1-knockout 
mouse model demonstrated a trend toward reduced MM tumour burden was observed in Grem1 
knockout mice compared to wildtype controls, however this was not statistically significant. This 
knowledge supports the use of anti-Grem1 therapies to reduce MM disease burden and provides 





































MM accounts for approximately 10% of all haematological malignancies, and is characterised by the 
clonal proliferation of malignant plasma cells within the BM. While recent treatment advances have 
improved the median overall survival for MM to approximately 6 years251, the majority of patients 
relapse and MM remains a largely incurable disease 2-4.  The recent history of molecular oncology 
informs us that a greater understanding of the biology and complexity of human cancer can lead to the 
development of chemoprevention strategies, as well as identification of novel prognostic biomarkers 
and therapeutics that drive improvements in patient management. In this regard, while the vast majority 
of research on MM has focused on the malignant MM PC themselves5, it is now evident that the tumour 
BM microenvironment also plays a major role in MM cancer development and progression6-8. As such, 
it remains to be elucidated which BM stromal cells and factors are required for the continued growth, 
spread and survival of the MM PC8-10.  
A recent study by Lawson, et al. highlighted that the metaphyseal and endosteal regions of the bone are 
synonymous with MM PC tumour growth11. Interestingly, these locations are home to a rare, discrete 
population of osteochondroreticular stem cells (OCR-SC), recently described by Worthley, et al12. The 
OCR-SC population are defined by their expression of a highly conserved cysteine-knot secreted 
protein, Grem1. Given that Grem1 is one of the most upregulated genes within the tumour 
microenvironment in numerous solid cancers and has been identified as promoting tumour growth and 
spread in colorectal cancer, lung cancer, cervical cancer, pancreatic cancer, mesothelioma and glioma13-
21, it could also play a role in MM disease progression.  
Overexpression of GREM1 in the tumour supportive tissue of basal cell carcinoma, as well as 
carcinomas of the bladder, breast, lung, colon and pancreas has been shown to promote tumour cell 
proliferation in vitro and disease progression in vivo15 18 22 23. Furthermore, aberrant GREM1 expression 
in the bowel disease, hereditary mixed polyposis syndrome (HMPS), is sufficient to initiate colonic 
tumorigenesis24. In Chapter 3, GREM1 expression was found to be significantly upregulated in the BM 
stroma of MM patients. This was further supported in the 5TGM1-KaLwRij mouse model of MM, 
where a significant increase in Grem1 expression was observed in the bones of tumour-bearing mice 
compared to normal controls. Importantly, a positive correlation between PC tumour burden and Grem1 
expression was found. These findings are consistent with previous studies that reported upregulation of 
Grem1 within the tumour microenvironment in other cancers13 23 25. In keeping with these findings, co-
culture experiments conducted with both human and mouse MM PC lines with BM-derived stroma 
showed increases in GREM1/Grem1 expression within the stroma. These findings suggest that the 
increase in BM-derived Grem1 expression in MM is directly driven by MM PCs. These findings are in 
keeping with the known interplay between MM PCs and neighbouring BMSCs which functions to 
provide a tumour supportive niche within the BM6 26. The interaction and adhesion of MM PCs with the 
surrounding BM stroma has been shown to upregulate a number of critical pro-survival and/or anti-




apoptotic pathways, including NF-ĸB and Notch signalling pathways which regulate the expression of 
key downstream MM supportive factors, VEGF, IGF-1 and IL-627-29.  While previous studies have 
demonstrated an increase in Grem1 expression within the tumour supportive environment, the studies 
presented in Chapter 3 are the first to demonstrate that the interplay between MM PC and the BM stroma 
drives Grem1 upregulation in MM disease.  
While the upregulation of GREM1/Grem1 within the MM BM microenvironment appears to be driven 
by the interaction between MM PC and the BM stroma, the mechanism(s) through which this occurs 
are unclear. The studies presented in Chapter 3 suggest that the cytokine IL-6 may be responsible for 
the regulation of GREM1 in MM. Paracrine and autocrine upregulation of IL-6 within the MM BM 
microenvironment is a common feature of MM and it is well understood that IL-6 promotes the survival 
and proliferation of MM tumour cells, mediated through JAK/STAT upregulation of VEGF, Ras, Akt 
and MAPK pathways30-32. Furthermore, studies by Uchiyama, et al.,33and others27 34-36 have 
demonstrated that adhesion of MM PC to BM stromal cells triggers stromal secretion of IL-6. This is 
consistent with the findings presented in Chapter 3, whereby 5TGM1 MM PCs in direct contact with 
OP9 stromal cells stimulated an increase in Il-6 expression. Importantly, IL-6 has been shown to 
regulate the expression of GREM1 via STAT3-dependent mechanisms in the fibrotic condition of 
systemic sclerosis37. In Chapter 3, Il-6 was shown to promote an increase in Grem1 expression in BM 
stromal cells. Furthermore, inhibition of IL-6 signalling abrogated the MM PC-mediated increase in 
BM stromal Grem1 expression in MM PC-stromal co-cultures. Interestingly, the HMCL (U266) that 
caused the highest elevation in GREM1 expression in human BM stroma in co-culture experiments also 
expresses the highest levels of IL-6 mRNA (www.keatslab.org). Taken together, these data suggest that 
Il-6 is critical for the upregulation of BM-derived Grem1 in MM. Future studies assessing the interplay 
between Grem1 and other pro-inflammatory pathways, such as the TGF-β pathway, and the effect of 
these pathways in MM are also warranted, as Grem1 is reported to play a role in a range of inflammatory 
diseases, including fibrosis.  
The effects of Grem1 on cancer cells are conflicted, with both pro- and anti-tumorigenic roles reported 
in various malignancies. Overexpression of GREM1 in lung and colorectal cancers, as well as malignant 
mesothelioma, is associated with disease progression by promoting cell survival, proliferation and 
invasion in vitro13 15 20 38. In contrast, increased GREM1 expression in pancreatic neuroendocrine 
tumours is associated with an increase in patient progression-free survival and has been reported as a 
predictor of positive outcomes39. In this thesis MM PCs cultured with BM-stromal cells overexpressing 
Grem1 exhibited up to an 80% increase in MM PC proliferation, supporting a pro-tumorigenic role for 
Grem1 in MM.  
While no previous studies have described the potential of Grem1 in promoting MM growth, the 
inhibitory role of BMPs in MM disease is well documented139 140 159 252.  Notably, the Grem1 targets 




BMP-2, -4 and -7 have been demonstrated to have anti-proliferative and pro-apoptotic functions in MM, 
and as such Grem1 may act via a BMP-dependent mechanism in MM. However, these studies have 
largely assessed the role of BMP proteins on MM PC in vitro and in isolation from the host of other cell 
types and factors of the BM microenvironment139 140 159. A recent study by Gooding, et al. demonstrated 
that direct interaction between BM stromal cells and MM PC in co-culture abrogated the anti-
proliferative signalling of BMP proteins253. Furthermore, this study demonstrated that BMP signalling 
is upregulated in stromal progenitor cells of the MM BM microenvironment in a mouse model of MM, 
and that inhibition of this signalling in vivo results in a significant reduction in osteolytic lesions and 
restoration of bone mass when compared to tumour-only controls. Importantly, this study demonstrated 
that inhibition of BMP signalling in MM disease did not affect tumour burden. Therefore, the anti-
tumour effects of the anti-Grem1 neutralising antibody in the studies presented in this thesis (Chapter 
4) may not be due to a restoration of BMP signalling within the tumour microenvironment. As such, 
the mechanism by which Grem1-targeted therapy in MM significantly limits MM tumour burden 
warrants further exploration. Furthermore, careful consideration is required in relation to how anti-
Grem1 therapy may alleviate Grem1-mediated BMP inhibition and whether this contributes to the 
devastating bone loss observed in MM disease. While, microCT analysis of bone volume in Chapter 4 
did not demonstrate any difference in trabecular bone volume between anti-Grem1 antibody treated 
mice and IgG control antibody treated mice, assessment of bone volume during MM disease and over 
a longer treatment time course may be warranted. In addition, the difference in tumour burden between 
these treatment cohorts and the effect this has on bone loss will need to be taken into careful 
consideration in future studies.  
Given the inability to fully recapitulate the complexities of the MM BM microenvironment in vitro, the 
5TGM1/KaLwRij preclinical mouse model of MM was used to further investigate a role for Grem1 in 
disease development and to determine whether therapeutically targeting Grem1 represents a viable 
treatment option. Other studies have previously used neutralising antibodies against Grem1 and 
reported promising results 38 42. Kim, et al., first used a Grem1-neutralising antibody to inhibit Grem1 
induced migration, invasion and proliferation of the lung carcinoma cell line A549. A subsequent study 
by Ciuclan, et al., demonstrated that a Grem1-neutralising antibody was effective in treating a mouse 
model of pulmonary hypertension42. In Chapter 4, we demonstrate for the first time that the use of a 
Grem1-neutralising antibody in the 5TGM1/KaLwRij mouse model of MM resulted in more than 80% 
reduction in mean MM tumour burden. Given that the Grem1-neutralising antibody had no significant 
effect on the growth of 5TGM1 MM PCs in monoculture in vitro, the effects of the Grem1-neutralising 
antibody in vivo are consistent with the targeting of a PC-extrinsic factor. Considering that 
administration of Grem1-neutralising antibody treatment prior to the inoculation of tumour cells showed 
no significant difference in the ability of cells to home to the BM, it is also likely that the anti-tumour 
effect of the antibody can be attributed to an anti-proliferative role. While previous studies have also 




demonstrated that Grem1 is a key factor in maintaining skeletal homeostasis43 44, influencing HSC 
differentiation45,  and osteoblast numbers and activity43 46, the studies presented in Chapter 4 
demonstrated that anti-Grem1 antibody treatment did not significantly alter the cellular composition of 
the MM BM microenvironment. Collectively, these findings support the likelihood that BM stromal 
Grem1 acts directly upon the MM PC population rather than through secondary changes in the tumour 
microenvironment composition. The mechanism of action of Grem1 in promoting MM tumour growth 
warrants further study. 
Importantly, while tumour burden was reduced by more than 5-fold with anti-Grem1 neutralising 
antibody treatment, complete eradication of tumour burden was not achieved. Preliminary in vitro 
studies demonstrated anti-Grem1 antibody treatment resulted in only a limited reduction in MM PC 
growth when added to MM PC-stromal cell co-cultures, and MM PCs do not appear to be completely 
dependent on Grem1 for their growth and survival. Furthermore, since the studies presented in Chapter 
3 demonstrated a positive feedback loop, whereby MM PC upregulate stromal-derived Grem1, it is 
conceivable that the elevated levels of BM Grem1 cannot be effectively neutralised by the 
administration of a single anti-Grem1 agent. This may also explain the greater anti-tumour effect 
observed when treatment was commenced prior to tumour cell inoculation (81.2% reduction) compared 
to when treatment was started post-tumour cell inoculation (54.5% reduction). In the latter situation the 
tumour cells have a greater opportunity to interact with the BM stromal cells and initiate this positive 
feedback loop within the tumour microenvironment. As such, a combination therapy approach that 
utilizes current frontline therapies targeting the MM PCs and their interaction with the cellular 
compartment of the BM microenvironment may achieve a more complete response with the anti-Grem1 
antibody, by reducing the amount of Grem1 that needs to be neutralised. In support of this notion, 
previous clinical studies examining the effectiveness of the monoclonal antibody (elotuzumab) against 
the MM PC cell-surface protein SLAMF7, showed limited clinical activity as a single agent, but was 
able to limit MM disease progression and improve overall survival when combined with frontline MM 
therapies47-49. While anti-IL6 therapies were proposed to make a lasting impact on the treatment 
landscape of MM, these therapies, including siltuximab (anti-IL6 antibody) and tociluzimab (anti-IL6 
receptor antibody), have failed to make it into standard clinical practice152 153 184 254. Given the role of 
IL6 in upregulating Grem1 presented in this thesis, a combination therapy with anti-IL6 therapies and 
an anti-Grem1 antibody may demonstrate a greater impact on disease and warrants further study. Given 
promising pre-clinical results presented here and the favourable safety profile observed in monoclonal 
antibody therapies compared to standard chemotherapeutics50 51, further clinical investigation of anti-
Grem1 treatment is warranted. Moreover, since most MM patients inevitably relapse, future studies 
investigating the benefit of anti-Grem1 antibody therapy in a relapse model of MM may also 
demonstrate an alternative treatment modality for Grem1-targeted therapy. For these experiments, 
upfront treatment with a current standard of care agent, such as bortezomib or lenalidomide, may be 




used to directly target the bulk of tumour cells, while anti-Grem1 antibody treatment could be ideally 
placed to limit time to relapse following these initial cycles of therapy. Furthermore, even if not all MM 
PCs are eradicated by anti-Grem1 antibody treatment as a single agent, it may be sufficient in limiting 
MM tumour burden so as to turn MM into a chronic disease, whereby disease can be managed 
effectively with treatment and there are long-term survival benefits to MM patients. 
 
Figure 6.1: MM PC-driven stromal Grem1 upregulation can be targeted with a Grem1-
neutralising antibody to reduce disease progression. Stromal Grem1 expression is upregulated by 
the reciprocal interaction between the BM stroma and the MM PC (left). Subsequently, increased 
stromal Grem1 promotes MM PC proliferation and MM disease progression (middle). Inhibiting Grem1 
signalling through an anti-Grem1 neutralising antibody reduces MM proliferation, and as such reduces 
the progression of MM disease (right).   
While significant reductions in MM tumour development following anti-Grem1 neutralising antibody 
treatment were reported in Chapter 4, a secondary in vivo model approach was ideally needed to validate 
the specificity of these results. The success of these initial studies could not be replicated in the 
frequently used Vk*MYC MM transplant mouse model, detailed in Chapter 5. Critically, the Vk*MYC 
model exhibited a large degree of extramedullary tumour growth with minimal bone marrow tumour 
involvement. This contrasted to an initial study with this model that shows greater than 50% MM PC 
tumour burden within the BM of transplanted mice52. However, a detailed examination of the published 
studies utilizing this model revealed that over 60% of studies reported disease burden based primarily 
on detection of an M-spike by SPEP, rather than cell-and location-specific detection methods such as 
flow cytometry52-65.  The fact that Vk*MYC cells do not express any reporter proteins, such as GFP and 
luciferase, means that live monitoring of tumour burden and spatial distribution was not possible. In 
order to circumvent the considerable drawbacks observed in the Vk*MYC mouse model, the studies 
presented in Chapter 5 demonstrated for the first time the generation of a bone tropic, GFP+ and 
luciferase+ Vk*MYC subline. 




Genetically modified strains of mice are indispensable for the study of specific factors in disease 
development. To confirm that the specificity of the anti-Grem1 neutralising antibody anti-tumour 
effects observed in the 5TGM1/KaLwRij mouse MM model (Chapter 4) were due to therapeutically 
targeting Grem1, a Grem1 genetic knockout mouse was developed (Chapter 5). To date, the knockout 
of Grem1 in mice has only been performed under the control of gene-specific promoters to allow for 
Grem1-ablation in specific cell populations, the studies in Chapter 5 demonstrate for the first time 
conditional knockout of Grem1 in UBC-Cre-ERT2, Grem1-floxed mice in different cell compartments 
within the BM microenvironment. To attempt to avoid extramedullary disease spread, the newly 
generated GFP+ and luciferase+ syngeneic Vk*MYC bone tropic subline was injected directly into the 
tibial medullary cavity in the Grem1 knockout mouse model. Reduced MM tumour burden was 
observed in the Grem1-knockout mice compared to Grem1-wildtype controls, although this did not 
reach statistical significance. Future studies that utilize systemic injection of this Vk*MYC subline are 
warranted as this may more closely mimic the dissemination of tumour cells to the BM that occurs in 
MM disease. Furthermore, this mode of administration mitigates the risk of modifying the BM by direct 
injection and/or overwhelming the existing BM microenvironment with a bolus of tumour cells. These 
studies would further validate Grem1 as a therapeutic target in MM.  
In conclusion, the findings presented in this thesis demonstrate, for the first time, a novel positive 
feedback loop between MM PCs and BM stroma involving IL6 and Grem1 (Figure 6.1). In vitro co-
culture experiments suggest that the increased stromal-Grem1 expression in MM patients and MM 
tumour-bearing mice is driven by the reciprocal interaction between MM PCs and BM stromal cells. 
Further, increased stromal Grem1 promotes an increase in MM PC proliferation in vitro. Notably, we 
found that inhibiting this vicious cycle with a neutralising antibody can dramatically reduce tumour 
burden in a preclinical mouse model of MM. In a complementary study, a trend towards reduced MM 
tumour burden was also observed in Grem1 conditional knockout mice.  A significant setback in 
effectively treating MM patients relates to the diverse inter-patient heterogeneity of the genetic 
mutations observed in the PC tumours40 41. As such, using precision medicine to target tumour-specific 
dysregulated pathways will always be hampered by the small proportions of MM patients whose 
tumours have mutations dysregulating each specific pathway.   However, in our studies, ex vivo analysis 
of MM patient BM trephine biopsies showed that 93% of patients had greater stromal GREM1 
expression than the median normal BM sample. As such, GREM1 may represent a microenvironmental 
factor that is frequently upregulated in MM patients despite their diverse tumour genetics, and therefore 
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